var title_f33_39_34416="Hepatoma invading major vessels";
var content_f33_39_34416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatoma invading major vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A contrast-enhanced CT scan demonstrates an ill-defined mass in the dome of the liver representing the region of the hepatoma (long arrow). A filling defect in the contrast filled IVC (arrowhead) reflects tumor thrombus extending from the primary tumor into the IVC.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34416=[""].join("\n");
var outline_f33_39_34416=null;
var title_f33_39_34417="Patient information: Stye (hordeolum) (The Basics)";
var content_f33_39_34417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16336\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/6/2148\">",
"         Stye",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/6/26721\">",
"         Patient information: Conjunctivitis (pinkeye) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/51/20274\">",
"         Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Stye (hordeolum) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/stye-hordeolum-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6578453\">",
"      <span class=\"h1\">",
"       What is a stye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A stye is a red and painful lump on the eyelid. It happens when a small gland on the edge of the eyelid gets infected or inflamed. Styes can occur on the upper or lower eyelids. Most styes get better on their own after a few days to a week.",
"     </p>",
"     <p>",
"      Another word for stye is &ldquo;hordeolum.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6578460\">",
"      <span class=\"h1\">",
"       What are the symptoms of a stye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have a stye have a red and painful lump on the edge of their eyelid (",
"      <a class=\"graphic graphic_picture graphicRef81682 \" href=\"UTD.htm?2/6/2148\">",
"       picture 1",
"      </a>",
"      ). A stye usually develops over a few days. It can look like a pimple. Styes can cause other symptoms, too, such as tearing and eyelid pain and swelling.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6578467\">",
"      <span class=\"h1\">",
"       Is there a test for a stye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But your doctor or nurse should be able to tell if you have a stye by doing an exam and talking with you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6578474\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To ease your symptoms and help your stye get better, you can put warm, wet pressure on the stye. Wet a clean wash cloth with warm water and put it over your stye. When the wash cloth cools, reheat it with warm water and put it back over the stye. Repeat these steps for 15 minutes, 4 times a day. You can also put warm mashed potato in a sealed plastic bag on your stye. (Mashed potato might stay warm longer than a wash cloth).",
"     </p>",
"     <p>",
"      You should NOT squeeze or pop your stye. Also, you should not wear eye makeup or contact lenses until your stye is all better.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6578481\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your stye doesn&rsquo;t go away after you treat it on your own for 1 week",
"       </li>",
"       <li>",
"        Your stye gets very big, bleeds, or affects your vision",
"       </li>",
"       <li>",
"        Your whole eye is red, or your whole eyelid is red and swollen",
"       </li>",
"       <li>",
"        The redness or swelling spreads to your cheek or other parts of your face",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6578488\">",
"      <span class=\"h1\">",
"       What treatments might my doctor use?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your stye doesn&rsquo;t get better or if it leads to other problems, your doctor might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Prescribe a cream or ointment that goes in the eye",
"       </li>",
"       <li>",
"        Prescribe antibiotic medicines",
"       </li>",
"       <li>",
"        Drain the stye",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6578495\">",
"      <span class=\"h1\">",
"       Can styes be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To lower your chances of getting a stye, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands before you touch your eyes",
"       </li>",
"       <li>",
"        Wash your hands before you put in contact lenses and keep your contact lenses clean (if you wear contact lenses)",
"       </li>",
"       <li>",
"        Take off your eye makeup each night",
"       </li>",
"       <li>",
"        Not use old eye makeup and not share eye makeup with other people",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6578502\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?33/39/34417?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16336 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34417=[""].join("\n");
var outline_f33_39_34417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578453\">",
"      What is a stye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578460\">",
"      What are the symptoms of a stye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578467\">",
"      Is there a test for a stye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578474\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578481\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578488\">",
"      What treatments might my doctor use?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578495\">",
"      Can styes be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578502\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/6/2148\">",
"      Stye",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34418="The significance of urinary eosinophils";
var content_f33_39_34418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The significance of urinary eosinophils",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34418/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34418/contributors\">",
"     Abhijit V Kshirsagar, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34418/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34418/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34418/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/39/34418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute interstitial nephritis (AIN) is clinically suspected when a patient presents with acute renal failure, exposure to an offending drug, and sterile pyuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Activation of eosinophils and other mononuclear white cells plays a significant role in the pathophysiology of AIN [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], and case series describe the presence of eosinophils in the renal interstitium on histological examination along with macrophages, lymphocytes, and plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The demonstration of urinary eosinophils has been proposed as a noninvasive test to aide in the diagnosis of AIN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophils can be detected in the urine by applying stains that attach to their cytoplasmic granules. The three most commonly used stains are the Wright's, Giemsa, and Hansel's stains, and the latter is the most effective at staining eosinophils in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The presence of more than 1 percent eosinophils of the total white cells in the urine is considered a positive test by any of these three stains.",
"   </p>",
"   <p>",
"    However, the available data suggest that the presence of urinary eosinophils lacks the necessary test characteristics to definitively confirm or exclude a diagnosis of AIN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ACCURACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophiluria can be found in a variety of conditions other than acute interstitial nephritis, including transplant rejection, pyelonephritis, prostatitis, cystitis, atheroembolic disease, and rapidly progressive glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. As an example, eosinophiluria was demonstrated to be present in 4 percent of 148 consecutive hospitalized patients with pyuria (&gt;5 white blood cells per high power field), none of whom was clinically suspected to have AIN [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/11\">",
"     11",
"    </a>",
"    ]. Among 51 patients who were suspected to have AIN, eosinophiluria was present in 6 of 15 (40 percent) patients with a confirmed diagnosis of AIN and 10 of 36 (30 percent) with another renal diagnosis. Another report suggests that eosinophiluria is found in 90 percent of individuals with an ileal conduit [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported sensitivity and specificity of urinary eosinophils vary widely, probably related in part to differences in the definition of AIN, since most reports lack the \"gold standard\" test (eg, kidney biopsy), against which to compare urinary eosinophils. In fact, many studies have used the clinical impression of consulting nephrologists as the gold standard.",
"   </p>",
"   <p>",
"    In addition, the available series use stains with varying efficacy at identifying the cytoplasmic granules in eosinophils (eg, Hansel's stain, Wright's stain, or both). Using a definition of &ge;1 percent urinary eosinophils, the sensitivity and specificity eosinophiluria for the identification of AIN vary depending on the type of stain used. Eosinophiluria for the identification of AIN has a sensitivity and specificity of 63 to 91 percent and 85 to 93 percent, respectively, using Hansel's stain [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/6,7,13\">",
"     6,7,13",
"    </a>",
"    ], and a sensitivity and specificity of 11 to 89 percent and 52 to 93 percent, respectively, using Wright's stain [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34418/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical conditions that have eosinophiluria can usually be distinguished from AIN by the clinical history, including the absence of drugs associated with AIN, and the presence of urine sediment findings typical for the other conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapidly progressive glomerulonephritis is typically associated with red cells and red cell casts in the urine sediment.",
"     </li>",
"     <li>",
"      Patients with prostatitis complain of dysuria and have normal renal function.",
"     </li>",
"     <li>",
"      Renal atheroemboli occur in patients with severe atheromatous disease, usually after aortic manipulation. Signs of other systemic emboli are also frequently present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13528?source=see_link\">",
"       \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"       \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic accuracy of urinary eosinophils is limited. Although eosinophiluria may help suggest a diagnosis of acute interstitial nephritis in patients, a positive finding may be seen with other conditions, and a negative finding does not exclude the diagnosis.",
"   </p>",
"   <p>",
"    Thus, it would be a mistake to overemphasize this finding, and the interpretation of a finding of urinary eosinophils must be made in conjunction with the other historical and laboratory clues. A kidney biopsy remains the definitive diagnostic test for AIN and should be strongly considered when contemplating treatment for AIN with immunosuppressive medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=see_link\">",
"     \"Treatment of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/1\">",
"      Joh K, Aizawa S, Yamaguchi Y, et al. Drug-induced hypersensitivity nephritis: lymphocyte stimulation testing and renal biopsy in 10 cases. Am J Nephrol 1990; 10:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/2\">",
"      Shibasaki T, Ishimoto F, Sakai O, et al. Clinical characterization of drug-induced allergic nephritis. Am J Nephrol 1991; 11:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/3\">",
"      Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006; 17:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/4\">",
"      Ooi BS, Jao W, First MR, et al. Acute interstitial nephritis. A clinical and pathologic study based on renal biopsies. Am J Med 1975; 59:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/5\">",
"      Laberke HG, Bohle A. Acute interstitial nephritis: correlations between clinical and morphological findings. Clin Nephrol 1980; 14:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/6\">",
"      Corwin HL, Korbet SM, Schwartz MM. Clinical correlates of eosinophiluria. Arch Intern Med 1985; 145:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/7\">",
"      Nolan CR 3rd, Anger MS, Kelleher SP. Eosinophiluria--a new method of detection and definition of the clinical spectrum. N Engl J Med 1986; 315:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/8\">",
"      Helgason S, Lindqvist B. Eosinophiluria. Scand J Urol Nephrol 1972; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/9\">",
"      Corwin HL, Haber MH. The clinical significance of eosinophiluria. Am J Clin Pathol 1987; 88:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/10\">",
"      Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. Am J Med 1991; 91:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/11\">",
"      Ruffing KA, Hoppes P, Blend D, et al. Eosinophils in urine revisited. Clin Nephrol 1994; 41:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/12\">",
"      Lieske JC, Bonebrake D, Thesing J, Bella G. Eosinophiluria is common among patients after ileal conduit surgery. Clin Chem Lab Med 2011; 49:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34418/abstract/13\">",
"      Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60:804.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7232 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34418=[""].join("\n");
var outline_f33_39_34418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC ACCURACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13528?source=related_link\">",
"      Clinical presentation, evaluation, and treatment of renal atheroemboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=related_link\">",
"      Treatment of acute interstitial nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34419="Patient information: Sudden cardiac arrest (The Basics)";
var content_f33_39_34419=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82912\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/42/9888\">",
"         Normal heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"          Person having an ECG",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"           Transthoracic echocardiogram (echo)",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/37/16980\">",
"            Cardiac catheterization",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/2/6178\">",
"         Patient information: CPR for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/50/26402\">",
"         Patient information: CPR for children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/60/38850\">",
"         Patient information: Implantable cardioverter-defibrillators (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/12/25795\">",
"         Patient information: Ventricular fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/2/32803\">",
"         Patient information: What can go wrong after a heart attack? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/38/18020\">",
"         Patient information: Heart stents and angioplasty (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/20/11589\">",
"         Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sudden cardiac arrest (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sudden-cardiac-arrest-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29089507\">",
"      <span class=\"h1\">",
"       What is sudden cardiac arrest?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) is when the heart suddenly stops beating. This is a medical emergency that needs to be treated right away. SCA that isn&rsquo;t treated right away causes death (called &ldquo;sudden cardiac death.&rdquo;) But even with treatment, most people with SCA do not survive.",
"     </p>",
"     <p>",
"      The heart has a built-in electrical system that keeps it beating in a normal rhythm. In SCA, a problem happens with the electrical system. This leads to an abnormal heart rhythm. The abnormal heart rhythm that happens most often in SCA is called &ldquo;ventricular fibrillation&rdquo; or &ldquo;v fib.&rdquo; In this rhythm, the lower chambers of the heart (ventricles) twitch, but do not pump blood (",
"      <a class=\"graphic graphic_figure graphicRef56936 \" href=\"UTD.htm?9/42/9888\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      SCA is different than a heart attack. In a heart attack, one of the arteries that bring blood to the heart gets blocked, and heart muscle dies. But the heart still beats.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29089522\">",
"      <span class=\"h1\">",
"       What causes sudden cardiac arrest?",
"      </span>",
"      &nbsp;&mdash;&nbsp;SCA is most likely to happen in people who already have a heart problem, whether they know about their heart problem or not. Heart problems that can cause SCA include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Coronary heart disease, which is when the arteries that bring blood to the heart get clogged with fatty deposits",
"       </li>",
"       <li>",
"        A heart attack",
"       </li>",
"       <li>",
"        Thickening of the heart muscle, called &ldquo;cardiomyopathy&rdquo;",
"       </li>",
"       <li>",
"        Other problems with the heart&rsquo;s electrical system",
"       </li>",
"       <li>",
"        Heart failure, which is when the heart doesn&rsquo;t pump as well as it should",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other conditions and events that can also cause SCA include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Certain lung problems",
"       </li>",
"       <li>",
"        A severe injury, drowning, or getting electrocuted",
"       </li>",
"       <li>",
"        Illegal drugs, such as cocaine, heroin, or methamphetamine (&ldquo;meth&rdquo;)",
"       </li>",
"       <li>",
"        Electrolyte problems &ndash; Electrolytes are substances in the body (like sodium or potassium) that the body needs to work normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29089537\">",
"      <span class=\"h1\">",
"       What are the symptoms of sudden cardiac arrest?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people do not have any symptoms before their SCA. But some people have symptoms right before their SCA such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling their heart racing, skipping beats, or beating out of sync",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling weak or dizzy",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When SCA happens, a person loses consciousness, has no pulse, and is not breathing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29089552\">",
"      <span class=\"h1\">",
"       How is sudden cardiac arrest treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;SCA needs to be treated right away with both:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cardiopulmonary resuscitation (CPR) &ndash; CPR is a way to get blood and oxygen moving through the body of someone whose heart has stopped beating. It involves &ldquo;compressions,&rdquo; which is when another person presses hard and fast (over and over again) on the person&rsquo;s chest. This squeezes the heart and gets the blood moving again, although not as well as when the heart pumps blood on its own.",
"       </li>",
"       <li>",
"        Defibrillation &ndash; This involves using a device to send an electrical shock to the heart. This shock can sometimes get a normal heart rhythm started again. Defibrillation has the best chance of working when it is done right away.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these treatments are done within a few minutes of SCA, they sometimes work to restart the heart. After the heart is beating again and blood is flowing through the body, further treatment and tests will happen.",
"     </p>",
"     <p>",
"      Doctors or emergency workers sometimes start a treatment called &ldquo;hypothermia&rdquo; to cool the body down. This treatment can give people a better chance of surviving in the days after SCA. For this treatment, the body is cooled down to a few degrees below normal for 1 to 2 days. This helps reduce brain injury. This is important, because brain injury is the most common cause of death after SCA.",
"     </p>",
"     <p>",
"      Most people need a breathing tube. A breathing tube is a tube that goes down the throat and into the lungs. The other end is attached to a machine that helps with breathing.",
"     </p>",
"     <p>",
"      Your doctor will also look for the cause of your SCA and treat it, if it can be treated. To look for the cause, your doctor will do a lot of tests. These usually include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An electrocardiogram (ECG or EKG) &ndash; This test measures the electrical activity in your heart (",
"        <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        An echocardiogram (or &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create a picture of your heart as it beats (",
"        <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Other imaging tests &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a heart attack caused your SCA, you will have a procedure called cardiac catheterization, or &ldquo;cardiac cath&rdquo; for short. For a cardiac cath, the doctor puts a thin tube into a large artery in your leg and threads it up to your heart. When the tube is in place, he or she can do tests or unblock an artery that is blocked (",
"      <a class=\"graphic graphic_figure graphicRef77943 \" href=\"UTD.htm?16/37/16980\">",
"       figure 4",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Most people who survive SCA are also treated with an implantable cardioverter-defibrillator (ICD). An ICD is a device that goes under a person&rsquo;s skin near his or her heart. It can sense abnormal heartbeats and then treat them with an electrical shock.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29089567\">",
"      <span class=\"h1\">",
"       What will my life be like if I survive?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends, in part, on what caused your SCA and how quickly it was treated. Some people recover completely from SCA without any long-term problems. But many survivors have long-term brain problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29089582\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=see_link\">",
"       Patient information: What can go wrong after a heart attack? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/2/6178?source=see_link\">",
"       Patient information: CPR for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=see_link\">",
"       Patient information: CPR for children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=see_link\">",
"       Patient information: Ventricular fibrillation (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       Patient information: Heart stents and angioplasty (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?33/39/34419?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82912 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34419=[""].join("\n");
var outline_f33_39_34419=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29089507\">",
"      What is sudden cardiac arrest?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29089522\">",
"      What causes sudden cardiac arrest?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29089537\">",
"      What are the symptoms of sudden cardiac arrest?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29089552\">",
"      How is sudden cardiac arrest treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29089567\">",
"      What will my life be like if I survive?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29089582\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/42/9888\">",
"      Normal heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"       Person having an ECG",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"        Transthoracic echocardiogram (echo)",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/37/16980\">",
"         Cardiac catheterization",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/2/6178?source=related_link\">",
"      Patient information: CPR for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=related_link\">",
"      Patient information: CPR for children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=related_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34420="Rimantadine: Pediatric drug information";
var content_f33_39_34420=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rimantadine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"    see \"Rimantadine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/11/25780?source=see_link\">",
"    see \"Rimantadine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flumadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flumadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"      see \"Rimantadine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Monotherapy is not recommended. In order to control outbreaks in institutions, if influenza A virus subtyping is unavailable and oseltamivir-resistant viruses are circulating, rimantadine may be used in combination with oseltamivir if zanamivir cannot be used. Therapy should continue for &ge;2 weeks and until ~10 days after illness onset in the last patient (CDC, 2011; Harper, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-9 years: 5 mg/kg/day in 1-2 divided doses; maximum dose: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;10 years who weigh &lt;40 kg: 5 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;10 years who weigh &ge;40 kg and Adults: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dosages for treatment and prophylaxis are the same; duration of treatment: 5-7 days; optimal duration not established; discontinue as soon as clinically warranted to reduce the emergence of antiviral drug resistant viruses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: Dose adjustment not required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adults: Severe dysfunction: 100 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flumadine&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13164316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of influenza A viral infection (FDA approved in ages &ge;17 years and adults); prophylaxis of influenza A virus (FDA approved in ages &ge;1 year and adults); please refer to current ACIP guidelines for recommendations during current flu season)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rimantadine may be confused with amantadine, ranitidine, Rimactane",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flumadine&reg; may be confused with fludarabine, flunisolide, flutamide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Concentration impaired, dizziness, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Agitation, ataxia, bronchospasm, cardiac failure, confusion, convulsions, depression, diarrhea, dyspnea, euphoria, gait abnormality, hallucinations, heart block, hyperkinesias, hypertension, lactation, palpitation, parosmia, pedal edema, rash, syncope, tachycardia, taste alteration, tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rimantadine, amantadine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver disease, renal impairment, epilepsy, uncontrolled psychosis, severe psychoneurosis, and in patients receiving CNS stimulant drugs. May increase seizure activity in patients with pre-existing seizure disorders; discontinue use if seizure occurs. Modify dosage in patients with severe renal impairment, severe hepatic dysfunction, or active seizure disorder; use in patients &lt;1 year of age has not been adequately assessed",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2854705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resistance of influenza A virus to rimantadine may develop spontaneously or rapidly during treatment; cross-resistance between amantadine and rimantadine occurs. Due to increased resistance, the CDC has recommended that rimantadine and amantadine no longer be used as monotherapy for the treatment or prophylaxis of influenza A in the United States until susceptibility has been re-established. Consult current CDC guidelines for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect rate or extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal data suggest embryotoxicity, maternal toxicity, and offspring mortality at doses 7-11 times the recommended human dose. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Influenza infection may be more severe in pregnant women. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Oseltamivir and zanamivir are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Appropriate antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (consult current CDC guidelines).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to influenza vaccine, or who have taken an antiviral medication during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the uncoating of influenza A viral RNA and prevents penetration of the virus into host cell; inhibits M",
"     <sub>",
"      2",
"     </sub>",
"     protein in the assembly of progeny virions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 17-25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively in the liver via hydroxylation and glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-8 years: 13-38 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 25.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;25% excreted unchanged in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: Negligible effect",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/11/25780?source=see_link\">",
"      see \"Rimantadine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness or confusion and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not active against influenza B; treatment or prophylaxis in immunosuppressed patients has not been fully evaluated; duration of fever and other symptoms can be reduced if rimantadine therapy is started within the first 48 hours of influenza A illness",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     During an outbreak of influenza, administer rimantadine prophylaxis for 2-3 weeks after influenza vaccination until vaccine antibody titers are sufficient to provide protection",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10297270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rimantadine 10 mg/mL Suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     To prepare suspension, 10 mL of Ora-Sweet&reg; will be required for every 100 mg tablet of rimantadine. (Do not prepare more than a 14-day supply).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     - Calculate the total dose needed (daily dose x number of days = mg of rimantadine needed) and round the final mg of rimantadine needed up to the next 100 mg (eg, 750 mg would be 800 mg, or eight 100 mg tablets).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     - Calculate the total volume of Ora-Sweet&reg; by taking the rounded mg of rimantadine and dividing by 10 mg/mL (eg, 800 mg divided by 10 mg/mL = 80 mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     - Grind required number of tablets in mortar and triturate to a fine powder. Slowly add",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the total volume of Ora-Sweet&reg; to the mortar and triturate until a uniform suspension is achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     - Transfer to an amber glass or PET plastic bottle. Slowly add another",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the total volume of Ora-Sweet&reg; to the mortar, rinsing the mortar, then transferring the contents into the bottle. Repeat using the final 1/3 of Ora-Sweet&reg;. Add additional vehicle to bottle, if needed, to achieve the total calculated volume.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     - Shake well to ensure homogeneous suspension. Some inert ingredients in the tablet may be insoluble.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     - Label: Shake gently prior to each use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     - Suspension is stable for 14 days when stored at room temperature (25&deg;C/77&deg;F).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/39/34420/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, \"Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(1):1-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/39/34420/abstract-text/21248682/pubmed\" id=\"21248682\" target=\"_blank\">",
"        21248682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harper SA, Bradley JS, Englund JA, et al, \"Seasonal Influenza in Adults and Children - Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(8):1003-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/39/34420/abstract-text/19281331/pubmed\" id=\"19281331\" target=\"_blank\">",
"        19281331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Influenza,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12769 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34420=[""].join("\n");
var outline_f33_39_34420=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216937\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216938\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055276\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055271\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216915\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216901\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055279\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164316\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055278\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216965\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216962\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055282\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055270\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2854705\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300002\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216910\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055284\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216911\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055269\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055281\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055275\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055283\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10297270\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=related_link\">",
"      Rimantadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/11/25780?source=related_link\">",
"      Rimantadine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34421="Stage II repair for HLHS";
var content_f33_39_34421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stage II repair for HLHS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 571px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Connection of the superior vena cava to the pulmonary arteries and takedown of previous systemic-to-pulmonary artery shunts constitutes the stage II procedure. The bidirectional Glenn shunt is a direct anastomosis of the superior vena cava to the central pulmonary artery. The principle advantage of the bidrectional Glenn shunt is the ease of construction; it can even be accomplished without the use of cardiopulmonary bypass in selected cases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7th, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34421=[""].join("\n");
var outline_f33_39_34421=null;
var title_f33_39_34422="Clamping cardinal ligament";
var content_f33_39_34422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Clamp placement across cardinal ligament during hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34422=[""].join("\n");
var outline_f33_39_34422=null;
var title_f33_39_34423="Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder";
var content_f33_39_34423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34423/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34423/contributors\">",
"     Stuart Berger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34423/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34423/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34423/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34423/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/39/34423/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of sudden unexpected deaths (SUD) among patients taking stimulant drugs for attention deficit hyperactivity disorder (ADHD) have led to concerns regarding the safety of psychotropic medications. In particular, the question of whether or not stimulant drugs increase the risk of adverse cardiovascular (CV) events has led to a debate on the appropriate evaluation to identify patients with undiagnosed at-risk congenital heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmias prior to starting a patient on medications for the treatment of ADHD.",
"   </p>",
"   <p>",
"    The risk of sudden cardiac death in patients receiving stimulant medications for ADHD and the cardiac evaluation of these patients will be reviewed here. The pharmacotherapy for ADHD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK OF SUDDEN UNEXPECTED DEATHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) is a common childhood disorder affecting up to 8 to 10 percent of all school-aged children. Stimulant drugs including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    (Ritalin&reg;, Methylin&trade;, Concerta&trade;, Focalin&trade;, Metadate&reg;),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    (Dexedrine&reg;), and mixed amphetamine salts (eg, Adderall) are effective in improving behavior in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link&amp;anchor=H3#H3\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898700#H2007898700\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Stimulants versus other medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports of unexpected deaths of children receiving stimulant therapy have led to concerns that these medications increase the risk of cardiovascular (CV) adverse events including sudden unexpected deaths (SUD) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, large cohort studies have not shown an increased risk of serious CV adverse events in children treated with stimulant therapy compared to the general pediatric population, as discussed in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Children without cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on currently available evidence, it appears that children without cardiac disease who receive stimulant therapy are",
"    <strong>",
"     not",
"    </strong>",
"    at increased risk for CV events compared with the general pediatric population. As a result, we follow the recommendations of the American Heart Association (AHA) and the American Academy of Pediatrics (AAP) that stimulant pharmacotherapy can be initiated in a child with ADHD if there is no evidence of cardiac disease based upon a comprehensive CV-focused history and physical examination. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Recommended approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This recommendation is based on several large cohort studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest cohort study based on data from four large health plans that was sponsored by the United States Food and Drug Administration (FDA) and the Agency for Healthcare Research, there was no difference in the risk for serious CV events (sudden cardiac death, acute myocardial infarction, or stroke) between children and young adults (age range, 2 to 24 years) receiving stimulant ADHD pharmacotherapy and nonusers (adjusted hazard ratio [HR] 0.75, 95% CI 0.31-1.85) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/4\">",
"       4",
"      </a>",
"      ]. The incidence of serious CV events in this cohort was 3.1 per 100,000 person years.",
"     </li>",
"     <li>",
"      In another cohort study from the United States that used two large pre-existing administrative databases, there was no difference in the rate of SUD in all children between 3 and 17 years of age who received stimulant therapy (users) from control patients matched by database source, gender, age, and state (HR 1.6, 95% CI 0.19-13.60) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, there was no difference in all-cause mortality between the two groups (HR 0.76, 95% CI 0.52-1.12). Although 241,417 users were identified, the HR could not be determined for predetermined events of interest because of the low or absent CV events. In the user group, there were no reported strokes or myocardial infarction, and the crude incidence rate for SUD was 0.06 per 10,000 years for SUD.",
"     </li>",
"     <li>",
"      In another population-based cohort study of over 1 million children from the United States, healthcare claims data for 28 state Medicaid programs from 1999 to 2006 showed that treatment with stimulant therapy did not increase the short-term risk of severe cardiac events in children between 3 and 18 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/6\">",
"       6",
"      </a>",
"      ]. In this study, there were 66 cases of sudden cardiac death, stroke, or acute myocardial infarction resulting in event rates of 2.8 per 100,000 patient years overall, and 3.5, 1.7, and 1.5 per 100,000 patient years for children who were nonusers, current users, and former users of stimulant therapy, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a retrospective study that used national mortality data reported an association between stimulant medication and SUD [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/7\">",
"     7",
"    </a>",
"    ]. In this study, which compared the rate of stimulant used in children who died as passengers in a motor vehicle accident to those who died suddenly, the rate of stimulant medication use was higher in the SUD group compared with those in the motor vehicle accident group (1.8 versus 0.4 percent). However, the FDA concluded that this study was not able to verify a relationship between the use of stimulant therapy and SUD because of methodologic limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/8\">",
"     8",
"    </a>",
"    ]. These limitations included potential bias as the recall of stimulant use was up to 20 years after a child's death, the possibility that medical evaluation was more thorough in children with SUD than those who died as a result of a motor vehicle accident, the low frequency of stimulant use in both groups (as the national estimated rate is 4.3 percent), and a 40 percent parental refusal rate of participation. Because of these concerns, the FDA has stated that the results of this study should not serve as a basis to discontinue stimulant therapy in children with ADHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHD is found in a significant number of children with congenital heart disease (CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Although data are limited, there is no evidence that the risk of SUD is higher in patients with CHD when they are treated with stimulant medications. In one small trial of 12 children with velocardiofacial syndrome (eight with CHD), patients had no evidence of hypertension, tachycardia, or electrocardiogram (ECG) changes when they received",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    for their ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, there are no data to suggest that specific forms of CHD carry an increased risk of SUD in association with ADHD drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86661007\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among adult patients who are either current or new users of stimulant medications, there appears to be no increased risk of serious CV events.",
"   </p>",
"   <p>",
"    This was illustrated in a large retrospective cohort study of adults (age range 25 to 64 years) based on data from four large health plans that was done in parallel with the study performed in children discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. Multivariant analysis demonstrated a lower risk of serious CV events (defined as myocardial infarction, stroke, and sudden cardiac death) in individuals who were current users of stimulant therapy versus nonusers (relative risk [RR] 0.83, 95% CI 0.72-096). In new users of ADHD medications compared with controls, the risk of serious CV events was even lower (RR 0.77, 95% CI 0.63-0.94). However, there may be a modest amount of healthy-user bias that favored the current users of stimulant therapy. To adjust for this potential bias, a multivariant analysis that compared current users with individuals who had used stimulant therapy more than one year ago (defined as remote use) found no difference in the risk of serious CV events (RR 1.03, 95% CI 0.86-1.24). The crude incidence of serious CV events in the overall cohort was 1.34 per 1000 person-years.",
"   </p>",
"   <p>",
"    These results showing no increased risk of serious CV events are consistent with previously discussed studies in pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/4,5,14\">",
"     4,5,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86661132\">",
"    <span class=\"h2\">",
"     FDA position",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an updated safety review, the United States FDA summarized the findings of the largest cohort study in children that did",
"    <strong>",
"     not",
"    </strong>",
"    show an association between ADHD pharmacotherapy and adverse CV events [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. Based on these results, the FDA continues to recommend clinicians prescribe these medications according to the professional prescribing label, and that patients continue to use prescribed therapy for the treatment of ADHD. Patients should be monitored for changes in heart rate and blood pressure. Stimulant therapy generally should not be prescribed in patients with serious heart problems or in whom an increase in blood pressure or heart rate would be problematic. In these individuals, if ADHD therapy is deemed necessary, it should be managed in consultation with a cardiologist. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Known cardiac effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10775178\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     KNOWN CARDIAC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the short and long-term cardiovascular (CV) effects of stimulant medications found the following modest CV changes in patients treated with a dosing regimen that is effective in improving behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulse increases of 3 to 10 beats per min (bpm)",
"     </li>",
"     <li>",
"      Systolic blood pressure (SBP) increases of 3 to 8 mmHg",
"     </li>",
"     <li>",
"      Diastolic blood pressure (DBP) increases of 2 to 14 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes were illustrated in a prospective study of 114 adolescents (mean age 14.1 years) who were treated with extended-release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/21\">",
"     21",
"    </a>",
"    ]. CV parameters were assessed at six weeks (when the mean dose of methylphenidate was 63 mg), three months, and at six months for 57 patients with a mean daily dose of 67 mg. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At six weeks compared to baseline, there was a small increase in mean heart rate (82 versus 86 bpm). This change persisted throughout six months of follow-up without any further change in heart rate.",
"     </li>",
"     <li>",
"      Mean SBP increased slowly throughout the entire six months (113, 115, 115, and 117 mmHg at baseline, six weeks, three months, and six months, respectively).",
"     </li>",
"     <li>",
"      There were no clinically significant changes in the DBP and electrocardiogram (ECG), and no serious CV event occurred.",
"     </li>",
"     <li>",
"      Although 10 patients had subjective CV complaints, six of these had a comorbid anxiety disorder, which was thought to be a main contributor to these symptoms. Symptoms of another patient were related to the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      during an asthma attack. All other complaints were one-time isolated reports that were judged to be mild or moderate in severity. No complaint was associated with a change in vital signs or ECG abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving stimulant therapy visited the emergency department or physician office more frequently than those who were not treated with medications because of cardiac symptoms (10.9 versus 9.1 events per 1000 patient-years, adjusted hazards ratio 1.2, 95% CI 1.04-1.38) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/22\">",
"     22",
"    </a>",
"    ]. The cardiac symptoms included syncope, tachycardia, or palpitations. However, the group that received stimulant therapy was more likely to receive other psychotropic medications (antidepressants and antipsychotic agents), be male, and non-Hispanic. The incidence of fatal and serious cardiac abnormalities was low and not different between the two groups, and was similar to the rates seen in the general pediatric population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CARDIAC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the United States Food and Drug Administration&rsquo;s (FDA) recommendation to apply warning labels regarding the association of sudden death with central nervous system (CNS) stimulant treatment, there is no evidence currently available that shows sudden cardiac death is more common in patients with attention deficit hyperactivity disorder (ADHD) or those with ADHD receiving stimulant medications compared to the general population.",
"   </p>",
"   <p>",
"    The critical clinical question remains as to whether there are any cardiac conditions including any associations with sudden cardiac death, in which there is a clear-cut contraindication to the use of a stimulant medication. There is no evidence-based information that allows us to definitively answer this question, but currently available evidence suggests that there is not a contraindication for stimulant medication in patients with ADHD who have no evidence of cardiac disease based upon a comprehensive cardiovascular (CV)-focused history and physical examination. Furthermore, there is no specific cardiac condition for which there is clear-cut evidence that the use of ADHD medications should be contraindicated. What is clear, however, is limiting or delaying children's access to effective treatment for ADHD could have serious implications (such as increase risk of adolescent substance abuse, academic failure, and accidents) in patients who are not effectively treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H16#H16\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The currently available data supports the initiation of ADHD pharmacotherapy in a patient if the history and examination are not suggestive of cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Further evaluation including cardiac studies is neither necessary nor indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine electrocardiogram (ECG) screening in all patients treated with ADHD stimulant therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended, as the incidence of sudden cardiac death appears to be either lower, albeit possibly underreported, or similar to that in the general pediatric population, and it may delay treatment for ADHD. Based upon currently available evidence, there are no specific cardiac diagnoses that are considered to be absolute contraindications to medical ADHD therapy. In addition, there are no data of any ECG findings associated with an increased likelihood of a serious cardiac adverse event due to ADHD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These points were illustrated in a retrospective study of 1470 children with ADHD receiving pharmacotherapy that were screened with an ECG from April to September of 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/25\">",
"     25",
"    </a>",
"    ]. In this cohort, ECG studies were interpreted as abnormal in 119 patients (8.1 percent). Further workup including transthoracic echocardiogram, stress, test and Holter monitor identified cardiac disease in five subjects (0.3 percent of the entire cohort). The diagnoses included ventricular pre-excitation syndrome (n = 2), bicuspid aortic valve (n = 2), and a moderate size secundum atrial septal defect (n = 1). The estimated cost to identify each case of cardiac disease was $17,162. In three of these cases, there is no contraindication of ADHD therapy, and in the other two (asymptomatic ventricular pre-excitation syndrome) it is unclear whether ADHD therapy would be withheld. These results suggest that ECG is not a cost-effective screen to detect cardiac disease in children with ADHD.",
"   </p>",
"   <p>",
"    A modeled economic evaluation studied various strategies of identifying children receiving ADHD at risk for sudden cardiac death (SCD) and concluded that there may be a borderline cost-effectiveness of screening with an ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/27\">",
"     27",
"    </a>",
"    ]. An accompanying editorial as well as the authors, however, point out that some of the assumptions used to develop the model are not well established or may vary greatly [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recommended approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In May 2008, the American Academy of Pediatrics (AAP) and the American Heart Association (AHA) released a joint advisory statement regarding the evaluation of children who need to receive treatment with drugs for ADHD based upon the currently available evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/24\">",
"     24",
"    </a>",
"    ]. We agree with the recommended approach of a careful assessment to detect cardiac disease based upon a CV-focused patient and family history and a physical examination.",
"   </p>",
"   <p>",
"    If the history and examination are not suggestive of cardiac disease, pharmacotherapy can be initiated or continued without additional evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/23\">",
"     23",
"    </a>",
"    ]. An electrocardiogram is",
"    <strong>",
"     not",
"    </strong>",
"    required before initiating stimulant therapy for patients with ADHD. However, if the child is known to have cardiac disease or the history or physical examination is suggestive of cardiac disease, further evaluation including ECG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consultation with a pediatric cardiologist is needed. In addition, an ECG may be obtained based upon the clinical judgment of the care provider.",
"   </p>",
"   <p>",
"    Other professional organizations that endorse this approach include the American Academy of Child and Adolescent Psychiatry (AACAP), the American College of Cardiology (ACC), Children and Adults with",
"    <span class=\"nowrap\">",
"     Attention-Deficit/Hyperactivity",
"    </span>",
"    Disorder (CHADD), the National Initiative for Children's Healthcare Quality (NICHQ), and the Society for Developmental and Behavioral Pediatrics (SDBP).",
"   </p>",
"   <p>",
"    We suggest that clinicians who prescribe medications for ADHD discuss the benefits and potential adverse effects of treatment with parents and patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This discussion should include the current evidence that does not support a causal association between serious CV risks and stimulant medications. This includes patients without CV abnormalities and those with either undiagnosed or known CV abnormalities. Each and every patient should undergo a comprehensive, CV-focused patient history, family history, and physical examination as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history is focused upon detecting any sign of cardiac disease in the patient or family, including sudden cardiac death in family members. Important aspects of the history include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient history of cardiac disease, rheumatic fever, fainting or dizziness, especially with exercise, seizures, chest pain or shortness of breath with exercise, unexplained change in exercise tolerance, palpitations, high blood pressure, and heart murmur.",
"     </li>",
"     <li>",
"      Prescribed and over-the-counter medications and nonprescribed health supplements, particularly those with CV effects.",
"     </li>",
"     <li>",
"      Family history of sudden or unexplained death or an event requiring resuscitation in children or young adults, cardiac arrhythmias (eg, Wolff-Parkinson-White syndrome), long QT syndrome, catecholaminergic paroxysmal ventricular tachycardia, Brugada syndrome, arrhythmogenic right ventricular dysplasia, hypertrophic cardiomyopathy, dilated cardiomyopathy, and Marfan syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link\">",
"       \"Causes of wide QRS complex tachycardia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"       \"Genetics of dilated cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"       \"Genetics of hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the physical examination include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34423/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of blood pressure and heart rate.",
"     </li>",
"     <li>",
"      Cardiac auscultation to detect the presence of a heart murmur, or irregular or rapid heart rhythm.",
"     </li>",
"     <li>",
"      Physical findings associated with Marfan syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10775178\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;During treatment with ADHD stimulant therapy, the patient should be assessed for any changes in CV symptoms (eg, fainting or dizziness, seizures, chest pain or shortness of breath with exercise, unexplained change in exercise tolerance, or palpitations). Evaluation should include measurement of heart rate and blood pressure to ascertain whether there have been any significant changes in these signs, especially if the blood pressure reaches either prehypertension or hypertension levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with concerning symptoms or findings, consultation with a pediatric cardiologist should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention deficit hyperactivity disorder (ADHD) is a common childhood disorder affecting up to 8 to 10 percent of all school-aged children. Stimulant drugs are effective in improving behavior in these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link&amp;anchor=H3#H3\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898700#H2007898700\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Stimulants versus other medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although there had been concerns of serious adverse cardiac effects, stimulant therapy does not appear to increase the risk of sudden unexpected cardiac death or other serious cardiac complications (eg, myocardial infarction or stroke) in patients without underlying cardiac disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk of sudden unexpected deaths'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stimulant medications are known to have modest cardiovascular (CV) effects including small elevations in heart rate (3 to 10",
"      <span class=\"nowrap\">",
"       beats/min),",
"      </span>",
"      systolic blood pressure (3 to 8 mmHg), and diastolic blood pressure (2 to 14 mmHg). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Known cardiac effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon the currently available evidence, we agree with the approach outlined by the American Academy of Pediatrics (AAP) and the American Heart Association (AHA) for a careful assessment of patients who need to be treated with drugs for ADHD to detect cardiac disease based upon a comprehensive history and a physical examination. If the history and examination are not suggestive of cardiac disease, pharmacotherapy can be initiated or continued without additional evaluation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiac evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An electrocardiogram (ECG) is",
"      <strong>",
"       not",
"      </strong>",
"      required before initiating stimulant therapy for patients with ADHD. However, if the patient is known to have cardiac disease, or if the history or physical examination is suggestive of cardiac disease, further evaluation including ECG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      consultation with a pediatric or adult cardiologist is needed. In addition, an ECG may be obtained based upon the clinical judgment of the care provider. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiac evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential risks of stimulants should be discussed with the family when deciding upon the management strategy for any patient with ADHD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898700#H2007898700\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Stimulants versus other medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who are prescribed ADHD stimulant therapy should be routinely evaluated for any changes in heart rate or blood pressure, as well as cardiovascular symptoms during treatment. (See",
"      <a class=\"local\" href=\"#H10775178\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/1\">",
"      Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/2\">",
"      Gorman RL. FDA Panel recommends black box warning on ADHD stimulant medications. AAP News 2006; 27:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/3\">",
"      Berger S, Kugler JD, Thomas JA, Friedberg DZ. Sudden cardiac death in children and adolescents: introduction and overview. Pediatr Clin North Am 2004; 51:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/4\">",
"      Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/5\">",
"      Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/6\">",
"      Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012; 345:e4627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/7\">",
"      Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166:992.",
"     </a>",
"    </li>",
"    <li>",
"     Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165858.htm (Accessed on November 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/9\">",
"      Mahle WT, Clancy RR, Moss EM, et al. Neurodevelopmental outcome and lifestyle assessment in school-aged and adolescent children with hypoplastic left heart syndrome. Pediatrics 2000; 105:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/10\">",
"      Bass JL, Corwin M, Gozal D, et al. The effect of chronic or intermittent hypoxia on cognition in childhood: a review of the evidence. Pediatrics 2004; 114:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/11\">",
"      Shprintzen RJ. Velocardiofacial syndrome. Otolaryngol Clin North Am 2000; 33:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/12\">",
"      Gothelf D, Gruber R, Presburger G, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 2003; 64:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/13\">",
"      Wilens TE, Biederman J, Lerner M, Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 2004; 24:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/14\">",
"      Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306:2673.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults file://www.fda.gov/Drugs/DrugSafety/ucm277770.htm (Accessed on November 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/16\">",
"      Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005; 147:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/17\">",
"      Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002; 22:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/18\">",
"      Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001; 40:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/19\">",
"      Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006; 21:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/20\">",
"      Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011; 50:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/21\">",
"      Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 2009; 155:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/22\">",
"      Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007; 120:e1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/23\">",
"      Perrin JM, Friedman RA, Knilans TK, et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008; 122:451.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD. Available at: americanheart.mediaroom.com/index.php?s=43&amp;item=422 (Accessed on June 09, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/25\">",
"      Mahle WT, Hebson C, Strieper MJ. Electrocardiographic screening in children with attention-deficit hyperactivity disorder. Am J Cardiol 2009; 104:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/26\">",
"      Thomas PE, Carlo WF, Decker JA, et al. Impact of the American Heart Association scientific statement on screening electrocardiograms and stimulant medications. Arch Pediatr Adolesc Med 2011; 165:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/27\">",
"      Denchev P, Kaltman JR, Schoenbaum M, Vitiello B. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 2010; 121:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/28\">",
"      Triedman JK, Alexander ME. Needle in a haystack: modeling the incidence of sudden cardiac arrest in healthy children. Circulation 2010; 121:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/29\">",
"      Stein MT. FDA preliminary report: safety of stimulant medications. Journal Watch Pediatr Adolesc Med 2006; 5:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/30\">",
"      Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do? Pediatrics 2006; 118:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34423/abstract/31\">",
"      Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117:2407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5763 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34423=[""].join("\n");
var outline_f33_39_34423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK OF SUDDEN UNEXPECTED DEATHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Children without cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86661007\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86661132\">",
"      FDA position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      KNOWN CARDIAC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CARDIAC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recommended approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10775178\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=related_link\">",
"      Causes of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34424="Pathophysiology; clinical clues and recovery of organisms in anaerobic infections";
var content_f33_39_34424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology; clinical clues and recovery of organisms in anaerobic infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34424/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34424/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34424/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34424/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34424/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/39/34424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic bacteria are the major constituents of normal human flora and have been recovered from a wide array of different infections. Isolating the organisms from specimens required discovery of specialized methods in the microbiology laboratory, but it has been more problematic to determine when these bacteria represent true pathogens or merely commensals.",
"   </p>",
"   <p>",
"    The pathophysiology of anaerobic infections, clinical clues to suspect anaerobes, and methods for recovering the organisms will be reviewed here. Clinical syndromes, history, and the composition of the normal flora are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=see_link\">",
"     \"Anaerobic bacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41511?source=see_link\">",
"     \"Anaerobic bacteria: History and role in normal human flora\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF ANAEROBIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic infections nearly always arise from leakage of endogenous bacteria into contiguous or other sites. Important exceptions are some of the clostridial syndromes, including botulism, Clostridium perfringens food poisoning, enteritis necroticans, tetanus, some cases of gas gangrene, and Clostridium difficile-associated diarrhea. (See related topics).",
"   </p>",
"   <p>",
"    The usual pathophysiologic mechanism for anaerobic infection is a breach in the mucocutaneous barrier resulting in displacement of the normal flora. Host defense mechanisms are presumably important, but the compromised host is not unusually susceptible. Exceptions are infections associated with defects of mucocutaneous barriers, such as carcinoma with obstruction, mucositis, perirectal lesions, or compromised consciousness with aspiration.",
"   </p>",
"   <p>",
"    Three major issues arise in the pathogenesis of anaerobic infections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Virulence factors of the organisms",
"     </li>",
"     <li>",
"      Mechanisms of abscess formation",
"     </li>",
"     <li>",
"      Bacterial synergy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of the pathogenic mechanisms of anaerobes also apply to aerobic infections, especially virulence factors. However, others figure far more prominently in infections involving anaerobes. As an example, abscesses represent an intriguing combination of pathology and host defense. Animal models of intraabdominal sepsis have contributed substantial insights into the pathogenesis of abscesses. Synergy among bacterial species is also a common feature of anaerobic infections. These three important components of the pathogenesis of anaerobic infections are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic bacteria contain a number of components that have been defined as virulence factors in facultative bacteria, including toxins, polysaccharide capsules, and lipopolysaccharides. Most of these also have been shown to be virulence factors in anaerobic species. The capacity to survive and grow under anaerobic conditions has also led to the identification of other properties of anaerobes that may play a role in virulence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most clearly identified virulence factors for anaerobic bacteria are the exotoxins produced by clostridial species, including botulinum toxins, tetanus toxin, C. difficile toxin A and B [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and five toxins produced by C. perfringens (as well as many other clostridial species); these are among the most virulent bacterial toxins in mouse lethality assays. Alpha toxin is the major toxin produced by C. perfringens, but studies have shown a complex interaction between alpha and theta toxin in the production of experimental gas gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Both toxins appear to be involved in upregulation of intercellular adhesion molecule (ICAM)-1 and platelet aggregating factor (PAF), which contributes to vascular leukostasis and the absence of a polymorphonuclear leukocyte (PMN) response to the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical expression of histotoxic clostridial syndromes depends upon the site of toxin production and the physiologic effects of the toxin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"     \"Botulism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An enterotoxin has also been identified in Bacteroides fragilis, which is a metalloprotease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/6\">",
"     6",
"    </a>",
"    ]. Strains producing the toxin have been recovered from patients with diarrhea and from healthy controls but seem to be more common in those with diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. There is evidence from mouse models that enterotoxin producing strains of B. fragilis may play a role in colon carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Capsular polysaccharides",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the same way that Clostridium spp serve as the prototypes for toxins produced by anaerobes, B. fragilis has been studied as a uniquely virulent anaerobe. The organism constitutes only 0.5 percent of cultivable normal colonic flora and yet is the most common anaerobe isolated from intraabdominal infections and is the most frequent anaerobic bacteremic isolate [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon a rat model of intraabdominal sepsis, it became apparent that B. fragilis alone among the anaerobes studied was capable of provoking abscesses without a synergistic facultative organism and that heat-killed B. fragilis retained this capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/14\">",
"     14",
"    </a>",
"    ]. Following extraction and purification of the polysaccharide capsule of a prototype strain, this sugar was also able to provoke abscesses in the model system. Further study of the capsular polysaccharide has led to an appreciation that it is actually a complex of polysaccharides with zwitterionic properties (containing alternating oppositely charged sugars) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Adherence of the capsular polysaccharide complex to mesothelial cells in vitro stimulates intracellular adhesion molecule (ICAM)-1 and tumor necrosis factor (TNF)-alpha; pretreatment of mice with antibodies to ICAM-1 or TNF-alpha resulted in failure of the animals to develop intraperitoneal abscesses in a mouse model of intraabdominal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/17\">",
"     17",
"    </a>",
"    ]. Polysaccharide A of Bacteroides spp has also been shown to be important for abscess formation via activation of toll-like receptor (TLR) 2, since abscess formation is impaired in TLR 2-deficient mice [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lipopolysaccharides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic gram-negative bacteria, like all gram-negative bacteria, contain lipopolysaccharide (LPS) that can be extracted from the envelope, but the biologic activity of this endotoxin (mouse lethality assays, the chick embryo death test, and the Shwartzman reaction) is 100 to 1000 times less than that of LPS from Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/19\">",
"     19",
"    </a>",
"    ]. The LPS of B. fragilis contains a lipid A moiety (the endotoxin portion of LPS), but there are structural and chemical composition differences that render this LPS less potent than the LPS of E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/19\">",
"     19",
"    </a>",
"    ]. The inability of B. fragilis LPS to activate toll-like receptor 2 may be responsible for this difference [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other anaerobic gram-negative bacteria, such as Fusobacteria, are thought to contain endotoxin with substantial biologic activity, including activation of toll-like receptor 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/21\">",
"     21",
"    </a>",
"    ]. One study of extracted LPS from a strain of Fusobacterium nucleatum found biologic activity equal to the LPS of Enterobacteriaceae and correlated this with inhibition of gingival fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, LPS of Fusobacteria may play a pathogenic role in periodontal disease and presumably accounts for the severity of illness associated with Lemierre disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=see_link\">",
"     \"Anaerobic bacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link&amp;anchor=H990947896#H990947896\">",
"     \"Deep neck space infections\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Volatile fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another virulence factor of anaerobes is the production of short chain volatile fatty acids. Production of these fatty acids is a characteristic feature of the metabolic system of anaerobes that is used to identify these microbes in the microbiology laboratory and may be responsible for the characteristic putrid drainage. These volatile fatty acids have been shown to inhibit phagocytic killing of bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ability to tolerate oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of anaerobic bacteria, including B. fragilis and Clostridia, can tolerate exposure to oxygen but do not replicate in atmospheric oxygen. These organisms contain varying concentrations of superoxide dismutase, an enzyme present in aerobic bacteria, which protects against the toxic effects of oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The ability to survive exposure to oxygen is a different type of factor that facilitates the survival and thus pathogenicity of the organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Formation of and host defense to abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, an abscess is a unique biologic phenomenon, representing the combination of a pathologic process and a host defense to contain infection. Within the fibrous capsule of a well-formed abscess, bacteria and neutrophils coexist; these same neutrophils in vitro will kill the bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intraabdominal sepsis model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rat and mice models of intraabdominal sepsis have been used extensively to study the role of anaerobes and mechanisms of formation and host defense to abscesses. These models closely simulate human infection. As an example, when rats are challenged with an intraperitoneal implant of fecal contents with an adjuvant, a two-stage infection results [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The initial phase of the infection is characterized by generalized peritonitis, followed by a second phase with abscess formation. Initial work showed a 43 percent mortality rate, all deaths occurring during the first four days after challenge. Abscesses were initially detected five days after challenge, and all animals sacrificed seven days or more after challenge had abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that this field of research has become far more complicated by the recognition that the colon contents include a microbiota (&ldquo;microbiome&rdquo;) composed predominantly of bacteria that cannot be cultivated and do not appear to play an important role in infections involving the fecal flora, but may play a fundamental role in other biologic processes such as obesity and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Role of anaerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the rat model were initially designed to distinguish the role of various bacteria in abscess formation through quantitative cultures, antimicrobial probes (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    for its selective activity against coliforms and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    for its selective activity against anaerobes), and monomicrobial challenge with the organisms recovered from infected sites. This work supported the role of E. coli as the major pathogen in the initial phase of infection characterized by generalized peritonitis, bacteremia, and death. B. fragilis appeared critical for the second phase of the infection characterized by abscess formation. Further testimony to the \"abscessogenic potential\" of B. fragilis was the demonstration of typical abscesses after challenge with the capsular polysaccharide of B. fragilis alone without facultative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The conclusion is that both coliforms and anaerobic bacteria represent pathogens in this model of intraabdominal sepsis, although they appear to be responsible for different biologic events as the infection evolves through its two stages. The practical application of these data is that antimicrobial therapy should be directed against both coliforms and anaerobes, a thesis that is well supported by the two published clinical trials that test outcome when anaerobes are treated or not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Role of T cells in abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The animal models of intraabdominal sepsis were also used to identify cells responsible for abscess formation. Early work with nude or cyclophosphamide-depleted mice suggested that T cells played a critical role in abscess formation due to B. fragilis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/36\">",
"     36",
"    </a>",
"    ]. Further studies demonstrated that the zwitterionic capsular polysaccharide of the organism described above activated CD4 T cells in vitro, and abscess formation in vivo was inhibited by CTLA4Ig, which blocks the CD28-B7 pathway activation of T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Another study has shown that interleukin-17, a proinflammatory cytokine produced by CD4 T cells, is necessary for abscess formation following challenge with B. fragilis or abscess-inducing zwitterionic polysaccharides [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation of T cells, in turn, appears to play a role in the prevention of abscess formation. Adoptive transfer of splenic T cells from mice immunized with B. fragilis capsular polysaccharide protects the recipient mice from abscesses caused by B. fragilis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/41\">",
"     41",
"    </a>",
"    ]. The unusual charge of the B. fragilis capsular polysaccharide directly affects T cell activation, which also needs major histocompatibility complex II on antigen-presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, B. fragilis -- specifically the capsular polysaccharide of the organism -- is involved in both the induction of abscesses and protection against abscess formation, with T cell activation being an important component of both arms of the pathway. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Capsular polysaccharides'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bacterial synergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymicrobial nature of the majority of anaerobic infections was appreciated by French investigators in the early 1900s. One of the most common observations is that they are polymicrobial, often with aerobic bacteria. This may represent synergy, but the mechanism of synergy is usually unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41511?source=see_link\">",
"     \"Anaerobic bacteria: History and role in normal human flora\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLUES TO ANAEROBIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical clues to the probable presence of anaerobic bacteria at infected sites are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef58669 \" href=\"UTD.htm?2/37/2651\">",
"     table 1",
"    </a>",
"    ). Infections that occur in continuity with mucosal surfaces where anaerobic bacteria compose the normal flora often involve these microbes. Thus, the assumption is that most cases of orodental infection, aspiration pneumonia, and intraabdominal infection involve anaerobes. These assumptions are usually correct.",
"   </p>",
"   <p>",
"    Anaerobes are often associated with tissue necrosis and abscess formation, as supported by their frequency in abscesses at virtually all anatomic sites, including cerebral, dental, peritonsillar, lung, intraabdominal, tuboovarian, prostatic, and cutaneous abscesses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=see_link\">",
"     \"Anaerobic bacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The putrid odor of infections or discharges, although diagnostic of infection containing anaerobes, may be a relatively late feature and is seen in only approximately one-third to one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The chemical basis for the odor is not well established, but it presumably reflects the metabolic products of anaerobic bacteria, including volatile fatty acids (eg, succinic and butyric acid and methylmercaptan). As noted, these short chain fatty acids are used to identify anaerobic bacteria; direct detection of these acids in exudate by gas-liquid chromatography may be used as an early clue to the presence of anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gas in the tissue is another clue to the presence of anaerobic bacteria, but it is not considered diagnostic because occasional aerobic bacteria produce gas [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/45\">",
"     45",
"    </a>",
"    ]. Gas may be detected by palpation, radiography, or scanning techniques. This may reflect not only gas production by microbes but also air introduced during irrigations or other manipulations, such as the release of carbon dioxide with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anaerobic infections often involve a polymicrobial flora, so a Gram stain of exudate usually shows multiple different morphotypes at infected sites. The Gram stain may also show the unique morphologic features of many anaerobes, especially Bacteroides spp, Fusobacterium spp, and clostridia. By contrast, Peptostreptococcus cannot be distinguished from aerobic gram-positive cocci on the basis of Gram stain appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     METHODS FOR RECOVERING ANAEROBES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paucity of anaerobes in clinical laboratories reflect several interrelated factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specimens for meaningful culture must be devoid of contamination by the normal flora.",
"     </li>",
"     <li>",
"      The organisms require anaerobic conditions for growth.",
"     </li>",
"     <li>",
"      Most anaerobic bacterial infections involve multiple different bacteria that grow slowly and require extensive testing for identification.",
"     </li>",
"     <li>",
"      Prior antibiotic therapy substantially reduces cultivability for these bacteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Culturing specimens for anaerobes is not always performed because anaerobic cultures are tedious and identification is expensive and slow. Many clinicians also feel that it is fairly easy to predict the presence of anaerobes and appropriate treatment is usually empiric based upon the site of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Specimen selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimens appropriate for anaerobic culture must be devoid of the normal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/47\">",
"     47",
"    </a>",
"    ]. Optimal specimens are normally sterile body fluids and aspirates or biopsy material from normally sterile sites (",
"    <a class=\"graphic graphic_table graphicRef57141 \" href=\"UTD.htm?15/58/16301\">",
"     table 2",
"    </a>",
"    ). On occasion, the problem of contamination may be obviated by quantitative cultures, although most laboratories do not provide this service. As a general rule, liquid or tissue specimens are preferred; swab specimens should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Specimen transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal way to transport specimens is by immediate delivery to permit prompt microbiologic processing or with anaerobic transport tubes. When specimens need to be held for 24 hours, they should be stored at 4&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. A variety of specialized transport devices are available that provide an atmosphere of oxygen-free gas, such as mixtures of carbon dioxide, hydrogen, and nitrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Most of these devices also include an indicator, such as resazurin, to document anaerobic conditions, and a reducing agent, such as cysteine, to eliminate small amounts of oxygen that are inadvertently introduced.",
"   </p>",
"   <p>",
"    Tissue specimens may be placed in a sterile tube flushed with carbon dioxide; if the tube is held upright with the stopper removed, the heavier carbon dioxide will exclude oxygen until the stopper is replaced [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/47\">",
"     47",
"    </a>",
"    ]. Although they are theoretically attractive, there is little evidence that such techniques are actually necessary for fluid specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/53\">",
"     53",
"    </a>",
"    ]. Swabs are different due to drying rather than oxygen sensitivity. When swab specimens are necessary, the best transport medium is a specially prepared, prereduced, and anaerobically sterilized semisolid medium such as Cary-Blair medium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram stain of exudate is an important clue to the presence of anaerobic bacteria due to their often unique morphology. The gram stain is also an important method of quality assurance of microbiology culture technique. Two systems are generally advocated for recovering anaerobes in culture:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The anaerobic jar (GasPak, evacuation-replacement and Bio-Bags)",
"     </li>",
"     <li>",
"      The anaerobic glovebox",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies indicate comparable results in the yield of anaerobes from clinical specimens with these various systems [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/47\">",
"     47",
"    </a>",
"    ]. Consequently, the decision of which system to use depends upon previous training of personnel, the volume of specimens, and the resources of the laboratory. Many clinical laboratories have found the GasPak jar method particularly convenient, although the jar should remain inviolate for at least 48 hours after the GasPak has been generated. An alternative, more convenient method for one or two plates is Bio-Bags. Anaerobic chambers may be preferred when a large number of specimens are processed.",
"   </p>",
"   <p>",
"    Quality assurance with anaerobic technology indicates that the major discrepancies in most clinical laboratories are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to use the initial Gram stained specimen to ensure that culture results account for all recognized morphotypes",
"     </li>",
"     <li>",
"      Improper use of anaerobic jars, especially by opening before 48 hours",
"     </li>",
"     <li>",
"      Failure to use prereduced plate media",
"     </li>",
"     <li>",
"      Premature discarding of plates",
"     </li>",
"     <li>",
"      Inadequate picking of colonies from primary isolation plates",
"     </li>",
"     <li>",
"      Inadequate selective and nonselective plate media or excessive dependence on broth cultures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinically significant anaerobes are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef61844 \" href=\"UTD.htm?36/15/37115\">",
"     table 3",
"    </a>",
"    ). Most clinical laboratories should be able to identify these organisms. Peptostreptococci, which account for approximately 25 percent of all anaerobic isolates in most microbiology laboratories, rarely merit speciation because these organisms lack distinctive virulence properties and appear to be predictably susceptible to the same antimicrobial agents. The non-spore-forming gram-positive bacilli require chromatographic analysis for genus designation and extensive biochemical testing for speciation. With the exception of Actinomyces, these organisms have minimal documented pathogenic potential, and cursory identification is generally adequate.",
"   </p>",
"   <p>",
"    A rational approach is to separate Propionibacterium, a common contaminant, from the others simply by a catalase test and indole reaction. Clostridia are identified by spores seen on Gram stain examination, by survival with exposure to ethanol for 30 minutes, or by survival following heating to 80&ordm;C for 10 minutes. Extensive biochemical testing is required for speciation, which generally is unnecessary except in selected cases, such as gas gangrene. C. difficile may be cultured from stool, but toxin assays or polymerase chain reaction to detect the B toxin genes are more practical [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/54\">",
"     54",
"    </a>",
"    ] . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The important gram-negative anaerobes for identification include: the B. fragilis group, Prevotella spp, and Fusobacterium spp. The B. fragilis group (B. fragilis, B. thetaiotaomicron, B. distasonis, B. ovatus, and B. vulgatus) is distinguished by the ability to grow in the presence of 20 percent bile, and most are catalase-positive. Formerly classified as B. melaninogenicus, pigmented Prevotella (P. melaninogenica, P. corporis, P. denticola, P. intermedia, P. loescheii, and P. nigrescens) are a clinically important group of anaerobes that are relatively fastidious. The frequency of recovery of these species depends upon the expertise of the laboratory. Fusobacteria are also relatively fastidious. These organisms can be distinguished from Bacteroides spp because they are susceptible to the 1000 mcg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    disk, indole-positive, nonmotile, produce butyric acid, and show distinctive morphologic features on Gram stain (slender, elongated gram-negative rods).",
"   </p>",
"   <p>",
"    Propionibacterium is usually a contaminant in clinical samples but may play an important role in septic arthritis complicating shoulder prostheses or infections following neurosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34424/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H460851979\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods to test the antibiotic susceptibility of anaerobes are well standardized, but not advocated for clinical laboratories. The reasons are that the standard method is difficult, it often takes many days to separate and test the components of these mixed infections, the testing is expensive, and most anaerobes have predictable susceptibility profiles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaerobic bacteria are the major constituents of normal human flora and have been recovered from a wide array of different infections. Isolating the organisms from specimens required discovery of specialized methods in the microbiology laboratory, but it has been more problematic to determine when these bacteria represent true pathogens or merely commensals. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaerobic infections nearly always arise from contamination by endogenous bacteria into contiguous or other sites. Important exceptions are some of the clostridial syndromes, including botulism, Clostridium perfringens food poisoning, enteritis necroticans, tetanus, some cases of gas gangrene, and Clostridium difficile-associated diarrhea. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology of anaerobic infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaerobic bacteria contain a number of virulence factors, including toxins, polysaccharide capsules, and lipopolysaccharides. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Virulence factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An abscess is a unique biologic phenomenon, representing the combination of a pathologic process and a host defense to contain infection. Within the fibrous capsule of a well-formed abscess, bacteria and neutrophils coexist; these same neutrophils in vitro will kill the bacteria. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Formation of and host defense to abscesses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The polymicrobial nature of the majority of anaerobic infections was appreciated by investigators in the early 1900s. One of the most common observations is that they are polymicrobial, often with aerobic bacteria. This may represent synergy, but the mechanism of synergy is usually unclear. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bacterial synergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical clues to the probable presence of anaerobic bacteria at infected sites are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef58669 \" href=\"UTD.htm?2/37/2651\">",
"       table 1",
"      </a>",
"      ). Infections that occur in continuity with mucosal surfaces where anaerobic bacteria compose the normal flora often involve these microbes. Thus, the assumption is that most cases of orodental infection, aspiration pneumonia, and intraabdominal infection involve anaerobes. Anaerobes are often associated with tissue necrosis and abscess formation as supported by their frequency in abscesses at virtually all anatomic sites, including cerebral, dental, peritonsillar, lung, intraabdominal, tuboovarian, prostatic, and cutaneous abscesses. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clues to anaerobic infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The putrid odor of infections or discharges, while diagnostic of infection containing anaerobes, may be a relatively late feature and is seen in only approximately one-third to one-half of patients. Gas in the tissue is another clue to the presence of anaerobic bacteria, but it is not considered diagnostic because occasional aerobic bacteria produce gas. Anaerobic infections usually involve a polymicrobial flora, so a Gram stain of exudate usually shows multiple different morphotypes at infected sites. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clues to anaerobic infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The paucity of anaerobes in clinical laboratories reflect several interrelated factors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Specimens for meaningful culture must be devoid of contamination by the normal flora.",
"     </li>",
"     <li>",
"      The organisms require anaerobic conditions for growth.",
"     </li>",
"     <li>",
"      Most anaerobic bacterial infections involve multiple different bacteria that grow slowly and require extensive testing for identification.",
"     </li>",
"     <li>",
"      Prior antibiotic therapy substantially reduces cultivability for these bacteria. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Methods for recovering anaerobes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Culturing specimens for anaerobes is not always performed because anaerobic cultures are tedious and identification is expensive and slow. Many clinicians also feel that it is fairly easy to predict the presence of anaerobes and appropriate treatment is usually empiric based upon the site of the infection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Methods for recovering anaerobes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal specimens are normally sterile body fluids and aspirates or biopsy material from normally sterile sites (",
"      <a class=\"graphic graphic_table graphicRef57141 \" href=\"UTD.htm?15/58/16301\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Specimen selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal way to transport specimens is by immediate delivery to permit prompt microbiologic processing or with anaerobic transport tubes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Specimen transport'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gram stain of exudate is an important clue to the presence of anaerobic bacteria due to their often unique morphology. The gram stain is also an important method of quality assurance of microbiology culture technique. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Laboratory processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinically significant anaerobes are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef61844 \" href=\"UTD.htm?36/15/37115\">",
"       table 3",
"      </a>",
"      ). Most clinical laboratories should be able to identify these organisms. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Identification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro susceptibility tests are usually not done by clinical laboratories for anaerobes because it is technically difficult, results are usually not available in sufficient time to impact antibiotic decisions, and treatment based on empiric selection is usually effective. (See",
"      <a class=\"local\" href=\"#H460851979\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/1\">",
"      Bobak DA. The molecular pathogenesis of Clostridium difficile-associated disease. Curr Infect Dis Rep 2008; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/2\">",
"      McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/3\">",
"      Bryant AE, Bergstrom R, Zimmerman GA, et al. Clostridium perfringens invasiveness is enhanced by effects of theta toxin upon PMNL structure and function: the roles of leukocytotoxicity and expression of CD11/CD18 adherence glycoprotein. FEMS Immunol Med Microbiol 1993; 7:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/4\">",
"      Awad MM, Bryant AE, Stevens DL, Rood JI. Virulence studies on chromosomal alpha-toxin and theta-toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of alpha-toxin in Clostridium perfringens-mediated gas gangrene. Mol Microbiol 1995; 15:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/5\">",
"      Ellemor DM, Baird RN, Awad MM, et al. Use of genetically manipulated strains of Clostridium perfringens reveals that both alpha-toxin and theta-toxin are required for vascular leukostasis to occur in experimental gas gangrene. Infect Immun 1999; 67:4902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/6\">",
"      Sears CL. The toxins of Bacteroides fragilis. Toxicon 2001; 39:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/7\">",
"      Zhang G, Svenungsson B, K&auml;rnell A, Weintraub A. Prevalence of enterotoxigenic Bacteroides fragilis in adult patients with diarrhea and healthy controls. Clin Infect Dis 1999; 29:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/8\">",
"      Durmaz B, Dalgalar M, Durmaz R. Prevalence of enterotoxigenic Bacteroides fragilis in patients with diarrhea: a controlled study. Anaerobe 2005; 11:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/9\">",
"      Pathela P, Hasan KZ, Roy E, et al. Enterotoxigenic Bacteroides fragilis-associated diarrhea in children 0-2 years of age in rural Bangladesh. J Infect Dis 2005; 191:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/10\">",
"      Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/11\">",
"      Housseau F, Sears CL. Enterotoxigenic Bacteroides fragilis (ETBF)-mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis. Cell Cycle 2010; 9:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/12\">",
"      Dorsher CW, Rosenblatt JE, Wilson WR, Ilstrup DM. Anaerobic bacteremia: decreasing rate over a 15-year period. Rev Infect Dis 1991; 13:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/13\">",
"      Lazarovitch T, Freimann S, Shapira G, Blank H. Decrease in anaerobe-related bacteraemias and increase in Bacteroides species isolation rate from 1998 to 2007: a retrospective study. Anaerobe 2010; 16:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/14\">",
"      Kasper DL, Onderdonk AB, Polk BF, Bartlett JG. Surface antigens as virulence factors in infection with Bacteroides fragilis. Rev Infect Dis 1979; 1:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/15\">",
"      Tzianabos AO, Kasper DL, Onderdonk AB. Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. Clin Infect Dis 1995; 20 Suppl 2:S132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/16\">",
"      Kalka-Moll WM, Wang Y, Comstock LE, et al. Immunochemical and biological characterization of three capsular polysaccharides from a single Bacteroides fragilis strain. Infect Immun 2001; 69:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/17\">",
"      Gibson FC 3rd, Onderdonk AB, Kasper DL, Tzianabos AO. Cellular mechanism of intraabdominal abscess formation by Bacteroides fragilis. J Immunol 1998; 160:5000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/18\">",
"      Wang Q, McLoughlin RM, Cobb BA, et al. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med 2006; 203:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/19\">",
"      Lindberg AA, Weintraub A, Z&auml;hringer U, Rietschel ET. Structure-activity relationships in lipopolysaccharides of Bacteroides fragilis. Rev Infect Dis 1990; 12 Suppl 2:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/20\">",
"      Mancuso G, Midiri A, Biondo C, et al. Bacteroides fragilis-derived lipopolysaccharide produces cell activation and lethal toxicity via toll-like receptor 4. Infect Immun 2005; 73:5620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/21\">",
"      Liu H, Redline RW, Han YW. Fusobacterium nucleatum induces fetal death in mice via stimulation of TLR4-mediated placental inflammatory response. J Immunol 2007; 179:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/22\">",
"      Onoue S, Niwa M, Isshiki Y, Kawahara K. Extraction and characterization of the smooth-type lipopolysaccharide from Fusobacterium nucleatum JCM 8532 and its biological activities. Microbiol Immunol 1996; 40:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/23\">",
"      Lemierre, A. On certain septicaemias. Lancet 1936; 1:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/24\">",
"      Sinave CP, Hardy GJ, Fardy PW. The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection. Medicine (Baltimore) 1989; 68:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/25\">",
"      Rotstein OD, Nasmith PE, Grinstein S. The Bacteroides by-product succinic acid inhibits neutrophil respiratory burst by reducing intracellular pH. Infect Immun 1987; 55:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/26\">",
"      Rotstein OD, Vittorini T, Kao J, et al. A soluble Bacteroides by-product impairs phagocytic killing of Escherichia coli by neutrophils. Infect Immun 1989; 57:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/27\">",
"      Bergan T. Pathogenicity of anaerobic bacteria. Scand J Gastroenterol Suppl 1984; 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/28\">",
"      Imlay JA. How obligatory is anaerobiosis? Mol Microbiol 2008; 68:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/29\">",
"      Onderdonk AB, Cisneros RL, Finberg R, et al. Animal model system for studying virulence of and host response to Bacteroides fragilis. Rev Infect Dis 1990; 12 Suppl 2:S169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/30\">",
"      Bartlett JG, Onderdonk AB, Louie T, et al. A review. Lessons from an animal model of intra-abdominal sepsis. Arch Surg 1978; 113:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/31\">",
"      NIH HMP Working Group, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome Res 2009; 19:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/32\">",
"      Ley RE, Lozupone CA, Hamady M, et al. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol 2008; 6:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/33\">",
"      Tsch&ouml;p MH, Hugenholtz P, Karp CL. Getting to the core of the gut microbiome. Nat Biotechnol 2009; 27:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/34\">",
"      Thadepalli H, Gorbach SL, Broido PW, et al. Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet 1973; 137:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/35\">",
"      diZerega G, Yonekura L, Roy S, et al. A comparison of clindamycin-gentamicin and penicillin-gentamicin in the treatment of post-cesarean section endomyometritis. Am J Obstet Gynecol 1979; 134:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/36\">",
"      Shapiro ME, Kasper DL, Zaleznik DF, et al. Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to Bacteroides fragilis. J Immunol 1986; 137:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/37\">",
"      Kalka-Moll WM, Tzianabos AO, Wang Y, et al. Effect of molecular size on the ability of zwitterionic polysaccharides to stimulate cellular immunity. J Immunol 2000; 164:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/38\">",
"      Tzianabos AO, Chandraker A, Kalka-Moll W, et al. Bacterial pathogens induce abscess formation by CD4(+) T-cell activation via the CD28-B7-2 costimulatory pathway. Infect Immun 2000; 68:6650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/39\">",
"      Tzianabos AO, Kasper DL. Role of T cells in abscess formation. Curr Opin Microbiol 2002; 5:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/40\">",
"      Chung DR, Kasper DL, Panzo RJ, et al. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 2003; 170:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/41\">",
"      Tzianabos AO, Kasper DL, Cisneros RL, et al. Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest 1995; 96:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/42\">",
"      Tzianabos AO, Finberg RW, Wang Y, et al. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem 2000; 275:6733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/43\">",
"      Altemeier, WA. The cause of the putrid odor of perforated appendicitis with peritonitis. Ann Surg 1938; 107:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/44\">",
"      Lorber B. \"Bad breath\": presenting manifestation of anaerobic pulmonary infection. Am Rev Respir Dis 1975; 112:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/45\">",
"      Gorbach SL, Mayhew JW, Bartlett JG, et al. Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest 1976; 57:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/46\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological Exercises. Case 49-1979. N Engl J Med 1979; 301:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/47\">",
"      Citron DM. Specimen collection and transport, anaerobic culture techniques, and identification of anaerobes. Rev Infect Dis 1984; 6 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/48\">",
"      Stoner KA, Rabe LK, Austin MN, et al. Quantitative survival of aerobic and anaerobic microorganisms in Port-A-Cul and Copan transport systems. J Clin Microbiol 2008; 46:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/49\">",
"      Stoner KA, Rabe LK, Hillier SL. Effect of transport time, temperature, and concentration on the survival of group B streptococci in amies transport medium. J Clin Microbiol 2004; 42:5385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/50\">",
"      Human RP, Jones GA. Evaluation of swab transport systems against a published standard. J Clin Pathol 2004; 57:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/51\">",
"      Hindiyeh M, Acevedo V, Carroll KC. Comparison of three transport systems (Starplex StarSwab II, the new Copan Vi-Pak Amies Agar Gel collection and transport swabs, and BBL Port-A-Cul) for maintenance of anaerobic and fastidious aerobic organisms. J Clin Microbiol 2001; 39:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/52\">",
"      Citron DM, Warren YA, Hudspeth MK, Goldstein EJ. Survival of aerobic and anaerobic bacteria in purulent clinical specimens maintained in the Copan Venturi Transystem and Becton Dickinson Port-a-Cul transport systems. J Clin Microbiol 2000; 38:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/53\">",
"      Bartlett JG, Sullivan-Sigler N, Louie TJ, Gorbach SL. Anaerobes survive in clinical specimens despite delayed processing. J Clin Microbiol 1976; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/54\">",
"      Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Intern Med 2009; 151:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34424/abstract/55\">",
"      Levy PY, Fenollar F, Stein A, et al. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin Infect Dis 2008; 46:1884.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5521 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34424=[""].join("\n");
var outline_f33_39_34424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY OF ANAEROBIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Virulence factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Toxins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Capsular polysaccharides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lipopolysaccharides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Volatile fatty acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ability to tolerate oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Formation of and host defense to abscesses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intraabdominal sepsis model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Role of anaerobes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Role of T cells in abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bacterial synergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLUES TO ANAEROBIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      METHODS FOR RECOVERING ANAEROBES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Specimen selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Specimen transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H460851979\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5521|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/37/2651\" title=\"table 1\">",
"      Clues for anaerobic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/58/16301\" title=\"table 2\">",
"      Specimens for anaerobic culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/15/37115\" title=\"table 3\">",
"      Clinically important anaerobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41511?source=related_link\">",
"      Anaerobic bacteria: History and role in normal human flora",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34425="Prognosis of the myelodysplastic syndromes in adults";
var content_f33_39_34425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis of the myelodysplastic syndromes in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34425/contributors\">",
"     Elihu H Estey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34425/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34425/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34425/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/39/34425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2100127\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to standard treatment.",
"   </p>",
"   <p>",
"    Most patients with MDS die because of the consequences of bone marrow failure, rather than transformation to AML. Thus, use of such terms as \"pre-leukemia\" or \"smoldering leukemia\" can be misleading, if taken to imply that death or morbidity from MDS results only when AML develops. Indeed, the distinction between MDS and AML is itself arbitrary, as patients with 20 to 30 percent blasts in the marrow were considered to have MDS by French-American-British (FAB) criteria, but AML by the World Health Organization (WHO). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H64020408#H64020408\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Acute myeloid leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of patients with MDS is varied. This heterogeneity reflects both known and unknown differences in the pathobiology of specific subtypes within MDS and patient related characteristics, such as age and prior exposure to chemotherapy. While the pathologic classification systems (eg, French American British classification system and WHO classification system) have been valuable as benchmarks for diagnosis, they have been less useful for the determination of prognosis. As a result, further dissection of these classification schemes has been performed, taking into account variables such as age and sex, morphologic features, blast percentage, clinical characteristics, the presence of cytopenias, transfusion requirements, and cytogenetic abnormalities.",
"   </p>",
"   <p>",
"    There are three main prognostic systems that have been developed and validated in patients with MDS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      International prognostic scoring system (IPSS) and a revised IPSS (IPSS-R)",
"     </li>",
"     <li>",
"      WHO prognostic scoring system (WPSS)",
"     </li>",
"     <li>",
"      MD Anderson Cancer Center (MDACC) MDS model",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The IPSS is the simplest and most commonly used. However, each system has strengths and limitations, which will be reviewed. Of importance, all prognostic systems probably explain only a minority of variability in outcome. Observation of the disease course without therapy can provide useful information regarding an individual&rsquo;s disease tempo and prognosis, especially for asymptomatic patients with apparently low risk disease by the prognostic scores described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H18197980#H18197980\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of MDS is reviewed here. The diagnosis of MDS, the prognostic importance of specific chromosomal abnormalities, and the management of MDS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=see_link\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link\">",
"     \"Overview of the treatment of myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14168401\">",
"    <span class=\"h1\">",
"     FAB CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The French American British (FAB) classification system classified patients with MDS into subgroups based, in part, upon the percentage of blasts in the bone marrow (",
"    <a class=\"graphic graphic_table graphicRef51895 \" href=\"UTD.htm?20/33/21020\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refractory anemia (RA) &mdash; less than 5 percent blasts",
"     </li>",
"     <li>",
"      Refractory cytopenia with multilineage dysplasia (RCMD) &mdash; less than 5 percent blasts but moderate to severe dysplasia present in two or three cell lineages",
"     </li>",
"     <li>",
"      Refractory anemia with ringed sideroblasts (RARS) &mdash; less than 5 percent blasts with &gt;15 percent ringed sideroblasts",
"     </li>",
"     <li>",
"      Refractory anemia with excess blasts (RAEB) &mdash; 5 to 19 percent blasts. RAEB has been further subdivided, with RAEB-I and RAEB-II having blast counts of 5 to 9 and 10 to 19 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic myelomonocytic leukemia (CMML) &mdash; up to 20 percent blasts plus peripheral blood monocyte count",
"      <span class=\"nowrap\">",
"       &gt;1000/microL.",
"      </span>",
"      CMML has been divided into two subtypes: patients with a white blood cell count (WBC)",
"      <span class=\"nowrap\">",
"       &le;12,000/microL",
"      </span>",
"      who are considered to have MDS, and the proliferative-type CMML with a WBC",
"      <span class=\"nowrap\">",
"       &gt;12,000/microL,",
"      </span>",
"      who are considered to have a chronic myeloproliferative disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/2\">",
"       2",
"      </a>",
"      ]. Based on retrospective data, a separate prognostic scoring system for CMML has been proposed [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Unlike the other categories of MDS, an absolute lymphocyte count",
"      <span class=\"nowrap\">",
"       &gt;2500/microL",
"      </span>",
"      was found to be an adverse prognostic factor in CMML [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/3,5\">",
"       3,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Refractory anemia with excess blasts in transformation (RAEB-T) &mdash; 21 to 30 percent blasts",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of Auer rods. Of note, patients in this category would be classified as having acute leukemia based upon the WHO classification system [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to being the classification system used to define patients with MDS including in the original reports of the IPSS, the FAB subtype provides some prognostic value. Using the FAB classification system and a meta-analysis of a large number of available studies, the following were noted (",
"    <a class=\"graphic graphic_table graphicRef50664 \" href=\"UTD.htm?24/36/25163\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with RAEB and RAEB-T were shown to have relatively poor prognoses, with median survivals ranging from 5 to 12 months. In contrast, those with RA and RARS had median survivals of approximately three to six years.",
"     </li>",
"     <li>",
"      The proportion of individuals who transformed to AML varied similarly, being 40 to 50 percent for patients with RAEB and RAEB-T, compared with 5 to 15 percent in patients with RA and RARS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate study evaluating the time to disease evolution, the incidence of transformation to AML at one and two years was zero in RARS, 5 and 10 percent in RA, 25 and 35 percent in RAEB, and 55 and 65 percent in RAEB-T [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2102498\">",
"    <span class=\"h1\">",
"     INTERNATIONAL PROGNOSTIC SCORING SYSTEMS (IPSS AND IPSS-R)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Prognostic Scoring System (IPSS) is the most widely used prognostic classification system for MDS. The original IPSS published in 1997 was derived from survival data of 816 patients with primary (de novo) MDS based upon the French American British (FAB) classification system and treated in general with supportive care only within the context of seven previously published studies (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2012, new cytogenetic categories were developed for a revised IPSS (IPSS-R) based upon data from 2902 patients with primary MDS diagnosed using the FAB or World Health Organization (WHO) classifications and validated in an independent cohort of 1632 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/9\">",
"     9",
"    </a>",
"    ]. The IPSS-R incorporates a larger number of cytogenetic abnormalities, divided into five prognostic categories, a lower cutoff for absolute neutrophil count",
"    <span class=\"nowrap\">",
"     (&lt;800/microL",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     &lt;1800/microL),",
"    </span>",
"    and different weights for the clinical parameters to better predict outcomes in newly diagnosed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14168401\">",
"     'FAB classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5960825\">",
"    <span class=\"h2\">",
"     Original IPSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To calculate the International Prognostic Scoring System (IPSS) for MDS, a score from zero to two is determined for each of three variables (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 3",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone marrow blast percentage &mdash; &lt;5 (0 points), 5 to 10 (0.5 points), 11 to 20 (1.5 points), 21 to 30 (2 points)",
"     </li>",
"     <li>",
"      Karyotype &mdash; Good karyotype (0 points) includes normal karyotype, -Y, del (5q), or del (20q); poor karyotype (1 point) includes complex karyotype (&ge;3 abnormalities) or abnormal chromosome 7; intermediate karyotype (0.5 points) is assigned to all others",
"     </li>",
"     <li>",
"      Cytopenias &mdash; Hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       g/L),",
"      </span>",
"      absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;1800/microL,",
"      </span>",
"      platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL.",
"      </span>",
"      If 0 to 1 cytopenias (0 points), 2 to 3 cytopenias (0.5 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The IPSS score equals the sum of each of these three values, and defines four risk groups for both overall survival and AML evolution: low (0 points), intermediate-1 (0.5 to 1.0 points), intermediate-2 (1.5 to 2.0 points) and high (2.5 to 3.5 points) (",
"    <a class=\"graphic graphic_figure graphicRef63397 \" href=\"UTD.htm?1/9/1183\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall median survival was 5.7, 3.5, 1.2, and 0.4 years for patients with low risk, intermediate-1 risk, intermediate-2 risk, and high risk IPSS scores, respectively.",
"     </li>",
"     <li>",
"      The time for 25 percent of the patients in each of the four risk groups to evolve into acute leukemia was 9.4, 3.3, 1.1, and 0.2 years, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, many patients with IPSS high risk disease already meet criteria for the diagnosis of AML based upon the WHO classification system (which uses a blast count threshold of 20 percent). In addition, most patients with MDS, even those with IPSS intermediate-2 risk, die because of the consequences of bone marrow failure rather than transformation to AML.",
"   </p>",
"   <p>",
"    The IPSS also stratified survival by patient age (",
"    <a class=\"graphic graphic_table graphicRef66149 \" href=\"UTD.htm?14/5/14427\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median survival of high risk patients was independent of age, being 0.3, 0.5, and 0.4 years in patients &le;60, &gt;60, and &gt;70 years of age, respectively.",
"     </li>",
"     <li>",
"      Median survival of low risk patients was strongly dependent on age, with median survivals of 11.8, 4.8, and 3.9 years in patients &le;60, &gt;60, and &gt;70 years of age, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate study of patients with MDS &lt;50 years of age with a median follow-up of 16 months, the median survival time for subjects with low, Int-1, Int-2, and high risk disease were not reached, 14.6 years, 8 months, and 7 months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, life expectancy for patients with untreated Int-2 or high risk disease is probably indistinguishable from that of patients with untreated AML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17339960\">",
"    <span class=\"h2\">",
"     Revised IPSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To calculate the revised International Prognostic Scoring System (IPSS-R) for MDS, a score from zero to four is determined for each of five variables (",
"    <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"     table 5",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone marrow blast percentage &mdash; &le;2 (0 points), &lt;2 to &lt;5 (1 point), 5 to 10 (2 points), &gt;10 (3 points)",
"     </li>",
"     <li>",
"      Karyotype &mdash; Very good karyotype (0 points) includes &ndash;Y or del(11q); good karyotype (1 point) includes normal karyotype, del (5q), del(12p), del (20q), or a double abnormality including del(5q); intermediate karyotype (2 points) includes del(7q), +8, +19, i(17q), and any other single or double independent clones; poor karyotype (3 points) includes -7,",
"      <span class=\"nowrap\">",
"       inv(3)/t(3q)/del(3q),",
"      </span>",
"      double abnormalities including",
"      <span class=\"nowrap\">",
"       -7/del(7q),",
"      </span>",
"      or three abnormalities; very poor karyotype (4 points) includes complex karyotype (&ge;3 abnormalities)",
"     </li>",
"     <li>",
"      Hemoglobin",
"      <span class=\"nowrap\">",
"       (g/dL)",
"      </span>",
"      &mdash; &ge;10 (0 points); 8 to &lt;10 (1 point); &lt;8 (1.5 points)",
"     </li>",
"     <li>",
"      Platelets",
"      <span class=\"nowrap\">",
"       (cells/microL)",
"      </span>",
"      &mdash; &ge;100,000 (0 points); 50,000 to 100,000 (0.5 points), &lt;50,000 (1 point)",
"     </li>",
"     <li>",
"      Absolute neutrophil count",
"      <span class=\"nowrap\">",
"       (cells/microL)",
"      </span>",
"      &mdash; &ge;800 (0 points); &lt;800 (0.5 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The IPSS-R score equals the sum of each of these five values, and defines five risk groups for both overall survival and AML evolution. In addition, patient age is an optional variable that can be incorporated to predict overall survival, but not evolution to AML.",
"   </p>",
"   <p>",
"    The IPSS-R was applied to an initial group of 7012 patients with primary MDS, who had at least two months of stable blood counts, &le;30 percent bone marrow blasts and &le;19 percent peripheral blood blasts, and who were observed until progression to AML transformation or death [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/10\">",
"     10",
"    </a>",
"    ]. After a median follow-up of 3.9 years, the estimated median overall survival (OS) times and median times until 25 percent of the population had developed AML, according to risk group, were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Very low risk (&le;1.5 points) &mdash; 8.8 years and &gt;14.5 years, respectively",
"     </li>",
"     <li>",
"      Low risk (&gt;1.5 to 3 points) &mdash; 5.3 years and &gt;10.8 years, respectively",
"     </li>",
"     <li>",
"      Intermediate risk (&gt;3 to 4.5 points) &mdash; 3.0 years and 3.2 years, respectively",
"     </li>",
"     <li>",
"      High risk (&gt;4.5 to 6 points) &mdash; 1.6 years and 1.4 years, respectively",
"     </li>",
"     <li>",
"      Very high risk (&gt;6 points) &mdash; 0.8 years and 0.7 years, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This model was validated in a separate cohort. Other factors that influenced survival, but not evolution to AML, were older age, decreased performance status, increased serum ferritin, and increased lactate dehydrogenase (LDH) level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5960833\">",
"    <span class=\"h2\">",
"     Strengths and limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IPSS was the first prognostic scoring system for MDS to gather widespread acceptance and use. Perhaps its biggest strengths are that it was created using data from a large group of previously untreated patients with MDS enrolled on clinical trials at many different centers, it provides information about the natural history of the disease, and it is simple to use. However, there are several potential limitations when applying the IPSS, many of which were addressed by the IPSS-R [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival is dated from the time of presentation to a \"tertiary\" center, although the diagnosis may have been established some time before. As such, this system was not designed for use at later time points during the disease course.",
"     </li>",
"     <li>",
"      The original analysis excluded patients who had received extensive chemotherapy, those with MDS secondary to other disorders, and patients with proliferative chronic myelomonocytic leukemia (CMML).",
"     </li>",
"     <li>",
"      The original IPSS does not consider the severity of the cytopenias, but only their presence. The IPSS-R incorporates the severity of cytopenias.",
"     </li>",
"     <li>",
"      The number of cytogenetic abnormalities included in the original IPSS was limited [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/14\">",
"       14",
"      </a>",
"      ]. The revised cytogenetic subgroups of the IPSS-R predict progression-free intervals more effectively than the standard IPSS categories [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=see_link&amp;anchor=H5#H5\">",
"       \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on 'Cytogenetics as a predictor of prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The IPSS gives more weight to the presence of &gt;20 percent bone marrow blasts (2.0 points) than to poor risk cytogenetics (1.0 point). However, in one study, median survival for patients with poor risk cytogenetics (11 months) was similar to that of patients with bone marrow blast counts exceeding 20 percent (9 months), suggesting that these two variables be given equal weight in future prognostic models [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. This was revised in the IPSS-R.",
"     </li>",
"     <li>",
"      The IPSS was designed for patients with MDS diagnosed using the FAB classification. Since its development, the WHO classification decreased the blast count threshold for defining acute leukemia to &gt;20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/6\">",
"       6",
"      </a>",
"      ]. The IPSS-R was designed for patients diagnosed using the FAB or WHO classification.",
"     </li>",
"     <li>",
"      There remains variability in the outcomes of patients with lower risk disease as defined by the IPSS. A prognostic model for lower-risk MDS using many of the variables contained in the IPSS was able to identify those patients with lower risk MDS and poorer prognosis who might benefit from early intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/17\">",
"       17",
"      </a>",
"      ]. Unlike the original IPSS, this system incorporated data on age and the degree of thrombocytopenia.",
"     </li>",
"     <li>",
"      The patients evaluated in the IPSS were collected during the 1970s and 1980s when there were few effective therapies for MDS and no approved chemotherapy agents. Management consisted primarily of transfusion support. Similarly, IPSS-R was developed using data from patients who were observed without treatment until evolution to leukemia. Outcomes might be different now that a variety of interventions are widely available.",
"     </li>",
"     <li>",
"      Both the IPSS and IPSS-R only consider patients with de novo MDS, that is, patients who have not previously received chemotherapy. Patients who have received chemotherapy (secondary MDS) are more likely to have shorter survival than de novo patients. Much of this reflects the association between secondary MDS and &ldquo;unfavorable cytogenetics&rdquo;, although other factors may contribute to the poorer outcome seen in secondary MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonetheless, the IPSS and IPSS-R remain the most clinically useful system for providing relevant prognostic information to patients and in helping to decide which patients should undergo high-risk treatment, such as chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515265#H515265\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Selection of initial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861596\">",
"    <span class=\"h1\">",
"     WHO PROGNOSTIC SCORING SYSTEM (WPSS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues has replaced the French-American-British (FAB) as the preferred classification system for MDS (",
"    <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/6\">",
"     6",
"    </a>",
"    ]. While the IPSS was created for use in patients diagnosed with MDS based upon the FAB classification, the WHO Prognostic Scoring System (WPSS) was designed for patients diagnosed with MDS based upon the WHO classification. It was also designed to incorporate information on red blood cell transfusion need, a characteristic shown to be an independent prognostic factor for patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359854#H359854\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'WHO Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The WPSS was initially developed using data from 426 patients with de novo MDS and validated in a second cohort of 739 patients with de novo MDS from another institution [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/20\">",
"     20",
"    </a>",
"    ]. A subset of patients with data from multiple timepoints was selected for a time-dependent analysis. This allowed for the validation of the WPSS at different time points during the disease course. The WPSS has the potential advantage over the IPSS of being able to be used at any time during the disease course and has prognostic value in the outcome of MDS patients following hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1081612\">",
"    <span class=\"h2\">",
"     Calculation and outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;To calculate the WPSS, a score from zero to three is determined for each of three variables [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      WHO classification",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Refractory anemia, refractory anemia with ring sideroblasts, or MDS with isolated 5q- (0 points)",
"     </li>",
"     <li>",
"      Refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia with ring sideroblasts (1 point)",
"     </li>",
"     <li>",
"      Refractory anemia with excess blasts-1 (2 points)",
"     </li>",
"     <li>",
"      Refractory anemia with excess blasts-2 (3 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytogenetics &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Good (0 points) include diploid, -Y, del(5q), del(20q)",
"     </li>",
"     <li>",
"      Intermediate (1 point) are those not classified as good or poor",
"     </li>",
"     <li>",
"      Poor (2 points) are those with &gt;3 abnormalities (ie, complex) or chromosome 7 alterations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red cell transfusion need",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      None (0 points)",
"     </li>",
"     <li>",
"      Regular (1 point) defined as a red cell transfusion every eight weeks for a period of at least four months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The WPSS score equals the sum of each of these three values, and defines five risk groups for both overall survival and AML evolution [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/20\">",
"     20",
"    </a>",
"    ]: very low (0 points), low (1 point), intermediate (2 points), high (3 to 4 points), and very high (5 to 6 points). When applied to a validation cohort of 739 patients with do novo MDS, median overall survival times differed by risk group: very low (141 months), low (66 months), intermediate (48 months), high (26 months), and very high (9 months). The percentage of patients having transformed to AML also varied by risk group: very low (3 percent), low (14 percent), intermediate (33 percent), high (54 percent), and very high (84 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4734677\">",
"    <span class=\"h2\">",
"     Strengths and limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A principal strength of the WPSS is that it incorporates red cell transfusion requirements. It does not, however, account for cytopenias. Furthermore, although the WPSS was developed for use at any time during the disease course, it is not clear whether the system formally accounts for length of time from diagnosis, a problem that it shares with the IPSS. Like the IPSS, it also does not account for whether patients have de novo or secondary MDS. The WPSS has not yet been validated using the 2008 WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861696\">",
"    <span class=\"h1\">",
"     MD ANDERSON CANCER CENTER MDS MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MD Anderson Cancer Center (MDACC) MDS model was created to be used in patients with de novo or therapy-related MDS and to better predict the outcomes of patients otherwise thought to have low risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/13\">",
"     13",
"    </a>",
"    ]. An initial prognostic model for lower-risk MDS was developed based upon a retrospective analysis of 856 patients with low or intermediate-1 risk disease by the IPSS [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/17\">",
"     17",
"    </a>",
"    ]. This system identified cytogenetics, age, anemia, degree of thrombocytopenia, and bone marrow blasts as important prognostic measures. The MDACC further refined these and other prognostic measures to create the MDACC MDS model to be used in patients with de novo or secondary MDS. An initial patient cohort of 958 patients was used to create this prognostic model, which was then validated in a test group of 957 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/23\">",
"     23",
"    </a>",
"    ]. The model was subsequently validated in a retrospective study of 775 patients with MDS treated at another institution [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4734715\">",
"    <span class=\"h2\">",
"     Calculation and interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MD Anderson Cancer Center (MDACC) MDS model is calculated based upon patient characteristics, markers of tumor burden, and tumor characteristics. Points are attributed for the following reasons (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?22/56/23425?source=see_link\">",
"     calculator 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Performance status &mdash; &ge;2 (2 points)",
"     </li>",
"     <li>",
"      Age &mdash; (1 point for age 60 to 64; 2 points if &ge;65)",
"     </li>",
"     <li>",
"      Platelet count &mdash; (3 points for &lt;30K, 2 points for 30 to 49K, 3 points for 50 to 199K)",
"     </li>",
"     <li>",
"      Hemoglobin &mdash; &lt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (2 points)",
"     </li>",
"     <li>",
"      Bone marrow blast percentage &mdash; (1 point if 5 to 10 percent; 2 points if 11 to 29 percent)",
"     </li>",
"     <li>",
"      WBC &mdash; &gt;20 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      (2 points)",
"     </li>",
"     <li>",
"      Karyotype &mdash; chromosome 7 abnormality or complex &ge;3 abnormalities (3 points)",
"     </li>",
"     <li>",
"      Prior transfusion &mdash; (1 point)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Points are given for each of the above characteristics present in the patient, for a total score ranging from zero to 17. When applied to the initial group of 1915 patients with MDS, median overall survival, survival at three years, and survival at six years were [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 4 points &mdash; (16 percent of patients) 54 months, 63 percent, and 38 percent, respectively",
"     </li>",
"     <li>",
"      5 to 6 points &mdash; (24 percent of patients) 25 months, 34 percent, and 13 percent, respectively",
"     </li>",
"     <li>",
"      7 to 8 points &mdash; (24 percent of patients) 14 months, 16 percent, and 6 percent, respectively",
"     </li>",
"     <li>",
"      &ge;9 points &mdash; (36 percent of patients) 6 months, 4 percent, and 0.4 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4734790\">",
"    <span class=\"h2\">",
"     Strengths and limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A principal strength of the MDACC model is that it incorporates more factors than the IPSS or WPSS. As a consequence, it refined prognoses in patients with IPSS scores of low or intermediate-1, while the IPSS did not do the same in patients scored using the MDACC system. The MDACC model also included patients with de novo MDS, secondary MDS, and chronic myelomonocytic leukemia (CMML) with leukocytosis, although apparently these entities had little prognostic effect as they were not included in the model. In addition, the model removes the arbitrary criterion of a 20 percent blast count that is used in the other models.",
"   </p>",
"   <p>",
"    The MDACC model should only be applied the population of patients with lower risk (low or intermediate-1 IPSS) MDS from which it was derived. Patients used to develop this model received a variety of treatments and these may have influenced prognosis. In contrast, patients used to develop the IPSS were essentially untreated until they developed AML. Finally the MDACC model, even with an online calculator, appears more cumbersome to use than the IPSS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2102505\">",
"    <span class=\"h1\">",
"     OTHER PROGNOSTIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other factors have been shown to add significant prognostic information to that provided by the prognostic scoring systems described above. It is not clear as of yet how they might be incorporated into clinical use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the most readily obtainable prognostic factors is serum ferritin concentration, which reflects the duration and degree to which the MDS patient has been red cell transfusion dependent [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Many MDS patients will already have an elevated ferritin at diagnosis if their anemia has been long-standing, due to increased compensatory iron absorption and also inappropriate iron supplementation before the underlying diagnosis is clear. Higher ferritin levels (eg, &gt;1000) tend to worsen the prognosis of lower risk patients to a greater extent than lower ferritin levels improve the prognosis of higher risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/17\">",
"       17",
"      </a>",
"      ]. What remains unknown is whether lowering serum ferritin levels with chelation therapy will improve morbidity and mortality in MDS.",
"     </li>",
"     <li>",
"      Another prognostic feature in MDS is mutation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of heterozygosity of the tumor suppressor gene P53. Such alterations in the P53 alleles have been commonly noted in MDS, especially in older patients and following exposure to alkylating agents [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/25\">",
"       25",
"      </a>",
"      ]. Their presence has been associated with complex karyotypic changes, an increased tendency to evolve into AML, reduced responses to chemotherapy, and shorter overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/25-30\">",
"       25-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with therapy-related MDS (t-MDS) were not included in the original IPSS or the WPSS. In contrast, the MDACC MDS model included patients with t-MDS. Patients with t-MDS account for a large percentage of patients with MDS and present a particularly difficult treatment challenge, although it is unclear the extent to which this represents the well-known association between unfavorable cytogenetics and t-AML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoplastic MDS is an uncommon subtype of MDS with features that overlap those of aplastic anemia, but with a prognosis that is worse than that of patients with aplastic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/31\">",
"       31",
"      </a>",
"      ]. In a retrospective analysis, the overall survival curve of 253 patients with hypoplastic MDS was similar to that of 1725 patients with hypercellular or normocellular MDS [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/32\">",
"       32",
"      </a>",
"      ]. For those with hypoplastic MDS, median survival was 28, 22, 16, and 7 months for patients with low, intermediate-1, intermediate-2, and high IPSS risk scores, respectively. Corresponding rates for two-year survival were 77, 47, 35, and 8 percent, respectively. However, multivariate analyses that account for treatment as well as other covariates are unavailable. As such, whether the prognosis of MDS varies according to marrow cellularity is uncertain. In addition, application of this information to the care of individual patients is difficult due to differences among pathologists in the interpretation of cellularity. This patient population poses diagnostic and treatment dilemmas, including questions regarding when to initiate therapy and when to consider hematopoietic cell transplantation.",
"     </li>",
"     <li>",
"      The presence of abnormal single nucleotide polymorphisms (SNPS) in patients who have a normal karyotype with standard (20 metaphase) methodology also seems to confer a worse prognosis than seen in patients with a normal karyotype without such abnormal SNPS [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ever-increasing number of adverse prognostic factors and risk models for MDS have been reported, many of which have been shown to improve the prognostic value of the IPSS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the WPSS. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased patient age [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poor performance status [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/23,34,35\">",
"       23,34,35",
"      </a>",
"      ], presence of comorbidities [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/36-39\">",
"       36-39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Total white blood cell count",
"      <span class=\"nowrap\">",
"       &gt;20,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Eosinophilia",
"      <span class=\"nowrap\">",
"       (&gt;350/microL)",
"      </span>",
"      and basophilia",
"      <span class=\"nowrap\">",
"       (&gt;250/microL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Absolute lymphocyte count",
"      <span class=\"nowrap\">",
"       &lt;1200/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severity of anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Refractory or severe",
"      <span class=\"nowrap\">",
"       (&lt;30,000/microL)",
"      </span>",
"      thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transfusion dependence [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/20,23,45,46\">",
"       20,23,45,46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CD34 positivity of bone marrow nucleated cells and their comparative genomic hybridization patterns [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gene expression profiling [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased DNA methylation [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Following treatment failure with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      RBC mean corpuscular volume &lt;100 fL [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased expression of the Wilms' tumor gene (WT1) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Downregulation of the granulopoiesis regulator lymphoid (lymphocyte) enhancer-binding factor 1 (LEF-1) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased serum beta-2 microglobulin concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/17,57\">",
"       17,57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mutations of the FLT3, EZH2, ETV6, or EZH2 genes [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/30,58-60\">",
"       30,58-60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Absence of TET2 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Monosomy 5 or del(5q) with other chromosomal changes [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased levels of tumor necrosis factor (TNF)-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/63\">",
"       63",
"      </a>",
"      ]; single nucleotide polymorphisms in the TNF gene [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased platelet mass (ie, mean platelet volume x platelet count) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/65-67\">",
"       65-67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of marrow fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/48,68,69\">",
"       48,68,69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lower levels of circulating endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34425/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal localization of immature precursors (ALIP) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4009103#H4009103\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Bone marrow biopsy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2105835\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation, due to a malignant transformation of hematopoietic progenitor cells. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to treatment. Of note, most patients with MDS die because of the consequences of bone marrow failure rather than transformation to AML. (See",
"      <a class=\"local\" href=\"#H2100127\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of patients with MDS is varied. This heterogeneity reflects both known and unknown differences in the pathobiology of specific subtypes within MDS and patient related characteristics, such as age and prior exposure to chemotherapy.",
"     </li>",
"     <li>",
"      There are three main prognostic systems that have been developed and validated in patients with MDS to predict both overall survival and AML evolution:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The original International prognostic scoring system (IPSS) (",
"      <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef50664 \" href=\"UTD.htm?24/36/25163\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and the revised IPSS (IPSS-R) (",
"      <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"       table 5",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) &mdash; The IPSS and IPSS-R are the most widely used prognostic classification systems for MDS. Both systems were developed based upon survival data from patients with primary (de novo) MDS based upon the French American British (FAB) classification system and treated with supportive care. While the IPSS and IPSS-R provide information regarding the natural history of MDS, they were not designed for patients with therapy-related MDS (t-MDS) or for the serial prognostication of patients as their disease evolves. (See",
"      <a class=\"local\" href=\"#H2102498\">",
"       'International prognostic scoring systems (IPSS and IPSS-R)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      WHO prognostic scoring system (WPSS) &mdash; The WPSS was designed for patients diagnosed with MDS based upon the World Health Organization (WHO) classification of MDS. It incorporates information regarding the MDS subtype, red blood cell transfusion need, and cytogenetics. Like the IPSS, the WPSS was not designed for use in patients with t-MDS, but it was validated for use at any time during the disease course and for patients undergoing a variety of treatment strategies, including hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H861596\">",
"       'WHO prognostic scoring system (WPSS)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MD Anderson Cancer Center (MDACC) MDS model &mdash; The MDACC MDS model incorporates information regarding the patient&rsquo;s performance status, age, number and degree of cytopenias, cytogenetics, bone marrow blast percentage, and red blood cell transfusion need (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?22/56/23425?source=see_link\">",
"       calculator 3",
"      </a>",
"      ). Like the WPSS, the MDACC MDS model was designed to be used in patients with a spectrum of treatments at any point during their disease course. Of importance, unlike the IPSS and the WPSS, the MDACC MDS model included patients with de novo MDS, secondary MDS, and chronic myelomonocytic leukemia (CMML) with leukocytosis. (See",
"      <a class=\"local\" href=\"#H861696\">",
"       'MD Anderson cancer center MDS model'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple other factors have been shown to add significant prognostic information to that provided by the prognostic scoring systems described above. It is not clear as of yet how they might be incorporated into clinical use. (See",
"      <a class=\"local\" href=\"#H2102505\">",
"       'Other prognostic features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/1\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/2\">",
"      Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/3\">",
"      Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/4\">",
"      Beran M, Wen S, Shen Y, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007; 48:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/5\">",
"      Germing U, Strupp C, Aivado M, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia. Blood 2002; 100:731.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     Greenberg, PL. Myelodysplastic Syndrome. In: Hematology: Basic Principles and Practice, 3rd, Hoffman, R, Benz, EJ, Shattil, SJ (Eds), Churchill Livingstone, New York 2000. p.1106.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/8\">",
"      Sanz GF, Sanz MA, Vallesp&iacute; T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/9\">",
"      Schanz J, T&uuml;chler H, Sol&eacute; F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/10\">",
"      Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/11\">",
"      Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006; 24:5358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/12\">",
"      Komrokji, RS, Bennett, JM. What is \"WHO\"? Myelodysplastic syndromes classification. Clinical Leukemia 2008; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/13\">",
"      Garcia-Manero G. Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010; 2010:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/14\">",
"      Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/15\">",
"      Sol&eacute; F, Lu&ntilde;o E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/16\">",
"      Steidl, C, Schanz, J, Pfeilstocker, M, et al. Growing evidence for an underestimation of poor-risk cytogenetics in the International Prognostic Scoring System in myelodysplastic syndromes. Clin Leukemia 2007; 1:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/17\">",
"      Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/18\">",
"      Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23:7594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/19\">",
"      Remacha AF, Arrizabalaga B, Del Ca&ntilde;izo C, et al. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol 2010; 89:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/20\">",
"      Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/21\">",
"      Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008; 112:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/22\">",
"      Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/23\">",
"      Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/24\">",
"      Komrokji RS, Corrales-Yepez M, Al Ali N, et al. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer 2012; 118:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/25\">",
"      Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/26\">",
"      Kita-Sasai Y, Horiike S, Misawa S, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 2001; 115:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/27\">",
"      Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 1998; 12:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/28\">",
"      Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/29\">",
"      J&auml;dersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/30\">",
"      Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/31\">",
"      Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA). Leuk Res 2010; 34:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/32\">",
"      Tong WG, Quint&aacute;s-Cardama A, Kadia T, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer 2012; 118:4462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/33\">",
"      Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117:4552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/34\">",
"      Itzykson R, Th&eacute;pot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/35\">",
"      Itzykson R, Th&eacute;pot S, Quesnel B, et al. Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood 2012; 119:6172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/36\">",
"      Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010; 21:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/37\">",
"      Breccia M, Federico V, Latagliata R, et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res 2011; 35:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/38\">",
"      Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011; 96:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/39\">",
"      Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011; 29:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/40\">",
"      Wimazal F, Germing U, Kundi M, et al. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer 2010; 116:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/41\">",
"      Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol 2010; 85:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/42\">",
"      Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008; 83:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/43\">",
"      Breccia M, Latagliata R, Cannella L, et al. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. Leuk Lymphoma 2010; 51:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/44\">",
"      Gonzalez-Porras JR, Cordoba I, Such E, et al. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 2011; 117:5529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/45\">",
"      Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med 2005; 352:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/46\">",
"      Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 2006; 106:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/47\">",
"      Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008; 112:3412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/48\">",
"      Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009; 27:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/49\">",
"      Mills KI, Kohlmann A, Williams PM, et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009; 114:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/50\">",
"      Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/51\">",
"      Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116:3830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/52\">",
"      Tennant GB, Al-Sabah AI, Burnett AK. Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol 2002; 119:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/53\">",
"      Wang H, Wang X, Xu X, Lin G. Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes. Ann Hematol 2010; 89:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/54\">",
"      Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/55\">",
"      Galimberti S, Ghio F, Guerrini F, et al. WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. Br J Haematol 2010; 149:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/56\">",
"      Pellagatti A, Marafioti T, Paterson JC, et al. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 2009; 146:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/57\">",
"      Gatto S, Ball G, Onida F, et al. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood 2003; 102:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/58\">",
"      Shih LY, Lin TL, Wang PN, et al. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer 2004; 101:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/59\">",
"      Georgiou G, Karali V, Zouvelou C, et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/60\">",
"      Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/61\">",
"      Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114:3285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/62\">",
"      Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 2009; 115:5202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/63\">",
"      Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/64\">",
"      Parnes A, Nikiforow S, Berliner N, Vanasse GJ. Single nucleotide polymorphisms in the human TNF gene are associated with anaemia and neutropenia in a cohort of patients with de novo myelodysplastic syndrome. Br J Haematol 2010; 150:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/65\">",
"      Bowles KM, Warner BA, Baglin TP. Platelet mass has prognostic value in patients with myelodysplastic syndromes. Br J Haematol 2006; 135:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/66\">",
"      Germing U, Platzbecker U, Giagounidis A, Aul C. Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. Br J Haematol 2007; 138:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/67\">",
"      Palmer SR, Tefferi A, Hanson CA, Steensma DP. Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. Br J Haematol 2008; 140:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/68\">",
"      Buesche G, Teoman H, Wilczak W, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 2008; 22:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/69\">",
"      Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34425/abstract/70\">",
"      Della Porta MG, Malcovati L, Rigolin GM, et al. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia 2008; 22:530.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15775 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34425=[""].join("\n");
var outline_f33_39_34425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2105835\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2100127\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14168401\">",
"      FAB CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2102498\">",
"      INTERNATIONAL PROGNOSTIC SCORING SYSTEMS (IPSS AND IPSS-R)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5960825\">",
"      Original IPSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17339960\">",
"      Revised IPSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5960833\">",
"      Strengths and limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861596\">",
"      WHO PROGNOSTIC SCORING SYSTEM (WPSS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1081612\">",
"      Calculation and outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4734677\">",
"      Strengths and limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861696\">",
"      MD ANDERSON CANCER CENTER MDS MODEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4734715\">",
"      Calculation and interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4734790\">",
"      Strengths and limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2102505\">",
"      OTHER PROGNOSTIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2105835\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/15775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15775|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/9/1183\" title=\"figure 1\">",
"      IPSS risk class outcome in MDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15775|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/33/21020\" title=\"table 1\">",
"      FAB classification of MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/36/25163\" title=\"table 2\">",
"      MDS outcome by FAB subgroup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/37/27228\" title=\"table 3\">",
"      IPSS in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/5/14427\" title=\"table 4\">",
"      Survival MDS by IPSS and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/16/20749\" title=\"table 5\">",
"      IPSS-R in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9996\" title=\"table 6\">",
"      MDS classification WHO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=related_link\" title=\"calculator 1\">",
"      Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=related_link\" title=\"calculator 2\">",
"      Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?22/56/23425?source=related_link\" title=\"calculator 3\">",
"      Calculator: MDACC Myelodysplastic syndrome prognostic model",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34426="Initial evaluation and management of blunt thoracic trauma in adults";
var content_f33_39_34426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and management of blunt thoracic trauma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34426/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34426/contributors\">",
"     Eric Legome, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34426/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/39/34426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/39/34426/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/39/34426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt chest trauma puts multiple structures at risk of injury. In addition to direct trauma, rapid deceleration and other mechanisms can cause injury to thoracic structures. Major concerns include chest wall injury, such as rib fractures or flail chest; cardiovascular injury, such as blunt aortic injury or cardiac contusion; and pulmonary injury, such as contusions or lacerations. Blunt aortic injury is the most lethal injury of the thorax if untreated.",
"   </p>",
"   <p>",
"    The clinician must first concentrate on assessing life-threatening conditions. Depending on the presentation, evaluation may consist solely of a thorough history and physical examination or may require multiple tests including plain x-rays, computed tomography (CT) scans, and echocardiography.",
"   </p>",
"   <p>",
"    This topic review will discuss the epidemiology, mechanisms, and general approach to the management of injuries sustained in adults from blunt thoracic trauma. Discussions of thoracic trauma in children and other aspects of trauma management are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"     \"Initial evaluation and management of rib fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motor vehicle collisions (MVC) represent the most common cause of major thoracic injury among emergency department (ED) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Several factors are associated with a higher risk of thoracic injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High speed",
"     </li>",
"     <li>",
"      Not wearing a seatbelt",
"     </li>",
"     <li>",
"      Extensive vehicular damage",
"     </li>",
"     <li>",
"      Steering wheel deformity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased mortality and morbidity is associated with multiple rib fractures, increased age, and higher injury severity scores (ISS) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"     \"Initial evaluation and management of rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of chest trauma are often based upon data from trauma registries that catalog admitted trauma patients. Patients with minor injuries or isolated rib fractures are often discharged and do not appear in such registries, leading to substantial bias in the trauma literature toward more seriously injured patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blunt aortic injury &ndash; The majority of blunt trauma patients who sustain a major aortic injury die immediately. Of those who reach the hospital alive, the majority either die during initial management or are unable to undergo aortic repair due to their injuries, both intra and extrathoracic [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A number of occupant and collision characteristics are independently associated with blunt aortic injury (BAI), the most lethal of blunt thoracic injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-risk occupant characteristics include:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age &ge;60 (RR 3.6; 95% CI 2.5-5.2)",
"     </li>",
"     <li>",
"      Front-seat occupancy (RR 3.1; 95% CI 1.5-6.3)",
"     </li>",
"     <li>",
"      Not wearing a seatbelt (RR 3.0; 95% CI 2.2-4.3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-risk collision characteristics include:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Front or near-side motor vehicle crash (RR 3.1; 95% CI 1.9-5.1; and RR 4.3; 95% CI 2.6-7.2, respectively)",
"     </li>",
"     <li>",
"      Abrupt deceleration &ge;40",
"      <span class=\"nowrap\">",
"       km/hour",
"      </span>",
"      (RR 3.8; 95% CI 2.6-5.6)",
"     </li>",
"     <li>",
"      Crushing of the vehicle (ie, &ge;40 cm) (RR 4.1; 95% CI 2.7-6.3)",
"     </li>",
"     <li>",
"      Intrusion &ge;15 cm (RR, 5.0; 95% CI 3.5-7.3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of injury to the thoracic aorta is also greater among passengers traveling in a car struck by a sports utility vehicle (RR 1.7; 95% CI 1.2-2.3).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blunt cardiac and pulmonary injury &ndash; Up to 20 percent of deaths from motor vehicle collisions are attributable to blunt cardiac injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Most patients with such injuries die in the field. Pneumothorax is a common complication of thoracic trauma. The incidence of occult pneumothorax among victims of blunt trauma is less clear, ranging from 2 to 55 percent in patients who undergo computed tomography (CT) of the chest or abdomen [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/11\">",
"       11",
"      </a>",
"      ]. The risk of pulmonary contusion appears to correlate with crash severity and the proximity of the site of impact to the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=see_link\">",
"       \"Cardiac injury from blunt trauma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rib fractures &ndash; Rib fractures occur in almost two-thirds of motor vehicle crash patients with chest trauma. These studies, however, evaluated major trauma patients admitted to trauma centers. In another study, researchers evaluated the chest radiographs of all alert blunt trauma patients presenting to their emergency department following blunt trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/2\">",
"       2",
"      </a>",
"      ]. They found that multiple rib fractures (&gt;2) was the most common serious thoracic injury, and occurred in approximately 5 percent of patients. The presence of multiple rib fractures, particularly ribs one through three, increases the risk of intrathoracic injury, especially in the elderly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"       \"Initial evaluation and management of rib fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fractures of the sternum and scapula &ndash; The epidemiology of these injuries is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28247?source=see_link&amp;anchor=H15009018#H15009018\">",
"       \"Initial evaluation and management of chest wall trauma in adults\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY AND MECHANISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179290\">",
"    <span class=\"h2\">",
"     Anatomy and physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rib cage, intercostal muscles, and costal cartilage form the basic structure of the chest wall. In addition, neurovascular bundles comprised of an intercostal nerve, artery, and vein run along each rib. The inner lining of the chest wall is the parietal pleura. Visceral pleura covers the major thoracic organs. Between the two is a potential space with a small amount of lubricating fluid. The anterior chest wall also contains the sternum and pectoralis major and minor muscles, as well as the clavicle at its superior border. Posteriorly, the scapula provides added protection to the superior thorax. The scapula is a dense bone encased in muscle and significant force is necessary to fracture it.",
"    <br/>",
"    <br/>",
"    The chest wall has two important functions: to assist in the mechanics of respiration and to protect the intrathoracic organs. Adequate ventilation is accomplished by creating negative intrathoracic pressure during inspiration and positive pressure during expiration. During inspiration, a combination of diaphragmatic excursion and contraction of the intercostal muscles to raise the ribs in a \"bucket-handle\" fashion increases intrathoracic volume and decreases intrathoracic pressure, which then pulls air passively into the lungs. In expiration, this process is reversed: all the muscles relax and intrathoracic pressure passively increases and volume decreases, forcing air out of the lungs.",
"    <br/>",
"    <br/>",
"    The chest wall protects against devastating injuries to the intrathoracic structures. In fulfilling this role, the chest wall is commonly injured. While generally not life-threatening, chest wall injuries can be extremely painful and can lead to significant morbidity if not recognized and treated appropriately.",
"    <br/>",
"    <br/>",
"    The mediastinum is an anatomic division of the thorax extending from the diaphragm inferiorly to the thoracic inlet superiorly. Its borders include the sternum anteriorly, the vertebral column posteriorly, and the parietal pleura laterally. Contained within the mediastinum are the heart, aorta, trachea, and esophagus. Injuries to any of these structures are potentially life-threatening. One lung is located lateral to each side of the mediastinum.",
"    <br/>",
"    <br/>",
"    With blunt trauma, the most common isolated mediastinal injury involves the aorta. Hemorrhage from other nearby structures, such as venous lacerations or fractures of the ribs, sternum or vertebra, can manifest as mediastinal blood, raising concern for aortic injury (",
"    <a class=\"graphic graphic_algorithm graphicRef73037 \" href=\"UTD.htm?39/59/40894\">",
"     algorithm 1",
"    </a>",
"    ). Aortic injuries are mainly transverse tears with relatively smooth margins. The underlying injury ranges from a simple subintimal hemorrhage, with or without intimal laceration, to complete aortic transection [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The diaphragm constitutes the floor of the thoracic cavity. The diaphragm exhibits substantial movement with inspiration and expiration, and thus posttraumatic pain in the lower thorax may reflect intraabdominal as well as intrathoracic injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179283\">",
"    <span class=\"h2\">",
"     Selected mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt chest trauma occurs through a variety of mechanisms, including motor vehicle collisions, assaults, and falls. Particularly in the elderly, apparently minor trauma (eg, fall from standing) can cause serious injury. Any of the mechanisms listed can cause rib fractures, flail chest, or chest wall contusions.",
"    <br/>",
"    <br/>",
"    Aortic tears usually occur from high-energy injuries to the thorax, often following rapid deceleration. Several theories for the mechanism of aortic disruptions have been proposed and it is likely that a number of forces are involved. These theories are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H1066952822#H1066952822\">",
"     \"Blunt thoracic aortic injury\", section on 'Pathophysiology of injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    Pulmonary contusions most often result from high-energy MVCs. Mortality is difficult to quantify because pulmonary contusions often occur in tandem with other severe injuries. Damage leads to ventilation-perfusion inequalities and decreased lung compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Researchers postulate several possible mechanisms for pulmonary contusion, including the implosion theory, where air expansion causes alveolar tearing; the \"inertia effect,\" which occurs when lighter alveoli are stripped from the heavier bronchi; and the \"spalling effect,\" which involves shearing at the gas-liquid interface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREHOSPITAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehospital management depends on patient symptoms and severity of illness. Prehospital providers should treat patients with possible underlying pulmonary, cardiac, or major extrathoracic injuries according to the principles of Advanced Trauma Life Support&reg; (ATLS&reg;), paying special attention to the patient's airway, breathing, and circulation. Rapid transport to the closest trauma center is crucial; interventions causing unnecessary delay must be avoided. Basic interventions, such as cervical spine immobilization, are appropriate, as is the use of high-flow oxygen and monitoring. Transport should not be delayed to place IV lines or perform endotracheal intubation, unless the patient is in extremis and cannot be stabilized with bag mask ventilation. More extensive intervention may be needed if prolonged transport time is expected. A detailed discussion of prehospital trauma care is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient shows no evidence of respiratory difficulty or underlying injury, no intervention may be necessary. Before leaving the scene of a vehicular accident, prehospital caretakers should quickly make note of important features associated with increased risk of injury and convey these findings to clinicians at the trauma center upon arrival. Such findings include: significant intrusion into the passenger compartment, deformed steering wheel, ejection of the patient from the vehicle, and fatality at the scene. Prehospital hypotension is an important indication of significant injury and this finding must be communicated to the clinicians assuming care of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRIMARY EVALUATION AND MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial resuscitation and management of the trauma patient is based upon protocols from Advanced Trauma Life Support&reg; (ATLS&reg;) and is reviewed separately; details related to initial management of blunt thoracic trauma (BTT) are discussed below. A basic algorithm for management of BTT is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef81674 \" href=\"UTD.htm?38/36/39489\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians first assess and stabilize the patient's airway, breathing, and circulation, in that order (ABCs). The one caveat to this principle in patients with respiratory distress following chest trauma is that breathing may take priority over airway. If the patient is in respiratory distress due to a tension pneumothorax, the clinician should relieve the pneumothorax before performing endotracheal intubation, if needed. Positive pressure ventilation following intubation will exacerbate a pneumothorax.",
"   </p>",
"   <p>",
"    After addressing the patient's ABCs, the clinician continues the initial evaluation taking into account vital signs, the initial presentation, and the mechanism of injury. Mechanism is less predictive of injury severity and ultimate disposition than abnormal vital signs in the setting of blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For any patient with unstable vital signs, hypoxia, or obvious severe injury (eg, flail chest, multiple rib fractures, large open wounds), the clinician performs a rapid search with concurrent management of immediate life-threatening injuries of the head, cervical spine, abdomen, chest, and pelvis. With blunt chest trauma such injuries include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aortic injury",
"     </li>",
"     <li>",
"      Tension pneumothorax",
"     </li>",
"     <li>",
"      Hemothorax with severe, active bleeding",
"     </li>",
"     <li>",
"      Pericardial tamponade from myocardial injury",
"     </li>",
"     <li>",
"      Tracheobronchial disruption",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with respiratory distress, marked hemodynamic instability, or severe injury are intubated. Rapid sequence intubation is the preferred approach whenever possible, avoiding pretreatment and induction agents with the potential to cause hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suspected tension pneumothorax is treated with immediate tube thoracostomy or needle decompression using a large angiocatheter (eg, 14 gauge). Needles as long as 7 cm may be necessary depending upon the size of the patient. Acceptable sites for needle insertion include the second or third intercostal space in the midclavicular line or the fifth intercostal space in the midaxillary line. If needle decompression is performed first, it is followed by tube thoracostomy. A chest tube size of at least 36 French is used. Needle decompression is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link&amp;anchor=H20#H20\">",
"     \"Prehospital care of the adult trauma patient\", section on 'Needle chest decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient stabilizes in the ED and does not require emergent operative treatment, a chest CT with contrast is performed to define the extent of thoracic injury and exclude aortic rupture. If the patient is unable to undergo CT, due to the need for immediate operation, transesophageal echocardiography can be performed in the ED or operating room to assess the aorta and heart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial tamponade, most likely from myocardial rupture, is detected by ultrasound as the first study of the standard FAST (Focused Assessment with Sonography for Trauma) examination (",
"    <a class=\"graphic graphic_movie graphicRef64027 \" href=\"UTD.htm?29/24/30094\">",
"     movie 1",
"    </a>",
"    ). Pericardiocentesis is performed immediately in patients with a pericardial effusion and significant hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If hemodynamic compromise is severe and tamponade cannot be relieved by percutaneous drainage or if the patient develops cardiac arrest while being resuscitated, emergency department thoracotomy (EDT) may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H4933905#H4933905\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Emergency department thoracotomy (EDT)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31801?source=see_link&amp;anchor=H1247118578#H1247118578\">",
"     \"Resuscitative thoracotomy: technique\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemothorax is treated with tube thoracostomy using a large (minimum 36 French) chest tube. Immediate bloody drainage of &ge;20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    is generally considered an indication for thoracotomy in the operating room. Vital signs, fluid resuscitation requirements, and concomitant injuries are also considered when determining the need for thoracotomy.",
"   </p>",
"   <p>",
"    The evaluation of hemodynamically stable patients without obvious signs of injury varies depending upon mechanism, age, and clinical suspicion. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Subsequent management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Emergent thoracotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of blunt trauma, emergency department thoracotomy (EDT) rarely results in successful resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. Among blunt trauma patients, EDT enables neurologically intact survival in approximately less than 5 percent of those in shock, 1 percent of those without vital signs upon arrival to the ED, and none of those without signs of life in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/21\">",
"     21",
"    </a>",
"    ]. A more complete discussion of EDT, including epidemiology, indications, and practice guidelines, is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H4933905#H4933905\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Emergency department thoracotomy (EDT)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the resources required and risks entailed in EDT, we recommend hospitals develop policies to determine the circumstances under which the procedure is to be performed. A trauma or thoracic surgeon should be readily available if EDT is performed: immediate surgical intervention may be necessary if the patient is to survive. The subset of",
"    <strong>",
"     blunt",
"    </strong>",
"    trauma patients most likely to survive an EDT neurologically intact includes either the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who lose vital signs in the ED and appear to have no obvious nonsurvivable injury (eg, massive head trauma, multiple severe injuries)",
"     </li>",
"     <li>",
"      Patients with cardiac tamponade rapidly diagnosed by ultrasound, with no obvious nonsurvivable injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EDT in blunt trauma patients appears to be futile in any one or more of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient required over 15 minutes of prehospital CPR",
"     </li>",
"     <li>",
"      Patient is apneic, pulseless, and has no rhythm on cardiac monitor in the field",
"     </li>",
"     <li>",
"      Patient has massive, nonsurvivable injuries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some observational data suggest that no blunt trauma patient who requires more than five minutes of CPR survives neurologically intact [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History, examination, and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute evaluation of blunt thoracic trauma consists of rapidly assessing whether injury has occurred to cardiopulmonary and mediastinal structures. Depending on the presentation, this may be as simple as a thorough history and physical examination or may require multiple tests, including x-rays, computed tomography (CT) scans, and echocardiography.",
"   </p>",
"   <p>",
"    The clinician first determines whether the patient is at low or high risk for significant injury. This determination is based on the vital signs (most important), the mechanism and potential for injury, and the patient's complaints and general clinical appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The limited utility of mechanism should be emphasized: a young, healthy patient involved in a severe, rollover motor vehicle crash (MVC) may sustain no injuries, while a frail elderly patient who trips and falls may incur multiple rib fractures accompanied by a pulmonary contusion. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Anatomy and mechanism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies suggest the history and physical examination are insensitive for detecting intrathoracic injury. This insensitivity stems in part from the nature of the studies, which often include a heterogeneous mix of patients and injuries, a low number of positive findings, and lack follow-up.",
"   </p>",
"   <p>",
"    The risk of serious injury is low among alert patients without discomfort, dyspnea, or tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Hypoxia and abnormal lung sounds are the most specific signs for pneumothorax or hemothorax, while chest pain and tenderness are most sensitive, albeit nonspecific. Normal lung sounds showed a high-negative predictive value for pneumothorax in one prospective, observational study, but the number of patients with abnormal findings was too low to draw definitive conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph (CXR) is the initial test for all patients with blunt thoracic trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/27\">",
"     27",
"    </a>",
"    ]. The CXR is inexpensive, noninvasive, easy to obtain, and in many instances reveals useful information; studies purporting to demonstrate in which blunt trauma patients CXR is unhelpful are unconvincing. For these reasons, we suggest a CXR be obtained in all patients who have sustained blunt thoracic trauma of any significance, unless the patient requires immediate surgery or warrants immediate chest CT.",
"   </p>",
"   <p>",
"    The CXR is systematically reviewed for evidence of hemothorax, pneumothorax, pulmonary contusion, fractures, and aortic injury. Studies to determine CXR findings suggestive of blunt aortic injury (BAI) are limited by their observational design and the small number of injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Nevertheless, although no single finding on CXR possesses high sensitivity or specificity for BAI, the following findings on a plain CXR increase the likelihood of BAI and indicate a need for further investigation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wide mediastinum (supine CXR &gt;8 cm; upright CXR &gt;6 cm)",
"     </li>",
"     <li>",
"      Obscured aortic knob; abnormal aortic contour",
"     </li>",
"     <li>",
"      Left \"apical cap\" (ie, pleural blood above apex of left lung)",
"     </li>",
"     <li>",
"      Large left hemothorax",
"     </li>",
"     <li>",
"      Deviation of nasogastric tube rightward",
"     </li>",
"     <li>",
"      Deviation of trachea rightward",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right mainstem bronchus downward",
"     </li>",
"     <li>",
"      Wide left paravertebral stripe",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A widened mediastinum is a sensitive but nonspecific sign of aortic injury. Such injuries account for about 20 percent of abnormal mediastinal widening on CXR after blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/31\">",
"     31",
"    </a>",
"    ]. Further study, usually CT of the chest, is performed if CXR abnormalities consistent with aortic injury are identified. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chest CT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Initial evaluation with a portable, anterior-posterior (AP) CXR is performed in patients at greater risk of significant injury who must remain in the ED for closer monitoring. Such patients include those with: major mechanism of injury, hemodynamic instability, severe tenderness, a seatbelt sign across the abdomen, hypoxia, or clinical signs of multiple rib fractures. The plain CXR may not have sufficient sensitivity to detect injury in these patients, and minor abnormalities on CXR or clinical concern are sufficient to justify more detailed imaging with chest CT or other modalities.",
"   </p>",
"   <p>",
"    The stable patient with minimal findings (eg, minor abrasion, mild tenderness, and normal vital signs) can be sent to radiology for standard posterior-anterior (PA) and lateral CXR, provided the physical examination is otherwise unremarkable and there is no suspicion of major injury. Patients with pain and tenderness of the lower ribs, especially with pleuritic complaints, or abdominal pain and tenderness, are at higher risk for both intrathoracic and intraabdominal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal PA and lateral chest radiographs in a low-risk patient obviate the need for additional studies to rule out intrathoracic or chest wall injury. Rib films are rarely needed. They may provide more information about fractures but rarely change management. The clinician can treat patients likely to have sustained a rib fracture on the basis of symptoms and signs, despite the absence of radiographic evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"     \"Initial evaluation and management of rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have evaluated the utility of a CXR in the assessment of blunt trauma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective cohort study of patients evaluated with a CXR for blunt trauma at two major urban trauma centers found that 31 of 492 patients had a significant chest injury [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/2\">",
"       2",
"      </a>",
"      ]. The presence of hypoxia or tenderness identified all patients with important chest radiographic findings. While a decision rule based on these findings would potentially eliminate the need for 46 percent of radiographs, a validation study has yet to be performed, and these preliminary findings should not be used to determine the need for CXR.",
"     </li>",
"     <li>",
"      Similar results were found in a prospective study of 523 stable blunt trauma patients at another major urban trauma center. The presence of tachypnea, pain or tenderness, or abnormal lung sounds identified all patients with pneumothorax or hemothorax [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/25\">",
"       25",
"      </a>",
"      ]. The utility of this study is limited by the small number of patients with disease, the use of portable AP CXRs, and lack of follow-up.",
"     </li>",
"     <li>",
"      Conflicting results were found in a retrospective study of 581 patients with minor blunt chest trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/35\">",
"       35",
"      </a>",
"      ]. In 6 of 20 patients with hemothorax or pneumothorax the physical examination was normal, suggesting clinicians should have a low threshold for obtaining a CXR in blunt trauma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound (ie, Focused Assessment with Sonography in Trauma, or FAST, exam) has become an integral part of trauma evaluation, primarily to assess for pericardial tamponade and intraabdominal injury. Ultrasound of the chest is also commonly performed in the ED to rule out or diagnose pneumothorax or hemothorax. Two signs, the sliding lung and \"comet tail\" artifact, appear to reliably rule out pneumothorax. The use of ultrasound in thoracic trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=see_link\">",
"     \"Emergency ultrasound in adults with abdominal and thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic accuracy of computed tomography (CT) is far greater than plain radiography for intrathoracic injury, and allows for detailed evaluation of the pulmonary and mediastinal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. CT provides greater sensitivity in diagnosing small pneumothoraces, as well as pneumomediastinum and pulmonary contusions and lacerations. When a multidetector CT scan is used, reconstructions of the aorta and bony structures can be completed rapidly if there are any findings or concerns raised in the initial physical examination or radiological evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/11,36,40\">",
"     11,36,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of chest CT for trauma evaluation has increased dramatically [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/41\">",
"     41",
"    </a>",
"    ], and in many centers, patients involved in high-energy trauma are sent almost immediately for CT before a chest radiograph can be performed. Patients with a low-risk mechanism, minor injuries, and normal chest radiographs generally do not require CT imaging, which may be overused in these circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/36,42,43\">",
"     36,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether to obtain a CT purely on the basis of a high-risk mechanism remains controversial. Results of studies have been mixed, but tend to favor performing a chest CT in patients with significant mechanisms of injury or severe concomitant injuries. As examples, one prospective study of consecutive trauma patients with a significant mechanism of injury found that 19.6 percent of chest CT scans revealed clinically important abnormalities despite the absence of external signs of thoracic injury in the 592 hemodynamically stable patients included [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/44\">",
"     44",
"    </a>",
"    ]. A prospective study of 609 blunt trauma patients imaged with CT noted that eleven percent of chest CT scans deemed unnecessary by emergency physicians prior to their being obtained were reported to have clinically meaningful findings, including two that resulted in critical actions (spinal surgery for a T8 burst fracture and chest tube insertion for a lung laceration) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/45\">",
"     45",
"    </a>",
"    ]. A retrospective study of 108 patients involved in high energy trauma but who were hemodynamically stable and had no abnormal examination findings reported that 11 patients had abnormalities noted on CT but none required intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pending more definitive study results, we believe the decision to obtain a chest CT for thoracic trauma should be based upon clinical findings, including the patient&rsquo;s mental status and distracting injuries, the mechanism of injury, available resources, clinician judgement, institutional tolerance for delayed diagnosis (eg, forgoing a CT in favor of serial examinations and close observation), and other relevant factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUBSEQUENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients manifesting hemodynamic instability, hypoxia, or obvious severe injury require immediate assessment for life-threatening injuries with concurrent management. This is discussed above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Primary evaluation and management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who appear clinically stable without apparent injury, but have sustained high-energy blunt trauma with rapid deceleration are at risk for severe injury. Their initial evaluation is performed in the trauma or critical care area within the emergency department (ED). A portable chest radiograph (CXR) is obtained as part of this immediate evaluation. If this study is normal and no severe extrathoracic injury is identified, a posterior-anterior (PA) CXR is subsequently obtained. A chest CT is obtained if any concerning findings are identified on CXR, the patient has persistent chest pain or dyspnea, or the patient is unable to undergo a thorough clinical examination because of an extrathoracic injury.",
"   </p>",
"   <p>",
"    Patients who appear clinically stable, without apparent injury, without a concerning mechanism, and without abnormal findings on standard PA and lateral CXR require no further evaluation, with the possible exception of an electrocardiogram (ECG). An ECG is performed in all patients with anterior chest trauma, the elderly, and patients with a history of coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=see_link\">",
"     \"Cardiac injury from blunt trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients without evidence of injury after appropriate evaluation may be discharged. Patients are informed of the possibility of delayed presentations of injury and told to return to the ED immediately for such symptoms as severe pain, difficulty breathing, and lightheadedness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPECIFIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Aortic injury",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients involved in high-energy blunt trauma involving rapid deceleration (eg, fall over 3 m [10 ft], motor vehicle crash at speeds over 65",
"    <span class=\"nowrap\">",
"     km/40",
"    </span>",
"    miles per hour) are at significant risk for blunt aortic injury (BAI). Almost 80 percent of BAIs cause immediate death from aortic transection. In a minority of patients the adventitia and mediastinal structures contain the rupture, allowing the patient to survive transport to the hospital. If BAI goes undiagnosed, these patients generally sustain an aortic rupture within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/47\">",
"     47",
"    </a>",
"    ]. Prompt ED diagnosis is crucial and may be lifesaving in some patients (",
"    <a class=\"graphic graphic_algorithm graphicRef73037 \" href=\"UTD.htm?39/59/40894\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are no clinical signs or examination findings with sufficient sensitivity or specificity to detect BAI. Therefore, the clinician should use appropriate radiographic studies to assess every patient involved in high-energy trauma with rapid deceleration or who shows signs of severe chest injury. The initial study is a chest radiograph (CXR), which should be closely scrutinized for any signs of aortic injury. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chest radiograph'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk of aortic injury is negligible in patients with a truly normal CXR, no significant injury on examination, and a mechanism that does not involve rapid deceleration [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/31,36,43,48\">",
"     31,36,43,48",
"    </a>",
"    ]. No further testing is needed in such patients.",
"   </p>",
"   <p>",
"    Any abnormality on CXR should be followed by a computed tomography (CT) scan of the chest. A normal CT scan essentially rules out BAI [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/29,49,50\">",
"     29,49,50",
"    </a>",
"    ]. Clinicians often have difficulty obtaining an upright, posterior anterior (PA) CXR in a trauma patient, and subtle abnormalities may be missed on supine studies. If the clinician has a strong suspicion for BAI, CT scan should be obtained, regardless of CXR appearance. CT scan is extremely sensitive and specific for BAI, and surgeons can determine the need for operative intervention on the basis of CT findings [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/48,51\">",
"     48,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other modalities used to diagnose BAI include angiography and transesophageal echocardiography. While angiography is the traditional gold standard, and is theoretically more sensitive than CT, its use should be reserved for those patients with equivocal CT scans. Angiography is more time consuming and invasive, and rarely improves upon CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should obtain CT of the chest to assess for BAI if mechanistic, clinical, or radiographic evidence suggests the possibility of intrathoracic injury (",
"    <a class=\"graphic graphic_table graphicRef62204 \" href=\"UTD.htm?34/54/35691\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73037 \" href=\"UTD.htm?39/59/40894\">",
"     algorithm 1",
"    </a>",
"    ). Such evidence includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-energy trauma involving rapid deceleration",
"      <strong>",
"       AND",
"      </strong>",
"      any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chest wall contusions or deformity OR",
"     </li>",
"     <li>",
"      Multiple rib fractures OR",
"     </li>",
"     <li>",
"      Pneumothorax or hemothorax OR",
"     </li>",
"     <li>",
"      Abnormal chest x-ray (eg, wide mediastinum) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Chest radiograph'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chest CT has great sensitivity and specificity for BAI and is used most often to make the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. CT also enables detection of other intrathoracic injuries.",
"   </p>",
"   <p>",
"    Among patients with abnormal CXR findings, chest CT identifies injuries that would not otherwise be found, resulting in significant changes in management, between 20 and 30 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/36,55\">",
"     36,55",
"    </a>",
"    ]. Among patients without abnormal CXR findings in whom chest CT is performed solely based on mechanism, the study leads to changes in management only 5 percent of the time. An equivocal CT scan should be followed by angiography to exclude aortic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/48,51\">",
"     48,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies that assess the use of CT in chest trauma involve critically ill or multiply injured patients. Therefore it is difficult to draw conclusions about the appropriate use of CT in patients without evidence of severe injury, based solely on mechanism. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chest CT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) is an excellent modality to assess for BAI in patients too unstable for chest CT. TEE has high sensitivity and specificity for BAI, can be performed in the emergency department or the operating room, requires no contrast, and provides information about cardiac injury and function.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) is operator dependent and suffers in some studies from loss of sensitivity as the interposition of the air-filled trachea between the aorta and esophagus creates a blind spot, precluding adequate evaluation of the distal ascending aorta and proximal arch. It should not be performed in patients with unstable cervical spine injuries or esophageal injuries.",
"   </p>",
"   <p>",
"    TEE compares favorably to angiography or CT scan in the majority of cases and diagnoses some intimal tears not seen on corresponding angiography, although the clinical significance of these tears is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. It also has utility in diagnosing valvular injuries and pericardial effusions. Unlike transesophageal imaging, transthoracic echocardiography, while excellent for diagnosing significant pericardial effusions, cannot reliably diagnose BAI [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BAI awaiting transport to the operating room or a monitored setting for medical management require careful control of their blood pressure and heart rate. The medical management of patients with blunt thoracic injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H2670133#H2670133\">",
"     \"Blunt thoracic aortic injury\", section on 'Heart rate and blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for surgical treatment of aortic injury include open repair (via thoracotomy) or endovascular repair. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8921?source=see_link\">",
"     \"Surgical and endovascular repair of blunt thoracic aortic injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, emergent surgery is not feasible. The relative risks and benefits of immediate versus delayed repair are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H2669935#H2669935\">",
"     \"Blunt thoracic aortic injury\", section on 'Approach to management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac injury",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cardiac contusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should obtain an electrocardiogram (ECG) on all blunt trauma patients with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain and tenderness directly over the mid-anterior chest",
"     </li>",
"     <li>",
"      Sternal fracture",
"     </li>",
"     <li>",
"      History suggestive of cardiac disease (eg, accident precipitated by syncope, severe chest pain, or shortness of breath)",
"     </li>",
"     <li>",
"      Active symptoms or signs suggestive of cardiac disease",
"     </li>",
"     <li>",
"      Major mechanism of injury (eg, rollover, high speed, fatality at scene)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings such as unexplained persistent tachycardia, new bundle branch block, or dysrhythmia raise concern for cardiac contusion and patients with such findings should be admitted for cardiac monitoring and possibly echocardiography. Unexplained tachycardia should also prompt the clinician to look for other injuries or ongoing hemorrhage. Blunt cardiac injury, including the use of cardiac biomarkers, is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=see_link\">",
"     \"Cardiac injury from blunt trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Myocardial rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with severe blunt cardiac injury do not reach the ED alive [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Of those who do, hypotension may have reduced pressure on the injured myocardium, which may subsequently rupture as fluid resuscitation restores systemic pressure. Other injuries may lead to delayed rupture within several days of admission.",
"   </p>",
"   <p>",
"    Nonspecific signs and concomitant injuries make clinical diagnosis of myocardial injury difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/10\">",
"     10",
"    </a>",
"    ]. Signs such as hypotension associated with distended neck veins and muffled heart sounds suggest tamponade, which often occurs with severe cardiac injury. Immediate bedside ultrasound (US) by a skilled ultrasonographer can reveal the diagnosis rapidly (",
"    <a class=\"graphic graphic_movie graphicRef64027 \" href=\"UTD.htm?29/24/30094\">",
"     movie 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/9,59,60\">",
"     9,59,60",
"    </a>",
"    ]. The clinician should perform or obtain bedside echocardiography in any patient with unexplained shock out of proportion to apparent injuries or despite aggressive resuscitation. When immediate bedside US is unavailable and the clinician strongly suspects tamponade, pericardiocentesis should be performed.",
"   </p>",
"   <p>",
"    Emergency department thoracotomy (EDT) rather than pericardiocentesis may be the best treatment for tamponade from blunt myocardial injury if the patient is too unstable to be moved to the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/9\">",
"     9",
"    </a>",
"    ]. For patients amenable to operative intervention, intubation should be delayed if possible until just before sternotomy because abundant anecdotal evidence suggests induction may precipitate hemodynamic collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Emergent thoracotomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial Infarction (MI) is a rare complication of blunt chest trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Causes include coronary artery dissection and thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The left anterior descending artery appears to be involved most often, but any coronary artery may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/62,65\">",
"     62,65",
"    </a>",
"    ]. A rapid ECG is obtained in the blunt thoracic trauma patient to screen for cardiac contusion and to rule out the rare MI. The management of MI in the setting of blunt thoracic injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=see_link&amp;anchor=H17#H17\">",
"     \"Cardiac injury from blunt trauma\", section on 'Acute coronary syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pulmonary injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major pulmonary injuries that require treatment and admission include: pneumothorax, hemothorax, pulmonary contusion, pulmonary parenchymal injuries, and tracheobronchial injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax is a common complication of blunt trauma, often sustained from a fractured rib [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients may manifest tachypnea, chest pain, hypoxia, unilateral diminished or absent breath sounds, or unilateral hyperresonance to percussion, depending on the extent of the pneumothorax. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The supine chest radiograph has high specificity for diagnosing a pneumothorax from blunt injury, but its sensitivity is variable. Ultrasound may be a more sensitive initial screening tool. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Ultrasound'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Chest radiograph'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with historical features (eg, pleuritic pain, dyspnea) or examination findings (eg, rib fracture) that place them at risk for pneumothorax should be evaluated with an upright PA chest x-ray using inspiratory and expiratory views or a CT scan of the chest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53428 \" href=\"UTD.htm?3/4/3139\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58226 \" href=\"UTD.htm?32/20/33090\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73669 \" href=\"UTD.htm?35/19/36149\">",
"     image 3",
"    </a>",
"    ). Another approach in patients whose initial x-ray does not reveal a pneumothorax but who are at risk is to repeat the radiograph in six hours.",
"   </p>",
"   <p>",
"    One meta-analysis and several prospective studies support the use of a first generation cephalosporin to decrease the incidence of pneumonia, but not empyema, in patients undergoing tube thoracostomy following chest trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179627\">",
"    <span class=\"h3\">",
"     Occult pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the increased use of helical CT to evaluate trauma patients, the question of how to manage an occult pneumothorax arises frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/70\">",
"     70",
"    </a>",
"    ]. Occult pneumothorax is one not visible on a plain chest radiograph but seen on cervical, chest, or abdominal CT. In approximately 5 to 10 percent of patients, occult pneumothoraces expand and become clinically significant, in some cases developing into a tension pneumothorax. The potential risk of an expanding pneumothorax is greater in patients receiving positive pressure ventilation either during surgery or for long-term pulmonary support [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies support treating",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    blunt trauma patients with occult pneumothoraces less than 8 mm in length (as determined by CT) with observation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/11,72,73\">",
"     11,72,73",
"    </a>",
"    ]; a chest tube is placed if the pneumothorax enlarges or the patient becomes symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/73\">",
"     73",
"    </a>",
"    ]. We believe this is a reasonable approach. &nbsp;",
"   </p>",
"   <p>",
"    There is conflicting data on the need for tube thoracostomy in patients with occult pneumothorax who require positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/69,74-76\">",
"     69,74-76",
"    </a>",
"    ]. One randomized trial found that such patients are at significant risk of developing a life-threatening tension pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/69\">",
"     69",
"    </a>",
"    ]; a subsequent randomized trial reported that observation of such patients, without chest tube placement, was not associated with an increased incidence of pneumothorax progression [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/76\">",
"     76",
"    </a>",
"    ]. Both trials involved few patients and thus it is difficult to draw meaningful conclusions. Until results from large randomized trials become available, we suggest placement of a chest tube for all patients with occult pneumothorax who will be mechanically ventilated. We believe tube thoracostomy is particularly important if such patients have other potential causes for hypotension, such as intraperitoneal or retroperitoneal hemorrhage, or for impaired oxygenation, such as pulmonary contusion.",
"   </p>",
"   <p>",
"    However, not all trauma surgeons advocate tube thoracostomy in such cases. Practice guidelines from the Eastern Association for the Surgery of Trauma state that observation is an acceptable option [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/70\">",
"     70",
"    </a>",
"    ]. If tube thoracostomy is not performed in patients requiring mechanical ventilation, careful monitoring looking for signs that the pneumothorax may be expanding is critical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hemothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries leading to massive hemothorax include aortic rupture, myocardial rupture, and injuries to hilar structures. Other causes include injuries to the lung parenchyma and intercostal or mammary blood vessels. A volume of 300 mL is needed for hemothorax to manifest on an upright CXR. In skilled hands, ultrasound can diagnose hemothorax accurately. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hemothorax is treated with tube thoracostomy using a large (minimum 36 French) chest tube. Immediate bloody drainage of &ge;20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    (approximately 1500 mL) is generally considered an indication for surgical thoracotomy. Shock and persistent, substantial bleeding (generally &gt;3",
"    <span class=\"nowrap\">",
"     mL/kg/hour)",
"    </span>",
"    are additional indications. Vital signs, fluid resuscitation requirements, and concomitant injuries are considered when determining the need for thoracotomy.",
"   </p>",
"   <p>",
"    In general, a pneumohemothorax is treated with drainage by tube thoracostomy. Small, clinically insignificant collections may be treated with needle aspiration or drainage, at the discretion of the trauma surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pulmonary contusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary contusion is another common consequence of blunt chest trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/14,78\">",
"     14,78",
"    </a>",
"    ]. Pulmonary contusions generally develop over the first 24 hours and resolve in about one week. Irregular, nonlobular opacification of the pulmonary parenchyma on chest x-ray is the diagnostic hallmark. About one-third of the time the contusion is not evident on initial radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/78\">",
"     78",
"    </a>",
"    ]. Chest CT provides better resolution, but rarely alters management, unless other injuries are found. Contusions evident on CT but not plain x-ray have better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain control and pulmonary toilet are the mainstays of treatment. Prophylactic endotracheal intubation is unnecessary, but patients with hypoxia or difficulty ventilating require airway management. While opinions vary, fluid resuscitation with crystalloid to euvolemia appears appropriate. Common complications include pneumonia and acute respiratory distress syndrome (ARDS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Tracheobronchial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheobronchial injuries occur in less than 1 percent of patients with blunt thoracic trauma, and few studies exist to guide diagnosis and management [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Most patients who sustain such injuries die at the scene [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/81\">",
"     81",
"    </a>",
"    ]. The trachea is protected from injury by its position relative to the mandible, sternum and vertebral column, and its relative elasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/81\">",
"     81",
"    </a>",
"    ]. Injury of the cervical trachea is uncommon but can occur from a direct blow, which may be of low energy; injury of the intrathoracic trachea results from high-energy trauma, generally motor vehicle crashes (MVC) and sometimes crush injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Most tracheal or bronchial injuries occur as part of multiple trauma, including additional injuries to the lungs and chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/80,83\">",
"     80,83",
"    </a>",
"    ]. The right main bronchus is involved most often, generally within 1 to 2 cm of the carina, followed by the left main bronchus.",
"   </p>",
"   <p>",
"    Diagnosis is difficult and often delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/83\">",
"     83",
"    </a>",
"    ]. Intrathoracic injury can be subtle and indolent, presenting with retained secretions, recurrent pneumothoraces, and obstruction. The sine qua non of intrathoracic tracheobronchial injury is a significant air leak and pneumothorax or pneumomediastinum that reaccumulates despite tube thoracostomy. A cervical injury may present without a significant air leak, if the tear or rupture is contained by the adventitia. Signs of cervical tracheal injury include dyspnea, hoarseness, and subcutaneous emphysema.",
"   </p>",
"   <p>",
"    Radiographs generally reveal marked air in local soft tissue (ie, subcutaneous emphysema). If tracheal disruption occurs, the larynx can rise, allowing the hyoid bone to ascend above the level of the third cervical vertebra, an unusual finding otherwise. Fractures of the first three ribs are associated with intrathoracic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Other radiologic findings on plain film include: persistent pneumothorax with a dependent lung, interstitial air in the wall of the trachea or mainstem bronchus, abnormal location of the endotracheal tube (ETT), and a distended ETT cuff due to protrusion of the trachea. Of note, an isolated finding of air outlining the trachea or mainstem bronchus from pneumomediastinum does not correlate significantly with tracheobronchial rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive diagnosis is made in the operating room or by bronchoscopy. Multidetector CT scan (MDCT) enables diagnosis of some tracheal tears, but its sensitivity is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82\">",
"     82",
"    </a>",
"    ]. If tracheobronchial injury is suspected, obtain a MDCT or consult a thoracic surgeon for evaluation and possible bronchoscopy. Most patients undergo primary repair or possible lung resection, although good results using selective nonoperative management have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/81,83,84\">",
"     81,83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diaphragm rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt diaphragmatic rupture occurs in approximately 1 percent of thoracic trauma patients, although it has been reported in up to 8 percent of those requiring laparotomy. Its incidence is increasing, however, as the resolution and diagnostic accuracy of multidetector CT scanners improves. While case reports exist of diaphragmatic rupture following minor trauma, [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], the great majority of cases result from high-energy injuries, most often motor vehicle crashes (MVC). Data from studies of highway MVCs suggest that significant intrusion (&ge;30 cm) into the passenger compartment following head-on or near-side collisions and rapid deceleration (&ge;40",
"    <span class=\"nowrap\">",
"     km/hour)",
"    </span>",
"    increase the risk of sustaining a diaphragmatic rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/87\">",
"     87",
"    </a>",
"    ]. Left-sided rupture occurs approximately twice as often as right sided [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Anatomic differences account for this discrepancy: the posterolateral aspect of the left hemidiaphragm is relatively weak and the bowel and stomach provide less protection than the liver.",
"   </p>",
"   <p>",
"    Diaphragmatic rupture can occur from several possible mechanisms: increased abdominal pressure from forceful impact can cause stretching and avulsion; the same pressure can cause direct lacerations; or fractured ribs can penetrate the muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82\">",
"     82",
"    </a>",
"    ]. Tears tend to be in a radial orientation along the posterolateral aspect of the diaphragm. Diagnosis is easiest in left sided injuries when bowel enters the thoracic cavity. Small tears may require years before negative intrathoracic pressure and the positive intraabdominal pressure ultimately lead to herniation of viscera.",
"   </p>",
"   <p>",
"    Severe concomitant injuries occur in 50 to 90 percent of cases. Injuries to the spleen and liver are most common. Pelvic and long bone fractures, closed head injuries, and blunt aortic injury can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82,87,90-92\">",
"     82,87,90-92",
"    </a>",
"    ]. Diaphragmatic injuries are often diagnosed incidentally during laparotomy or thoracotomy to treat coexistent injuries. Symptoms vary and generally reflect the severity of both the diaphragmatic injury (eg, tear versus rupture with herniation) and associated injuries.",
"   </p>",
"   <p>",
"    Diaphragmatic injury may be associated with epigastric and abdominal pain, referred shoulder pain, shortness of breath, vomiting, dysphagia, or shock. The initial chest x-ray (CXR) is normal or nondiagnostic in up to 50 percent of patients. Nevertheless, the CXR may reveal diagnostic findings, such as abdominal viscera in the hemithorax, a nasogastric tube in the thorax, or a focal constriction of herniated viscera at the site of the tear, producing circumferential compression (collar sign). CXR may also reveal nonspecific findings such as atelectasis, pleural effusion, loss of the usual hemidiaphragm contour, eventration of the diaphragm, and pneumothorax or hemothorax, although none of these is sensitive or specific for diaphragmatic injury. Serial CXRs may be useful, especially in patients in whom positive pressure ventilation has prevented bowel herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82,93\">",
"     82,93",
"    </a>",
"    ]. Because many studies do not differentiate between penetrating and blunt injuries, plain CXR may have greater accuracy in detecting injuries due to blunt trauma than has been thought.",
"   </p>",
"   <p>",
"    The multidetector CT (MDCT) has improved our ability to diagnose diaphragmatic injury and is the best available test. In addition to improved resolution, MDCT allows for production of sagittal and coronal reformatting, which appears to improve accuracy. Conventional CT scanning has limited accuracy. At one institution with a large experience using single-slice CT, the sensitivity for diagnosing left-sided diaphragmatic tear was 78 percent and right-sided tear 50 percent with 100 percent specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/94\">",
"     94",
"    </a>",
"    ]. However, if visceral herniation was not present, accuracy was poor. Right-sided injuries are more difficult to diagnose because the liver and diaphragm have a similar appearance on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82,95\">",
"     82,95",
"    </a>",
"    ]. Coexisting injuries, atelectasis, and aspiration can obscure the diaphragm and decrease sensitivity. Congenital left hemidiaphragmatic defects may represent a normal variant in a significant subset of patients, further decreasing accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Esophageal rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt trauma patients rarely sustain esophageal rupture. Esophageal injury lacks specific symptoms and generally occurs in multiple trauma making it difficult to diagnose. Injuries may be seen in the cervical, thoracic, and distal esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82,96-98\">",
"     82,96-98",
"    </a>",
"    ]. Given the small number of reported cases, it is difficult to describe any specific patterns of injury. Potential mechanisms include: compression, traction from cervical hyperextension, and direct penetration from thoracic fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82\">",
"     82",
"    </a>",
"    ]. Signs of injury may include: blood in the nasogastric aspirate, subcutaneous cervical air, and neck hematoma, but none is sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain x-ray may reveal pneumomediastinum, pleural effusion, mediastinal contour changes (which progress with inflammation), or a gas bubble in the nasogastric tube or esophagus, if a tracheoesophageal communication exists. Diagnosis is made by endoscopy or esophagography using water-soluble contrast. CT may show subtle air leaks beside the site of perforation, although the sensitivity or specificity of such findings is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82\">",
"     82",
"    </a>",
"    ]. Pneumomediastinum without a clear cause suggests the need for further evaluation. Esophageal injuries are often associated with severe concomitant injuries that may mask findings, delaying diagnosis until mediastinitis or an empyema develops [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/82,96\">",
"     82,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Sternal fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of sternal fracture displacement correlates with the risk for associated thoracic injury, although even nondisplaced fractures carry a substantial risk [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. Common associated injuries include: rib fracture, myocardial contusion, hemopericardium, spinal fracture, retrosternal hematoma, hemothorax, and pneumothorax.",
"   </p>",
"   <p>",
"    In a small autopsy study, AP chest radiograph had approximately 50 percent sensitivity for detecting sternal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/104\">",
"     104",
"    </a>",
"    ]. Lateral views improve sensitivity, but it is unclear by how much. CT appears to be more sensitive, but no gold standard exists. We suggest a CT of the chest and an electrocardiogram (ECG) be obtained to rule out associated injuries if a sternal fracture is diagnosed on plain film. Depending upon clinical circumstances, cardiac biomarkers may also be obtained.",
"   </p>",
"   <p>",
"    In a hemodynamically stable patient with an isolated, nondisplaced sternal fracture and no ECG abnormalities, cardiac monitoring is rarely warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/103\">",
"     103",
"    </a>",
"    ]. We suggest patients with associated intrathoracic injuries, severe pain, or poor pulmonary reserve, particularly the elderly, be admitted for observation. Some sternal fractures may be treated better by subperiosteal anesthesia or operative fixation. Clinicians should obtain consultation with a general or trauma surgeon if complicating factors are present.",
"   </p>",
"   <p>",
"    Sternal fractures usually result from a high-energy direct blow to the anterior chest wall. Typically these fractures occur during a motor vehicle crash when the driver's chest strikes the steering column or rapid deceleration causes an occupant's chest to slam against their cross-shoulder seatbelt [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/103,105\">",
"     103,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Scapular fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scapular fractures occur from trauma involving significant force and raise concern for further injury [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/106\">",
"     106",
"    </a>",
"    ]. High-speed motor vehicle crashes and falls from heights are common mechanisms. Associated injuries include intrathoracic injuries, clavicle fractures, rib fractures, spine fractures, spleen and liver injuries, and tibial fractures (usually in pedestrians struck by motor vehicles). The association between scapular fracture and blunt aortic injury may be overestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We obtain a chest CT in most patients with a scapular fracture following significant blunt chest trauma because of the forces involved and the risk of concomitant injury. We further suggest clinicians obtain consultation with trauma and orthopedic surgery. If the chest CT and workup for extrathoracic trauma reveal no injuries, and no concerns exist about analgesia, comorbidities, or the patient's social circumstances, patients with scapular fractures may be discharged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Rib fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with three or more rib fractures, especially elderly patients, are at significant risk for complications, such as pulmonary contusion and pneumonia, even in the absence of other injuries, and should be admitted for observation. Rarely, healthy, younger individuals with three rib fractures, having undergone a thorough clinical and radiographic evaluation by clinicians experienced in trauma management, and an appropriate period of observation, may be discharged from the emergency department. The management and disposition of patients with rib fractures and no other injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and management of rib fractures\", section on 'Disposition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link\">",
"     \"Inpatient management of traumatic rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Flail chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flail chest occurs when three or more adjacent ribs are each fractured in two places, creating one floating segment comprised of several rib sections and the soft tissues between them (",
"    <a class=\"graphic graphic_figure graphicRef79746 \" href=\"UTD.htm?23/19/23857\">",
"     figure 1",
"    </a>",
"    ). This unstable section of chest wall exhibits paradoxical motion (ie, it moves in the opposite direction of the uninjured, normal-functioning chest wall) with breathing, and is associated with significant morbidity from pulmonary contusion. Abnormal motion can be difficult to detect making the diagnosis difficult.",
"   </p>",
"   <p>",
"    Initial management of flail chest consists of oxygen and close monitoring for early signs of respiratory compromise, ideally using both pulse oximetry and capnography in addition to clinical observation. Stabilization of the segment with manual or object pressure restricts chest wall expansion thereby interfering with proper respiratory mechanics and is no longer used. Use of noninvasive positive airway pressure by mask may obviate the need for endotracheal intubation in alert patients. Patients with severe injuries, respiratory distress, or progressively worsening respiratory function require endotracheal intubation and mechanical ventilatory support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link&amp;anchor=H1068084913#H1068084913\">",
"     \"Inpatient management of traumatic rib fractures\", section on 'Flail chest'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2471727\">",
"    <span class=\"h2\">",
"     Sternoclavicular dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sternoclavicular (SC) joint is a diarthrodial, saddle-type, synovial joint that can sublux or dislocate anteriorly or posteriorly. The usual mechanism is a direct, high velocity blow to the medial clavicle or medial compression of the shoulder girdle. If the shoulder and arm are posterior to the plane of the body during compression, an anterior dislocation results; if the shoulder and arm are anterior, a posterior dislocation results.",
"   </p>",
"   <p>",
"    Although uncommon, posterior SC joint dislocations can cause significant internal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Posterior displacement of the clavicle can cause breathing difficulty from tracheal compression, lacerate or occlude the subclavian or brachiocephalic vessels, damage the lung parenchyma causing a pneumothorax, or injure the laryngeal nerve (which may present as hoarseness). Patients commonly present with anterior chest and shoulder pain exacerbated by arm movement, but may also complain of dyspnea, dysphagia, or upper extremity paresthesias depending upon the internal injury sustained. Examination may reveal a prominence at the SC joint with anterior dislocation, but a corresponding depression may be difficult to detect with a posterior dislocation. It is important to check pulses in the affected extremity.",
"   </p>",
"   <p>",
"    Plain radiographs are not sensitive for detecting SC dislocation. While special views can be obtained to improve sensitivity (eg, &ldquo;serendipity view&rdquo; with beam angled approximately 45 degrees cephalad), it is best to obtain a contrast-enhanced CT of the chest if there is any suspicion for posterior dislocation or internal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?33/39/34426/abstract/109\">",
"     109",
"    </a>",
"    ]. This study enables evaluation for both bony and vascular injury.",
"   </p>",
"   <p>",
"    Initial treatment of SC dislocation depends upon the type of dislocation and the severity of associated symptoms.",
"    <strong>",
"     Anterior",
"    </strong>",
"    subluxations require no immediate treatment. However, a true anterior dislocation should be reduced within 12 to 24 hours. This can often be done as an outpatient by orthopedic surgery.",
"   </p>",
"   <p>",
"    <strong>",
"     Posterior",
"    </strong>",
"    SC dislocations become increasingly difficult to reduce after 24 hours so timely diagnosis and treatment is important. Many can be reduced under procedural sedation in the ED. In general reduction should be performed by an orthopedist, but airway compromise may mandate immediate reduction by the emergency physician. Consultation with cardiovascular surgery is necessary, especially when underlying hematoma is seen on CT, as bleeding from a vascular injury may occur following reduction. Unless emergent reduction must be performed due to airway compromise, the cardiovascular surgeon should evaluate the patient and make needed preparations before the reduction is performed.",
"   </p>",
"   <p>",
"    Several reduction techniques have been proposed. Most are variations of a traction-abduction method, where traction is applied to the affected arm, which is held in 10 to 15 degrees of extension and 90 degrees of abduction, while pressure is applied to the posterior aspect of the clavicle. Another option is to grasp the proximal clavicle using a sterile towel clip and sterile technique and pull it anteriorly, while traction is maintained on the arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of the patient with blunt thoracic trauma (BTT) follows the basic principles of Advanced Trauma Life Support&copy;. A basic algorithm for management of BTT is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef81674 \" href=\"UTD.htm?38/36/39489\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians managing BTT first assess and stabilize the patient's airway, breathing, and circulation. The one caveat to this principle is that breathing may take priority over airway if a tension pneumothorax is present. In this case, the clinician should relieve the pneumothorax before performing tracheal intubation, if needed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When determining the likelihood of severe injury from blunt thoracic trauma, abnormal vital signs are more important than mechanism of injury. Immediate life-threatening injuries from blunt chest trauma include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aortic injury",
"     </li>",
"     <li>",
"      Tension pneumothorax",
"     </li>",
"     <li>",
"      Hemothorax with severe, active bleeding",
"     </li>",
"     <li>",
"      Pericardial tamponade from myocardial injury",
"     </li>",
"     <li>",
"      Tracheobronchial disruption",
"      <br/>",
"      <br/>",
"      Emergent management of life-threatening injuries is discussed above. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initial management'",
"      </a>",
"      above.) Subsequent management of specific injuries is discussed separately above. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Aortic injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Pulmonary injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Cardiac injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the setting of blunt trauma, emergency department thoracotomy (EDT) rarely results in successful resuscitation. The subset of blunt trauma patients most likely to survive an EDT neurologically intact include either of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who lose vital signs in the ED and appear to have no obvious nonsurvivable injury (eg, massive head trauma, multiple severe injuries)",
"     </li>",
"     <li>",
"      Patients with cardiac tamponade rapidly diagnosed by ultrasound, with no obvious nonsurvivable injury (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Emergent thoracotomy'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a chest x-ray (CXR) be obtained in all patients who have sustained blunt thoracic trauma of any significance, unless the patient requires immediate surgery or warrants immediate chest CT. The CXR is systematically reviewed for evidence of hemothorax, pneumothorax, pulmonary contusion, fractures, and aortic injury. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chest radiograph'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients involved in high-energy blunt trauma involving rapid deceleration are at significant risk for blunt aortic injury (BAI). Almost 80 percent of BAIs cause immediate death. No clinical signs or examination findings and no single finding on CXR possess adequate sensitivity or specificity for BAI. The following CXR findings increase the likelihood of BAI and indicate a need for further investigation, usually chest CT:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wide mediastinum (supine CXR &gt;8 cm; upright CXR &gt;6 cm)",
"     </li>",
"     <li>",
"      Obscured aortic knob; abnormal aortic contour",
"     </li>",
"     <li>",
"      Left \"apical cap\" (ie, pleural blood above apex of left lung)",
"     </li>",
"     <li>",
"      Large left hemothorax",
"     </li>",
"     <li>",
"      Deviation of nasogastric tube rightward",
"     </li>",
"     <li>",
"      Deviation of trachea rightward",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right mainstem bronchus downward",
"     </li>",
"     <li>",
"      Wide left paravertebral stripe",
"      <br/>",
"      <br/>",
"      BAI is discussed in detail above. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Aortic injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bedside ultrasound is a critical tool for the diagnosis of traumatic pericardial tamponade. Ultrasound is more sensitive for diagnosing pneumothorax than CXR and is also useful for diagnosing hemothorax. We suggest a chest CT be obtained if any concerning findings are identified on CXR, the patient has persistent chest pain or dyspnea, or the patient is unable to undergo a thorough clinical examination because of an extrathoracic injury. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Ultrasound'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Chest CT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2654747\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/1\">",
"      Liman ST, Kuzucu A, Tastepe AI, et al. Chest injury due to blunt trauma. Eur J Cardiothorac Surg 2003; 23:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/2\">",
"      Rodriguez RM, Hendey GW, Marek G, et al. A pilot study to derive clinical variables for selective chest radiography in blunt trauma patients. Ann Emerg Med 2006; 47:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/3\">",
"      Nirula R, Talmor D, Brasel K. Predicting significant torso trauma. J Trauma 2005; 59:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/4\">",
"      Newman RJ, Jones IS. A prospective study of 413 consecutive car occupants with chest injuries. J Trauma 1984; 24:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/5\">",
"      Gaillard M, Herv&eacute; C, Mandin L, Raynaud P. Mortality prognostic factors in chest injury. J Trauma 1990; 30:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/6\">",
"      Arthurs ZM, Starnes BW, Sohn VY, et al. Functional and survival outcomes in traumatic blunt thoracic aortic injuries: An analysis of the National Trauma Databank. J Vasc Surg 2009; 49:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/7\">",
"      Fitzharris M, Franklyn M, Frampton R, et al. Thoracic aortic injury in motor vehicle crashes: the effect of impact direction, side of body struck, and seat belt use. J Trauma 2004; 57:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/8\">",
"      McGwin G Jr, Reiff DA, Moran SG, Rue LW 3rd. Incidence and characteristics of motor vehicle collision-related blunt thoracic aortic injury according to age. J Trauma 2002; 52:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/9\">",
"      Fitzgerald M, Spencer J, Johnson F, et al. Definitive management of acute cardiac tamponade secondary to blunt trauma. Emerg Med Australas 2005; 17:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/10\">",
"      Fulda G, Brathwaite CE, Rodriguez A, et al. Blunt traumatic rupture of the heart and pericardium: a ten-year experience (1979-1989). J Trauma 1991; 31:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/11\">",
"      Ball CG, Kirkpatrick AW, Laupland KB, et al. Incidence, risk factors, and outcomes for occult pneumothoraces in victims of major trauma. J Trauma 2005; 59:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/12\">",
"      O'Connor JV, Kufera JA, Kerns TJ, et al. Crash and occupant predictors of pulmonary contusion. J Trauma 2009; 66:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/13\">",
"      von Oppell UO, Dunne TT, De Groot MK, Zilla P. Traumatic aortic rupture: twenty-year metaanalysis of mortality and risk of paraplegia. Ann Thorac Surg 1994; 58:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/14\">",
"      Wanek S, Mayberry JC. Blunt thoracic trauma: flail chest, pulmonary contusion, and blast injury. Crit Care Clin 2004; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/15\">",
"      Ullman EA, Donley LP, Brady WJ. Pulmonary trauma emergency department evaluation and management. Emerg Med Clin North Am 2003; 21:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/16\">",
"      Kohn MA, Hammel JM, Bretz SW, Stangby A. Trauma team activation criteria as predictors of patient disposition from the emergency department. Acad Emerg Med 2004; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/17\">",
"      Grove CA, Lemmon G, Anderson G, McCarthy M. Emergency thoracotomy: appropriate use in the resuscitation of trauma patients. Am Surg 2002; 68:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/18\">",
"      Fialka C, Seb&ouml;k C, Kemetzhofer P, et al. Open-chest cardiopulmonary resuscitation after cardiac arrest in cases of blunt chest or abdominal trauma: a consecutive series of 38 cases. J Trauma 2004; 57:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/19\">",
"      Stockinger ZT, McSwain NE Jr. Additional evidence in support of withholding or terminating cardiopulmonary resuscitation for trauma patients in the field. J Am Coll Surg 2004; 198:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/20\">",
"      Powell DW, Moore EE, Cothren CC, et al. Is emergency department resuscitative thoracotomy futile care for the critically injured patient requiring prehospital cardiopulmonary resuscitation? J Am Coll Surg 2004; 199:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/21\">",
"      Cothren CC, Moore EE. Emergency department thoracotomy for the critically injured patient: Objectives, indications, and outcomes. World J Emerg Surg 2006; 1:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/22\">",
"      Rhee PM, Acosta J, Bridgeman A, et al. Survival after emergency department thoracotomy: review of published data from the past 25 years. J Am Coll Surg 2000; 190:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/23\">",
"      Dubinsky I, Low A. Non-life-threatening blunt chest trauma: appropriate investigation and treatment. Am J Emerg Med 1997; 15:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/24\">",
"      Chen SC, Markmann JF, Kauder DR, Schwab CW. Hemopneumothorax missed by auscultation in penetrating chest injury. J Trauma 1997; 42:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/25\">",
"      Bokhari F, Brakenridge S, Nagy K, et al. Prospective evaluation of the sensitivity of physical examination in chest trauma. J Trauma 2002; 53:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/26\">",
"      Rodriguez RM, Hendey GW, Mower W, et al. Derivation of a decision instrument for selective chest radiography in blunt trauma. J Trauma 2011; 71:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/27\">",
"      Ho ML, Gutierrez FR. Chest radiography in thoracic polytrauma. AJR Am J Roentgenol 2009; 192:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/28\">",
"      Marnocha KE, Maglinte DD, Woods J, et al. Blunt chest trauma and suspected aortic rupture: reliability of chest radiograph findings. Ann Emerg Med 1985; 14:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/29\">",
"      Kram HB, Appel PL, Wohlmuth DA, Shoemaker WC. Diagnosis of traumatic thoracic aortic rupture: a 10-year retrospective analysis. Ann Thorac Surg 1989; 47:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/30\">",
"      Ekeh AP, Peterson W, Woods RJ, et al. Is chest x-ray an adequate screening tool for the diagnosis of blunt thoracic aortic injury? J Trauma 2008; 65:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/31\">",
"      Woodring JH. The normal mediastinum in blunt traumatic rupture of the thoracic aorta and brachiocephalic arteries. J Emerg Med 1990; 8:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/32\">",
"      Holmes JF, Ngyuen H, Jacoby RC, et al. Do all patients with left costal margin injuries require radiographic evaluation for intraabdominal injury? Ann Emerg Med 2005; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/33\">",
"      Thompson BM, Finger W, Tonsfeldt D, et al. Rib radiographs for trauma: useful or wasteful? Ann Emerg Med 1986; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/34\">",
"      Bansidhar BJ, Lagares-Garcia JA, Miller SL. Clinical rib fractures: are follow-up chest X-rays a waste of resources? Am Surg 2002; 68:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/35\">",
"      Rossen B, Laursen NO, Just S. Chest radiography after minor chest trauma. Acta Radiol 1987; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/36\">",
"      Omert L, Yeaney WW, Protetch J. Efficacy of thoracic computerized tomography in blunt chest trauma. Am Surg 2001; 67:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/37\">",
"      Shanmuganathan K, Mirvis SE. Imaging diagnosis of nonaortic thoracic injury. Radiol Clin North Am 1999; 37:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/38\">",
"      Brink M, Deunk J, Dekker HM, et al. Added value of routine chest MDCT after blunt trauma: evaluation of additional findings and impact on patient management. AJR Am J Roentgenol 2008; 190:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/39\">",
"      Dissanaike S, Shalhub S, Jurkovich GJ. The evaluation of pneumomediastinum in blunt trauma patients. J Trauma 2008; 65:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/40\">",
"      Hauser CJ, Visvikis G, Hinrichs C, et al. Prospective validation of computed tomographic screening of the thoracolumbar spine in trauma. J Trauma 2003; 55:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/41\">",
"      Lee J, Kirschner J, Pawa S, et al. Computed tomography use in the adult emergency department of an academic urban hospital from 2001 to 2007. Ann Emerg Med 2010; 56:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/42\">",
"      Plurad D, Green D, Demetriades D, Rhee P. The increasing use of chest computed tomography for trauma: is it being overutilized? J Trauma 2007; 62:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/43\">",
"      Kaiser ML, Whealon MD, Barrios C Jr, et al. Risk factors for traumatic injury findings on thoracic computed tomography among patients with blunt trauma having a normal chest radiograph. Arch Surg 2011; 146:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/44\">",
"      Salim A, Sangthong B, Martin M, et al. Whole body imaging in blunt multisystem trauma patients without obvious signs of injury: results of a prospective study. Arch Surg 2006; 141:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/45\">",
"      Gupta M, Schriger DL, Hiatt JR, et al. Selective use of computed tomography compared with routine whole body imaging in patients with blunt trauma. Ann Emerg Med 2011; 58:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/46\">",
"      Millo NZ, Plewes C, Rowe BH, Low G. Appropriateness of CT of the chest, abdomen, and pelvis in motorized blunt force trauma patients without signs of significant injury. AJR Am J Roentgenol 2011; 197:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/47\">",
"      PARMLEY LF, MATTINGLY TW, MANION WC, JAHNKE EJ Jr. Nonpenetrating traumatic injury of the aorta. Circulation 1958; 17:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/48\">",
"      Dyer DS, Moore EE, Ilke DN, et al. Thoracic aortic injury: how predictive is mechanism and is chest computed tomography a reliable screening tool? A prospective study of 1,561 patients. J Trauma 2000; 48:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/49\">",
"      Mirvis SE, Shanmuganathan K, Buell J, Rodriguez A. Use of spiral computed tomography for the assessment of blunt trauma patients with potential aortic injury. J Trauma 1998; 45:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/50\">",
"      Woodring JH, Dillon ML. Radiographic manifestations of mediastinal hemorrhage from blunt chest trauma. Ann Thorac Surg 1984; 37:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/51\">",
"      Dyer DS, Moore EE, Mestek MF, et al. Can chest CT be used to exclude aortic injury? Radiology 1999; 213:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/52\">",
"      Bruckner BA, DiBardino DJ, Cumbie TC, et al. Critical evaluation of chest computed tomography scans for blunt descending thoracic aortic injury. Ann Thorac Surg 2006; 81:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/53\">",
"      Demetriades D, Velmahos GC, Scalea TM, et al. Diagnosis and treatment of blunt thoracic aortic injuries: changing perspectives. J Trauma 2008; 64:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/54\">",
"      Steenburg SD, Ravenel JG. Acute traumatic thoracic aortic injuries: experience with 64-MDCT. AJR Am J Roentgenol 2008; 191:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/55\">",
"      Guerrero-L&oacute;pez F, V&aacute;zquez-Mata G, Alc&aacute;zar-Romero PP, et al. Evaluation of the utility of computed tomography in the initial assessment of the critical care patient with chest trauma. Crit Care Med 2000; 28:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/56\">",
"      Chirillo F, Totis O, Cavarzerani A, et al. Usefulness of transthoracic and transoesophageal echocardiography in recognition and management of cardiovascular injuries after blunt chest trauma. Heart 1996; 75:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/57\">",
"      Goarin JP, Cluzel P, Gosgnach M, et al. Evaluation of transesophageal echocardiography for diagnosis of traumatic aortic injury. Anesthesiology 2000; 93:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/58\">",
"      Vignon P, Boncoeur MP, Fran&ccedil;ois B, et al. Comparison of multiplane transesophageal echocardiography and contrast-enhanced helical CT in the diagnosis of blunt traumatic cardiovascular injuries. Anesthesiology 2001; 94:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/59\">",
"      MacFarlane C. Blunt trauma cardiac tamponade: what really counts in management. Emerg Med Australas 2005; 17:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/60\">",
"      Mangram A, Kozar RA, Gregoric I, et al. Blunt cardiac injuries that require operative intervention: an unsuspected injury. J Trauma 2003; 54:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/61\">",
"      Atalar E, A&ccedil;il T, Aytemir K, et al. Acute anterior myocardial infarction following a mild nonpenetrating chest trauma--a case report. Angiology 2001; 52:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/62\">",
"      Naseer N, Aronow WS, McClung JA, et al. Circumflex coronary artery occlusion after blunt chest trauma. Heart Dis 2003; 5:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/63\">",
"      Foussas SG, Athanasopoulos GD, Cokkinos DV. Myocardial infarction caused by blunt chest injury: possible mechanisms involved--case reports. Angiology 1989; 40:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/64\">",
"      Banzo I, Montero A, Uriarte I, et al. Coronary artery occlusion and myocardial infarction: a seldom encountered complication of blunt chest trauma. Clin Nucl Med 1999; 24:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/65\">",
"      Dahle TG, Berger A, Tuna N, Das G. Coronary artery stenting for acute myocardial infarction secondary to mild, blunt chest trauma in a soccer player. J Invasive Cardiol 2005; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/66\">",
"      Kulshrestha P, Munshi I, Wait R. Profile of chest trauma in a level I trauma center. J Trauma 2004; 57:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/67\">",
"      Luchette FA, Barrie PS, Oswanski MF, et al. Practice Management Guidelines for Prophylactic Antibiotic Use in Tube Thoracostomy for Traumatic Hemopneumothorax: the EAST Practice Management Guidelines Work Group. Eastern Association for Trauma. J Trauma 2000; 48:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/68\">",
"      Maxwell RA, Campbell DJ, Fabian TC, et al. Use of presumptive antibiotics following tube thoracostomy for traumatic hemopneumothorax in the prevention of empyema and pneumonia--a multi-center trial. J Trauma 2004; 57:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/69\">",
"      Enderson BL, Abdalla R, Frame SB, et al. Tube thoracostomy for occult pneumothorax: a prospective randomized study of its use. J Trauma 1993; 35:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/70\">",
"      Mowery NT, Gunter OL, Collier BR, et al. Practice management guidelines for management of hemothorax and occult pneumothorax. J Trauma 2011; 70:510.",
"     </a>",
"    </li>",
"    <li>",
"     Pasternak, GS, O'Cain, CF. Thoracic complication of respiratory interventions. In: Iatrogenic Thoracic Complications, Herman, PC (Eds), Springer Verlag, New York 1983. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/72\">",
"      Wilson H, Ellsmere J, Tallon J, Kirkpatrick A. Occult pneumothorax in the blunt trauma patient: tube thoracostomy or observation? Injury 2009; 40:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/73\">",
"      Moore FO, Goslar PW, Coimbra R, et al. Blunt traumatic occult pneumothorax: is observation safe?--results of a prospective, AAST multicenter study. J Trauma 2011; 70:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/74\">",
"      Wolfman NT, Myers WS, Glauser SJ, et al. Validity of CT classification on management of occult pneumothorax: a prospective study. AJR Am J Roentgenol 1998; 171:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/75\">",
"      Garramone RR Jr, Jacobs LM, Sahdev P. An objective method to measure and manage occult pneumothorax. Surg Gynecol Obstet 1991; 173:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/76\">",
"      Brasel KJ, Stafford RE, Weigelt JA, et al. Treatment of occult pneumothoraces from blunt trauma. J Trauma 1999; 46:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/77\">",
"      Delius RE, Obeid FN, Horst HM, et al. Catheter aspiration for simple pneumothorax. Experience with 114 patients. Arch Surg 1989; 124:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/78\">",
"      Richardson JD, Adams L, Flint LM. Selective management of flail chest and pulmonary contusion. Ann Surg 1982; 196:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/79\">",
"      Deunk J, Poels TC, Brink M, et al. The clinical outcome of occult pulmonary contusion on multidetector-row computed tomography in blunt trauma patients. J Trauma 2010; 68:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/80\">",
"      Cassada DC, Munyikwa MP, Moniz MP, et al. Acute injuries of the trachea and major bronchi: importance of early diagnosis. Ann Thorac Surg 2000; 69:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/81\">",
"      Balci AE, Eren N, Eren S, Ulk&uuml; R. Surgical treatment of post-traumatic tracheobronchial injuries: 14-year experience. Eur J Cardiothorac Surg 2002; 22:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/82\">",
"      Mirvis SE. Imaging of acute thoracic injury: the advent of MDCT screening. Semin Ultrasound CT MR 2005; 26:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/83\">",
"      Kiser AC, O'Brien SM, Detterbeck FC. Blunt tracheobronchial injuries: treatment and outcomes. Ann Thorac Surg 2001; 71:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/84\">",
"      G&oacute;mez-Caro A, Aus&iacute;n P, Moradiellos FJ, et al. Role of conservative medical management of tracheobronchial injuries. J Trauma 2006; 61:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/85\">",
"      Goh BK, Wong AS, Tay KH, Hoe MN. Delayed presentation of a patient with a ruptured diaphragm complicated by gastric incarceration and perforation after apparently minor blunt trauma. CJEM 2004; 6:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/86\">",
"      Toh CL, Yeo TT, Chua CL, Low CH. Diaphragmatic injuries: why are they overlooked? J R Coll Surg Edinb 1991; 36:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/87\">",
"      Reiff DA, McGwin G Jr, Metzger J, et al. Identifying injuries and motor vehicle collision characteristics that together are suggestive of diaphragmatic rupture. J Trauma 2002; 53:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/88\">",
"      Chen JC, Wilson SE. Diaphragmatic injuries: recognition and management in sixty-two patients. Am Surg 1991; 57:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/89\">",
"      Voeller GR, Reisser JR, Fabian TC, et al. Blunt diaphragm injuries. A five-year experience. Am Surg 1990; 56:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/90\">",
"      Ilgenfritz FM, Stewart DE. Blunt trauma of the diaphragm: a 15-county, private hospital experience. Am Surg 1992; 58:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/91\">",
"      Rodriguez-Morales G, Rodriguez A, Shatney CH. Acute rupture of the diaphragm in blunt trauma: analysis of 60 patients. J Trauma 1986; 26:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/92\">",
"      Chughtai TS, Sharkey P, Brenneman F, Rizoli S. Blunt diaphragmatic rupture mandates a search for blunt aortic injury: an update. Ann Thorac Surg 2007; 83:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/93\">",
"      Barkin AZ, Fischer CM, Berkman MR, Rosen CL. Blunt abdominal trauma and a diaphragmatic injury. J Emerg Med 2007; 32:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/94\">",
"      Killeen KL, Mirvis SE, Shanmuganathan K. Helical CT of diaphragmatic rupture caused by blunt trauma. AJR Am J Roentgenol 1999; 173:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/95\">",
"      Morgan AS, Flancbaum L, Esposito T, Cox EF. Blunt injury to the diaphragm: an analysis of 44 patients. J Trauma 1986; 26:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/96\">",
"      Beal SL, Pottmeyer EW, Spisso JM. Esophageal perforation following external blunt trauma. J Trauma 1988; 28:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/97\">",
"      Moreno-Ramos MD, Serrano BV. Distal esophageal perforation secondary to blunt trauma diagnosed by computed tomography. Eur J Radiol 2004; 51:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/98\">",
"      Strauss DC, Tandon R, Mason RC. Distal thoracic oesophageal perforation secondary to blunt trauma: case report. World J Emerg Surg 2007; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/99\">",
"      Gill SS, Dierking JM, Nguyen KT, et al. Seatbelt injury causing perforation of the cervical esophagus: a case report and review of the literature. Am Surg 2004; 70:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/100\">",
"      Glatterer MS Jr, Toon RS, Ellestad C, et al. Management of blunt and penetrating external esophageal trauma. J Trauma 1985; 25:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/101\">",
"      von Garrel T, Ince A, Junge A, et al. The sternal fracture: radiographic analysis of 200 fractures with special reference to concomitant injuries. J Trauma 2004; 57:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/102\">",
"      Roy-Shapira A, Levi I, Khoda J. Sternal fractures: a red flag or a red herring? J Trauma 1994; 37:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/103\">",
"      Peek GJ, Firmin RK. Isolated sternal fracture: an audit of 10 years' experience. Injury 1995; 26:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/104\">",
"      Lederer W, Mair D, Rabl W, Baubin M. Frequency of rib and sternum fractures associated with out-of-hospital cardiopulmonary resuscitation is underestimated by conventional chest X-ray. Resuscitation 2004; 60:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/105\">",
"      Wojcik JB, Morgan AS. Sternal fractures--the natural history. Ann Emerg Med 1988; 17:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/106\">",
"      Stephens NG, Morgan AS, Corvo P, Bernstein BA. Significance of scapular fracture in the blunt-trauma patient. Ann Emerg Med 1995; 26:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/107\">",
"      Brown CV, Velmahos G, Wang D, et al. Association of scapular fractures and blunt thoracic aortic injury: fact or fiction? Am Surg 2005; 71:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/108\">",
"      Groh GI, Wirth MA. Management of traumatic sternoclavicular joint injuries. J Am Acad Orthop Surg 2011; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/39/34426/abstract/109\">",
"      Macdonald PB, Lapointe P. Acromioclavicular and sternoclavicular joint injuries. Orthop Clin North Am 2008; 39:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 353 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34426=[""].join("\n");
var outline_f33_39_34426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY AND MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3179290\">",
"      Anatomy and physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3179283\">",
"      Selected mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREHOSPITAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRIMARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Emergent thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History, examination, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUBSEQUENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPECIFIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Aortic injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cardiac contusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Myocardial rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3179627\">",
"      - Occult pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hemothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pulmonary contusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Tracheobronchial injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diaphragm rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Esophageal rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Sternal fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Scapular fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Rib fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Flail chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2471727\">",
"      Sternoclavicular dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2654747\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/353|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/59/40894\" title=\"algorithm 1\">",
"      Algorithm for management of blunt aortic injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/36/39489\" title=\"algorithm 2\">",
"      Blunt chest trauma in adults algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/353|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/4/3139\" title=\"diagnostic image 1\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/20/33090\" title=\"diagnostic image 2\">",
"      Hemopneumothorax I PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/19/36149\" title=\"diagnostic image 3\">",
"      Tension pneumothorax I PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/353|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23857\" title=\"figure 1\">",
"      Flail chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/353|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/24/30094\" title=\"movie 1\">",
"      Pericardial effusion with tamponade subcostal view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/54/35691\" title=\"table 1\">",
"      Summary of tests for blunt aortic injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=related_link\">",
"      Blunt thoracic aortic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=related_link\">",
"      Cardiac injury from blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=related_link\">",
"      Emergency ultrasound in adults with abdominal and thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28247?source=related_link\">",
"      Initial evaluation and management of chest wall trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=related_link\">",
"      Initial evaluation and management of rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=related_link\">",
"      Inpatient management of traumatic rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31801?source=related_link\">",
"      Resuscitative thoracotomy: technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8921?source=related_link\">",
"      Surgical and endovascular repair of blunt thoracic aortic injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_39_34427="Fondaparinux in ACS";
var content_f33_39_34427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Study drug administration during PCI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Time since last injection(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        &le;6 hours",
"       </td>",
"       <td class=\"subtitle2\">",
"        &gt;6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Last injection",
"        </p>",
"        <p>",
"         <strong>",
"          Double",
"         </strong>",
"        </p>",
"        <p>",
"         (fonda/placebo + enox/placebo)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Last injection",
"        </p>",
"        <p>",
"         <strong>",
"          Single",
"         </strong>",
"        </p>",
"        <p>",
"         (enox/placebo ONLY)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Last injection",
"        </p>",
"        <p>",
"         <strong>",
"          Double or single",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With GP IIb/IIIa",
"       </td>",
"       <td>",
"        No study drug",
"       </td>",
"       <td>",
"        Fonda/placebo 2.5 mg IV",
"       </td>",
"       <td>",
"        Fonda/placebo 2.5 mg IV + UFH/placebo 0.013 mL/kg IV (65 u/kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Without GP IIb/IIIa",
"       </td>",
"       <td>",
"        Fonda/placebo 2.5 mg IV",
"       </td>",
"       <td>",
"        Fonda/placebo 5.0 mg IV",
"       </td>",
"       <td>",
"        Fonda/placebo 5.0 mg IV + UFH/placebo 0.02 mL/kg IV (100 u/kg)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. N Engl J Med 2006; 354(14):464. Copyright &copy;2006 Dr. Salim Yusuf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34427=[""].join("\n");
var outline_f33_39_34427=null;
var title_f33_39_34428="Stepwise diagnostic evaluation for cardiac sarcoidosis";
var content_f33_39_34428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F85756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F85756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stepwise diagnostic evaluation for cardiac sarcoidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <p>",
"         <strong>",
"          Step 1",
"         </strong>",
"        </p>",
"        Initial evaluation for cardiac disease in all patients with sarcoidosis",
"       </td>",
"       <td>",
"        History and physical examination",
"       </td>",
"       <td>",
"        Findings may include dyspnea, dizziness, bradycardia, ventricular or atrial arrhythmia, although some patients are asymptomatic and have no physical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrocardiogram",
"       </td>",
"       <td>",
"        Abnormal: heart block",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <p>",
"         <strong>",
"          Step 2",
"         </strong>",
"        </p>",
"        Initial noninvasive evaluation for patients with suspected cardiac disease",
"       </td>",
"       <td>",
"        Holter monitor",
"       </td>",
"       <td>",
"        Abnormal: &gt;100 extra ventricular beats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiogram",
"       </td>",
"       <td>",
"        Abnormal: hypokinesia, aneurysmal dilatation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <p>",
"         <strong>",
"          Step 3",
"         </strong>",
"        </p>",
"        Additional noninvasive imaging in patients with suspected cardiac disease: CMR plus PET are suggested if available",
"       </td>",
"       <td>",
"        Cardiovascular magnetic resonance (CMR) imaging",
"       </td>",
"       <td>",
"        Useful in detecting granulomatous inflammation (more sensitive than gallium, thallium, or technetium scans)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FDG PET",
"       </td>",
"       <td>",
"        Useful in assessing granulomas or ischemia (more sensitive than gallium, thallium, or technetium scans)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radionuclide (gallium, thallium, technetium sestamibi) scans",
"       </td>",
"       <td>",
"        Useful in assessing granulomas or ischemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Step 4",
"         </strong>",
"        </p>",
"        In selected patients",
"       </td>",
"       <td>",
"        Coronary angiography",
"       </td>",
"       <td>",
"        Useful in excluding coronary artery disease when noninvasive testing reveals regional abnormalities which may be caused by either coronary disease or sarcoidosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Step 5",
"         </strong>",
"        </p>",
"        In selected patients",
"       </td>",
"       <td>",
"        Endomyocardial biopsy",
"       </td>",
"       <td>",
"        Only if the patient has no histological confirmation from any other source",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Step 6",
"         </strong>",
"        </p>",
"        In selected patients",
"       </td>",
"       <td>",
"        Electrophysiologic study",
"       </td>",
"       <td>",
"        In selected patients with high risk features (eg, abnormalities on CMR or PET imaging) who lack established indications for implantable-cardioverter defibrillator (ICD) placement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and expanded from: Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Mon 2005; 32:130.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34428=[""].join("\n");
var outline_f33_39_34428=null;
var title_f33_39_34429="Nocturnal asthma - effect of prednisone on BAL";
var content_f33_39_34429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Effect of prednisone on BAL cellularity in nocturnal asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of a 3 PM prednisone dose on 4 AM bronchoalveolar lavage finding in nocturnal asthma. Prednisone (red column) led to a significant fall in the number of total white blood cells, neutrophils, eosinophils, lymphocytes, and macrophages when compared to placebo (blue column).",
"    <div class=\"footnotes\">",
"     <p>",
"      BAL: bronchoalveolar lavage.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Beam WR, Weiner DE, Martin RJ, Am Rev Respir Dis 1992; 146:1524.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34429=[""].join("\n");
var outline_f33_39_34429=null;
var title_f33_39_34430="Main airway management algorithm";
var content_f33_39_34430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Main emergency airway management algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 522px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34430=[""].join("\n");
var outline_f33_39_34430=null;
var title_f33_39_34431="Posterior shoulder dislocation and fracture";
var content_f33_39_34431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior shoulder dislocation and fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 305px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAExAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD57kLGRsMQcnjNRhmB+81X5IAXbPPNRFVH8OfegCoS5P3m/OlAfu5H41O0Zxkcj6VEQ2cYoAaeOrsR9aXew+7uH1NAA701s9ulACmRh1dj+NMMjsfvNj60BRRgZoATc395vzpdzf3j+dJ9BRyaADc/95vzpNz/AN5vzpaAKAE3N/eb86Te/wDeP50uKTb70AJvf+8fzpN0mfvn86dikP1oAN792P50F2/vN+dJmk4NACl2I4c/nQC+OWbP1pu3n5aUAjr0oAXcwH3m/OmszY4Jz9aeMHvTSATQBGWb+8350m5v7x/OnlaaVoAaxb+8fzqM7j/G351MVpuPagCu2/8AvN+dRkv/AHm/OrRXNMdB2oArFnH8TfnSb3/vN+dSMvqKYV9KAE3v/eb86N7/AN5vzppFFADt7/3m/Oje/wDeb86bRQA7e/8Aeb86N7/3m/Om0UAO3v8A3m/Oje/95vzptFADt7/3m/Oje/8Aeb86bRQA7e395vzptFFABRRRQAUUUUAFFFFABRRRQAUUUUAFS7mE+Azfe9feoqkP/Hx/wL+tAHe3EP7xiAQc1VeDgnGTW5dQjccDPOaoSo2T2+lAGay4xk4qJyc4K8etXHhweDURj5oApOikcdaiKkdqutHg96jZMe1AFXbmkZSD6VOy/lQQCKAIAtGKkKkdelN6UAJimtjinmo2IoAaTTSacQAMt+AqW3t5bzhMLGvG40AVWIH8XNIoeQ4jVm+grYTToIyPMBkfPfgflVpTtIA4x2AoAw1s7lhxGR9SBSmwuB1Cf99CtpwSCOMg0zJJUYGOtAGN9luF5MZI9jmo8sDggg+h4rdK7QDzj1FQylZYzuVWUHHuaAMnrQKsy2vzYg+uDVXnOCMY60ALQRSgUu2gBlIEGOalK468n0pp560ARnkYHA7CoyPap8U0r1IoAgZevFROmKtFetMI4oAplaYVxVtowelRMuKAK9FSFaYRQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFP/wCW/wDwL+tMqQ/8fH/Av60Aez3MADHAIOaz5rfkkLXU3tqQ7HaD6VmTQHt6UAc5Jb45wc1UaKuilhJ4xVKWHOTgD1oAxHi68c1XkTFa0sJGcAVVdCDnFAGe0fFV3j+taLpjr0qvKOaAKfI68imkADI5FTSL1FV2GPWgBrHjvTOByT+FPbHU1oadZlGE06kN/CpH60AJYacGHm3Q+btGT/Or5HHBxgkDtipFjYvnrj2pzR5GenUE9qAIEUYG4A9AalVI1VWZuTkEdTj0FEh2kZygbhhn+dQA7ZDwNpGMe/vQAkzAHACjL8H1oC/KgwdvPbmpDbmUxtt2gnAParMSpEpEmcJ8uWHQkdaAMxsNE2304B4qGeJhIE2kAD8M1pzAMYz5YHmKeCMd8ZFZdy7pK2/J5xQBA0h35UYHSpTFHcDDYSU/db1+tRq2V2Nk4Oc04RusvGCR+tAFJ43icpICrDtTlHHtVq4czQgsnzxHGe5HvVYc0ANIpMVIPQCkK0AREUhFTHpTSO5oAiIppWpSM9qRhQBAVA7imFQetWCKjZeOOtAFZo+eKiZat4qN0zQBVZaZVllPpUbJQBFRSlSKSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKep3Sg+rZplOj/1i/UUAfTlzCoJwAc1k3FuNzcYyM11mrWUttMUuYWhk9HXFZM8A7YoA5eWADJxz61Rlg+8e3pXS3EOARj8azp7cEnAH1oA5+SHjp19RVSWLkggVtzQc81Smj29fwoAxZowFJFUpV9K2pU+XG0VQnQhjxQBmyIOoFV5EHb0q/InWq7wsSAoyWOAKADSbQTzmSVCYY+T6MewraKFmJIGT+lX44FtbaKFQMqPm46nvUciZBBUA4zkdRQBSIKrjjk5z3BphPc8c9MdvWrZRsltoZTwQBUTwyrkx8egoAYI0ZjG+cHHzD9DQbcu7ebiSJTndH1PbH1p8NszSoM7Sp3Edfwq/JEoZiP3cjLl1IxgjuPXNAFXy1TaDnGPkDHHHbNJDi52rIV2pliO7YqcwxSFW3CMsvBYHqOKhdZo7SNgmU3EMFHJ+tAFOUrMyZPyq/c1nXkJjvJlZdwU4BPT2rUjmWNWyVyegccioZYJGtjceXvjHyhwc96AMvyCJQFDZ7n2qewUifO8BgSAD3qxbJJJKuW3ccY7f/WqxPYskWCqlicrtPP4UAY0kLxzDdgg5zzxVRkKSMpHetJoS+URcMh+YNximOqMpjcZkH3WHagCiBTiB65oxhsEcjrmnLjGPSgBm3HakI96kIJpCtAERpCDUuM8UmMUAQnOeg/Kmc+gqfbTCvtQBCw46D8qjYe1WCtIRQBVIyKieM1aZT2qMoT2oAqstRstWnQg81Gy+lAFaipWX86jIwaAEooooAKKKKACiiigAooooAKKKKACiiigAp0f+sX6im06P/WL9RQB+kWuaJputR4niDMM4PcfSvMfEHgmezMklnN50Y5CPw2PrXpo4bGSD7GhlWRsPyCPWgD54uoiGZXBVh1BGKoTxL9BXv+s+GtP1BczWyOw/iHX864PVvBc0Du9oitH2Unn86APKbleOKzJ0LNwpP0FegXti8WQ8HluP7y1nS2j8FQPft/OgDgZYZNxxG/5VBJaTPnEbfU13ctpKRhQWY88EVSnspjjYGBHXPOKAOKfT5wPmUYPvVvRdGknvsuV2xDfjPftW7LZuScpjv/8ArrW8N2QEFy4wGLBSOtAGK2lyEkvJt7k9aG0l1zmUgEcHBNdWLNiozhcH7pHX8aiuLZ05YLuJIAV936CgDkX0tkY5nUEDK5XH40j6TtGZZWdR02gfzrqPsgVJPNZeRyGUYp9pajh4V3LjBPTH50AYOl6UPmabJJOVzzkD1xSyWcbvJK4y6EbkJ45OAVPpXT3m1PlKSpIVBUIwK/U4rInglMpaaRWSRSowSpUelAGC0Q+2iFyFLHaGxlQCe/tUUUDRwygOGCPjC9zn1rTlsTE+8zOqgZXacOPY+1Z9xujJaRg+9gAyv29aAMprczTsrxJkDIK/LVcxz26eT87R5LsAMLnp1rWJZMqpDgH7pGR+VRXQ86LcPkYjLAZA/wA4oAzo2Royy7o3Hy4XpirtvAdv7x8/KGG08r701rZ4VIGPmA5I61NAvlBDBIqS9QecZ/woAlvLJZWO87TwTxy/496x7zTfnMkQxET1PUV2eh+TdXHlyAx3RGSuPlk+lXJ9N3zzBTmMqd8Lj94D2xQB5bqEOGDhQOcH3qpjGPeuu1jTg9lcTwjKw/fHQj3xXMbMrmgCPGR2o29zVhY8gcUvleooAqlaTZxVjyz6UhjPSgCvsH1ppXg1Y2c8Cgp9BQBWKGmeVuzx+NWSo7DJ96ayk0AViij3pjJkcVaKe1Jt5oAoMhGeAahaInJFam3HWmMgPUUAZJQ1Gy1qNbbjxUL22TwKAMxhikq3Lbuo5XiqzIQaAG0UUUAFFFFABRRRQAUUUUAFFFFABTo/9Yv1FNp0f+sX6igD9KZ7dg+eD+FQNE5PPt2rqXgRu2PpVSWzGemV60AYqIwI2859TUgt45+DlW+lXXtguMDApWhwASGx7UAc7qnh+C6UqwJxXG6t4LMSM8IEkYydpPP516p85zsIx71I21kXzApx/doA8Cn0hIg+8GN/Rv8APNUJtIDJnfI4PXFe+XujWF/Eyyxxs7dN3UVyWs+DXkb/AEdQyIPlVXIoA8nu9IZInChOn8WBV/QdNjXSXY7g5kJ+UjkADitjUNFvIrg+fazBDwzD5s1HHKFt/LjAVEcjaVII4GaAM5rJJ3Edu2x2H3X5Bqulu9q4SLyXDDHGf51vSw228PEhR1Ue2f8A61ZTWE0rCVVVo+/OAKAMmeFFumjkMRDLgkjgf40skUkFl5lm8ZDDawk4wfWt64gK6UWVoWvYjwF5LKenSuWmvW/ePOXjnjG0KVG1uemaAEubaVoVw0HnLgEoepPb8qwNQLZUyFmySc4xj8q15dZEkbAItvK4wx2Dn/CotMuLVwsNxN5j7SNw9e1AGNO7RqrjB2jo/OR2rLmugXDeSocHPsRXYahprwzIZYycDPBB7ZGK568hxlHiQMvQY60AZEyI86t5ZGedyngVOHeBlLgNgd+3+NTy2cnkiQKNpOAMUwLvn8uU4IGOO3FAGcXa2kYAAgjPrU0bJPGBjYT/ABdfwqbWLbZ5TK2ONvTrWeoLDA3A54oA1dPRhNuMuHTmM9a73R7mLU0QXQ8u9XGJOzY6GuBgcTqocuCvyg54rXsn2OpJZhkfMnDZHXNAHpz+DY9Z8P66kSKl5Jbu4Izhsc183zWz21xLbzKVkiYowPYivrL4Sa7ALxobyX52XYu8dawvjt8JJ9Wuz4i8JW0bzMha7t1bBkwOGQdz7UAfNkUZH07VOI+nSnRxssjRyAxuhwVYYIPoRU6x4PAyKAK/k8dKa9sDjBNaSRjA3AZp3lk8YGKAMc2xC8YzULxMM5FbrQegPNMMHPNAGC0Zx0qPb9eK22tRySBUD2g7UAY5GKQ/StR7Zh/CCKqy2xBOBQBT6UgXJ9KnED+oAFMYHGBigCM4IwOBUbDHB609kYdcU3oMEUAAb1FH2a2nP70Fc9wcUgIOQ3UUhUHPNACP4blmybKVJCOdjcE/SsS5t5rWdoriNo5F6qwwa34pZYWBViB6ZrQkvo9RtRb6lGJlUEI5Hzx/Q/0oA4uirN7aSW0hB+ZM/Kw71WoAKKKKACiiigAooooAKdH/AKxfqKbTo/8AWL9RQB+p9FV3vIkzkn8qYl/CxIzigC0yBhg0zyV96cjq4yjAj2p1AED2yMSeRntUU1vtXCDPoc1cooAw1hfzGOMsOR7VWuPPDEEgEdRXSEqvUgZqpdJD95gvPvQBzr3MSxE4cuvr0NYontGkmM0KnOOX4Brc1QxmJgm3d2IGcVx2sxtPOmGeRlH8J5FAEN5JBPdsVjRFOdrISTkevtWHeAkszN5jdBuBG38K24Xi06B3u2V5iMFe+P8AGuZ1HUY59RQ58tW42tgUAT2EJjYhWIDttKhev41y3i+xjjeWeVyNuDsx6nrXZeGLJvPnurxwtvFlslvbrXCeKNQjmeaSd2cMeF/vDPFAHM3kxJ3KqkoAAT2qiwlt3Dnq3cdDWjtW4B8oZUjlelZ86tIyoqn5e2aALUusX1u4ZJVKthmU8gcVZtr+31C7Ed7F5TuMCRT/AJxWTdQgRqrZDdeDUNsykqs2cBuWxzigD0N9H8rTxNDJ50Q56fMPciub1OzZfMkCKGJyD61e8H6l9l1DyJJMxMMIxOQwyOK6DxPaRfaDs3YIB46Z9qAPPb4FoFVmw2c4xyD3rKABBHGDwTXUXIPmEqm4gYrDlgVZS8R9sUAVTEVwBjAORzWpp7SKwPQjuDwKoiEAkhmwfWrloHV8Lhsd6AO1025miaNlILg7lY8EH2r2j4e+MPtFmljqQKuvCyY/nXgdrLI4AYDaK6bRbvy0BLHAOOuKAO6+Knwp03xA0uo2JNpqedxkXlZOO4/qK+evEHh+/wDDl79n1FAP7sifdavprw14pPEF25eIKBgjOK19Z0fTNftf9RFcRtzhhnFAHyFHg49OlSKQM/0r03xh8MLi0aWbSI/kBz5Wc15zc2txZymO7geF/RlxQAzH8qaUyMU4Ln/GpFjI560AVWjFRtb5PNaPlcZ5phiPNAGW8ZBxnio2g3cVsCDPJ6VDJERkDn6UAYssK5IC+1VXtgegrdeDnioGtwQRjmgDBazHbINQvbMOhBrckhI6VWeAEE45oAw5IG4K4zUOGzjGDWy6dmBNVLi3IJYcj2oAo7+eaeD0qTySe4NRtEydQce1ACyqs0ZRqx7q2MT+1au49j+Bpsq7xhgTQBhlcU2rk0W0kYqApQBFRTippuKACiiigAp0f+sX6im06P8A1i/UUAfpjJhiVJPHXNVWxG7E5x7UTfPkk/N3qEuBu/SgDSsrkRH5dwB67q1o50k4yM1y/ntlNxyO9SG8SOTLDaDxnNAHUMwUZqCa6EabsZFYi3rgsC2ewqO5ugRjcc96AK3irWpEtcWigSN1J7VwN5rWpW0is1y0iY+4Rwa3NTuHkcg7WVeeeK5fU5Mks6HueORj/CgCyPEbyt+9byn7KD3qSDVHabe0gII6jFcjdD5iAc4J2gDn8aitrhoGyzYB6Kw5oA7DUyl0zqwidcKyvnBH1+lYmrWNjCqqZDJt5BjxUbahE8BMpPmk8hu341HaxBuUUZZunBzxQBvSPbweC7uRd0asAu5jz+VeYaobZrRZHkY4bANegeM1W28HvHjDZ3EHgk9K8kvpZPs6IFPX7poAsq0SxqY1+Uc5J5qOWMJECihV6kjqfaqMNwywsrpySOTxU0RDxEKMK3QZ60ALc7S2BnoCOfbpVXZ5iZGSg5BNW5YipjBXLHBC9SKcEkKncCR9MYNAEC+YkKyx5U5B2kfp9a7HUrh7iytZIyS5RSctyRXHEbpEDP1Ycetb2lbvKe3IJCsQvrQBSLncSWyH7VUniMgMrbgOQeO9aFxCzcGLJHTAwDTlRBNtcfKw6Y6HFAGJGCSSyjI4wauQRIxDcAr2zU0lqYjnHLc806ONkPygN68UAWbOWTfhiMjp6CteyLkbhyfesu0jCvh2BNa0AIQKGUAdaAOgsLplZcZ3cZArq9F1ue2m/dttHueK4S2cxfxZNadpcMVYk9ecUAeu217bajGFkURyn34JrnfFHgqw1eLbdQ7j1DDII+lc5Z6g8bDDEDHb1rrNH1/bhLjLoeozQB414l+Ht5pZklsGa5gHOzadwritjIzB1ZH7gjBr62UW1/H+6ZTnqp4rmfEngqy1SI+daoWzw4GGH4igD50G/HABFOChge1dlrvgHVdNndrWP7Tb9Qq/eArlZUZHKSIyOOCrDBFAFZ12rhetQ9jxyOlXfLPpxTGiHUD5qAKLRjJ9qieMGtAxgD5s5xwRULQknsaAM+SLPSqzQDk5Oa1JIiGwVIqJo8jNAGJND7VVKMgOBweorceDnjpnpVWWD5jkcUAYk8IGCucVEVwORkVoPGVyrD6VBIntQBSeJW7c1A0G37pIq2wOSMYphB6frQBnXERIJZc+4qiyDt+tbjqeoAxVWeJW5K80AZBUimlatvCw+7URH94UAVmWmkVYK56Uxl9qAIadH/rF+opStIgxIv1oA/SOYkE7TWfPJIrHYx2irc7cnniqMzjn0oAZ9pkDDIz71K8qyNtfIGOtUGcj7pxUUlwUYZOV6GgDQO6NOH3DqBVabU2hi3MhyelUZrnyd2Qc4+Uj+dZV3czOrFHbyuNwPPP1oA0dTuE4DAo8mD07Vg30kbKGicMMYAJxima1dH7UZ/MbYQAMGsyeUPEHLcMPl9aAIbjExPIG3PynioZbb9wjEBkByATjFCyxtLypcH0HNU9QmjaNVLFcZ4IoAozs7TysFdZGGWGcgin6DPMl5EmflAL+WRyKquBEjMA2Mc7hggU7wuVn1KRY842FRnn04oA6P4gakslpb26r8xj8wqTyOeK8vv5vMCbhjkkEGug8f3fnaveOshIRRECDxgDGK4SO+zIolPIHBoAsPMuSSCWHTJqWC8AkX5VUjvVe4kBw6ruHU47VAzwso+8jevXNAHRR6oysvnIrkfcZD92tJ3ivY/NDMdwzy2MGuLBfIaJgcegq5Y6pLbyfP8y9wBwfqKANYpG7OwIDKN2M5/Kpor6S2lRkKt0bHcn/ABq7pGv+GmfOo2j+aw24C8H/AAr0bQdf+HEaK1zYqbhflBeDdgjuDnmgDjxvuQFm+8w9OM+lSR6fJG8ayq23qCwOMV6ha+JfDE7MLVVVTzkRgZNbFpd6TcfJGsfPI3qKAPE5rMjDICUViu0c0C3UJggow7Y617Rf+GLO+gP2dY0c8kx9D+Vc5e+DZouVQvgdgaAPOo4FjJ+UevAq5F8xzgjt05roW0GWJiDC6+xGKgl0yZS2xSpHPSgDOjjDRjqMdc96tIGQAIae0Ei43JjNOSHI+YEYHFAFqCQjGRn9Kv21yUJ2qBWYowBU8bYK/wAxQB0thqUilHQrn0rqbLXVk+W4XdgdutedwSgnuB2NX7adg2T0HB9KAPSBDBew74eR3Fcj4l8C6fqqHzIysmch06g0adqJiI2sykH1rqbDV4ZlCT8ZH3qAPCfEXgO/0xnazY3MAycFSGxXIBMSsCpRx1UjBFfWEtpFcrujKuDXM6/4JsNUiYPbJ5p53qMMD9aAPnWSLdknGfaomg54BzXc+IfAmraU7Pbxfa7f/Z+8v+Ncg/ysUOVcHG1hgigCiydM8/SomgwD3zWiyHutMZDxigDLlj6AACqssXJHFbLxk9QKryRcHpnpQBz13bkrnPI55qk8Y74ro5ocqQRWZc2+CdooAxZYsE1BLHk1pyoWHTkVVdD260AUBkHGOPeo3VT0H61bdDnkVBIhHagCjLHjkCqzx960nBxVZ46AM949p4NMwehq8yetQMnJoAqstIq/vF+tTshHT8qao/eL9RQB+hU8wBIzWbNJyfSmXEzAnris6e76gdaALckgIGDxULOG6gYrNluyjfN09qWK7VsEMDQBNOd+M9BxWTqErLjZwoyD71pS3A2c8LWRdTfPhGz3xQBQ1DzmjZl2kAAnBrFupWCRkg5B4rR1GeNlcBgJD2HBrnbqUnCiRyCe46UAWZHfdlXHByRVOe+/eP5hztAwMcfnVW4udmAVOeoI/rWdLM7S5Qj7hJ4oAkv7rPzENvz0HIro/BE3+tuBt3A8Z47VxE1zLMzhtu3OeMV1vgpN0Ij3b2LEkDtxQByOvXDSvduSOWYnjvXGGQua6nxdKkc9xEpBJznHauTUZGCcUAaFndbR5ZxzxViOOSTcEZSU5ANYTlkbntWlbyF4sgndigC9CSGYMCrdOKtujHeeGwPSqMDs5VWzx3qdmZSGJxnnOeooAbJbhSG4HfAqBD1OSPpVve8kSFI2JHovFL9mWIBrjq3QD0oAjF1cxMDHOwPtWpY+JtWtmDRXY4PdRWYbCRomeDLKDz7VFcxS2hEdzHJG5AbDDGQaAO90j4qavYOBNDFPGRyF+U13ug/GOK4KxzK8MndJMY/A14GhHcEf1pZ1BwwBxQB9c6f4r07V49l1Eh3Dqjirw0fT7pQ9s7Ke2TmvkTS9UvLGRXgmkAHbNejeGviFNbNGlxJIBkdf8aAPXr/ww4zg7gDwQOKwbvSHgYgDIHcitnQfHNvdhVkl+Ygda6XzbLUUztXOOo7UAeZzW7DBCnnjioSgTg8V3t9ojMjGMZX+Eg9K5680qWIAmM59aAMeMjnH1qwjmMjrj2pTbOhJZT+VAhb+H8jQBYjnzgN2NaVpcMOQelYpQ5yuMfyqWNpFcDPvQB2VhqMsO1lNdHaatFcEJMuxj/F2rziKdgMBiKtRXbxchjQB6U9skq7sqwPpXEeK/h5pmthpSrQXPUSoec+9SafrrQEfvCP611VjrEE6gSY6Zz2oA+d/E3gnV/DnzEfa7bs8SklfqK5cSBhhgRzzX1+UguVwpVl7iuL8VfDbSdYhmeK3W2vGHyyxnAz7gdaAPnVlGCVPJqu6eo5rqvEvgfXvD+ZLq0M1v0E9v8wx7jqK5kvk9eRwQetAFSWMgVRniOeOprXP3ce/eq0kYzkj8qAOflhwCaoypgk9Aa3p4uW44z0qjNAOcigDFlTOentVZl556VqzxYzgciqkseR0wRQBnSL3GcGoSm4cHmrzx4ByKryJjsaAKTJ1qJl4q649RUTJ3AoAqMvYimCMFh9assnPIpFT94uPWgD7cvGKn696x7nIBwKv3Upz6msi7kdWPB2/zoAgaTruOQRVSOcpKy9qjuJflOT9KzPP/wBJB5oA6Ga4PkFieABWDfXO4s3OOlWNUmaO0DAnnFc7PNlslsDtQAy6uWeViOp5rOlzM6gNjOenrUqRS3MrLHkqOSR2FTtb7IAoGMc5PagDD8nzFdTnI6nFVVhundkh2njPUDrWyyoJVUDocMaoT20uZIgr8jr2/OgDJkVIR+8OSPlyPWtzQNShtbaQsG3YOAo68+tYq2rg4POOT6CprJAZZUUgqRjnoKAMrxCp+03EjHJb5unrWGq/Lxnkdq6DxJgSMN2TtA96whgdiRQAyRGKAoM44Oau6fCTJtyAxpbSMyI4IIXoKfExjujtU7l7GgDWhtUjO92ORwcDrUsHlvIqpEBtwPUmqyyvK3yEAbeQauWm5SAifLnAYmgDWt7MzZeNHX+H2qSHRA8aSyscoccdKnjkLRqGZ9wOCM4CmrV5crCqxq+SwBOOeaANbw3pkMcrSThTBENzAgc+lcX8QtZj1vVAEjCtFhNwHbniui8Qal/ZXg9QrKLu4lIIHoP8k15lGWkbcck5yT6mgC1Eg2E4HApZBlMdOKkTIBFD5yeMjvQBHCuSDVxFyPWq8JGOKtID2zigC5YXdxZyK8L8DseRXdeG/GksBCz5U9x2rgoc8Cp1GeCP/r0AfQOj+K4p9g55rpEvoLxCHFfNFpfXNmVaGRsA/dPSuw0Hxi0bhbiUoexbkUAeuT6THMN0MmC3Y9KzLjSJYn+cYz6VT03xCjxxyLMrI3p2robbVo5hywIoA5uaxZWG75WBqtJHhsbTkV2skNtcrnjJ9KzbvTWXJUEr2oA51RyAQc1KhHQfj7VYmt5F3DbjHP1qthvegAbg5xirNvfSwuCDkDtVcMGUhhz2pvPBI4oA6nT9XBx5blX9D3rprHWMELcLnPda81hJUHHb0q3b30ykASHA7UAerIYbmM7cMp7EVwnjD4Y6Xrsj3CZguCPvR4HPv61LpuqtGwPm4bp7V1Fhq6SqomZdx7igD528RfDfVtIDyW0iXMa5yp4bH9a4S6R4JmjmUxyKcEGvtKa3guk+ZVYeorkfEngTSNXDfa7KOQnOHAww/EUAfKUhyRkCqkgG8kV6p4t+FV/p++bR91zECcROw3Aex715rfWN1p90Yr+3mt5QfuyLjP8AjQBkypyeKpSx/gK1Jz85PaoWUMoxigDHki7ZqBoiPpWtLEMcAfhUJhHAA5oAyni+Y96haLOcVrvAQelMMBYfd5oAx2h7UwRHevHetVoDnGOnWo1h/eDjvQB9ZXLYJwayL6UZwPTmrdzJ15zz61jXj8k+nvQBnXj55NZivvu1C846mrF3LnODzUVlEWLzN8qKOD6mgB99cb4fLBzt7VmR28t5cLBCCZHOAO31NWJBJNcLFCjySv02jrXdeH/D8OlWa3d2wM5+ds9vagDGi0mKxtBbqQZSvzPjGT61i3MZQPHngelbuq3jSlmUCMckGubuArSMTMS7DnceKAMifLSbSjEdd2O1UpJJCzxctxwDWtcq0cUhdsKVAWs1YC0nmSuyIDjhcFjQBmMrKpLDOeGbHT2qtqdw9raiKDCSOdzODgqOwrWuoGEbq2AigsOeprndREnmDd3AyGoAzLgPI26Qszj+JjULAngDjGCauOE3FmO4jtmoG4xvG0HpxigDR0eEiBT94E96LyILMrKcN04rPjupYATGc4OfatK1Q3H77erMSMoD0oA2dGtYnU+bjzRg8dKlliW2zkKVxnGe9Z8UskbsqcK2AcHGPetOzhN/FKjMAwHDMevNAEQm2o7K4GxcZXnLVPZb7jUIIhgszLwegHc1QurO5s2MTKSMbiAOtVre7ktI57kyYkQHaO+T6UAS+NtVj1LViltxbW42KPU9zWLA2GGzJPfNU8ktknO7kmrdvhBnuR0oA0UbGwbDjGaLuRY4tmDufpVQ3YXoST6ZqPzGlYs5+ntQBZhI6EVcjJxxiqMTAsMCrsJ6d6ALcWcdanUt2FV1cAYx9KsI2FwaAJg3HSj2xQpGOnFSqPloAmsLme1f9w7Lz0B4NdJp/iia3YGeIsvTKNXLjGRjORU8eSpBIGO1AHqui+KLe7UeW2WHUE4IrqbPVAw6nkV4CVkhcPDKyN1DKcVtaX4rv7J1FyTPGOM9GFAHuiyQ3CZYAHHXFVZ9O3A7QG9cdRXIaH4liu4Q6yDJ6jPIrprXUw207ufY9aAKF5amI8Dj6VWwAo+XPNdOGhuQfMCmqdxpaBSYmY98elAGKigqSmetSsG4I9Kka2aLgqwPqKbhsjI59+KAGLIUIGeT71bhmKkOrlXHbNRCNX4IwaeiBOOnfPXNAG9pWtSwNyCR35611VlrMFwgLfKe9eepwNwOB7ipba7eKQDccE8HsaAPR2ihuFOwqQetYWveF7TUoilxBFMno6A4qlZ6jIoBSQg1rW2t8BZlzjv0oA8T8V/B0l5J9JufJJORC6/L9BivMdb8I61pDH7XZMYx/HEdymvstHtLxOCpLdj1rN1Lw9bXIOY1YHsVzQB8SMvznqB0pPLwM8GvpnxB8K9GvTI/2XypDzuiyteZa78K7uzy1hcGQZ+7Ip/mKAPNBGrcnr6U0xc9a0tR0u902Zo720ljIP3yh2n8agWMN0PBoAoywHOAPxqNbc7xkcZFaxiVRz8xPTFMCAyAbcc0Ae23LFQSGP0zWLdT5LAnitC6c5IPU9qx7yPexB4zQBn3Mu8/LWlZW8s0UUEKGSRhkKPWqdvbPNcLDChdmOAor03QdLt9Gst0pD3JHJ/oPpQBV0bRrfQ7fz7gq90Ry2OnsKzNY1Jrp2wSF6Y7D3q1q909yGyQeOO2K5+4HzjIPPGc4FAEE25wxPA7AjpWdLGGdQqkls5wM4q5MzvmNSWA4DD1+lQySC1VtrfOww2ByDQBmyi3s1PmYlcAhRnhf8arxPFIkl1dSSPEEKqoH8X1qaYIiiZvuvnYvU/jVS+M0zFSNiBRtVRgKKAMYyq1uTCjZ/iJ9axL9ZWJ8wEu3IzxgV1djBbl4xLukkByPL4H5muZ1hmTVbnI29Dk80AZrKinbIOdvHHSq0oKrkjOT171duGBZmyWbGOegrOdtvUnNADMdxkL0FEMhjOYyVI7io/M7A5+tG7BJJ59hQBNJqU8bZbDe/Q1La3mp3JmayQt5EZmcqM7EHVvoMiqEpQoc+nevcv2YfCUWv6f4vubpB5M9kdLRiP+egJcj3GE/OgDyKPxVqxj8ua6Z4/TAqjPqBnJ8zJHoOlUrqCW1u5re4XZNC7Rup7MDgj9KjDAdRk0AXUuADkJStcO55b8BVQHcfQVKox0FAFlJPXFWUcsAAaooeQTViNsY4+lAGjCQvuauRkkDtWbE/PNXIZMDPegC9G5FWFlHeqUchyOealzmgC8rg45xViNjjA6VShZcdOasxHOPWgC2meOeTUiHb3/ACFVlYkVKjZ60AW1cEYPIaoWTDc80CTAOBUhG8FSeQMigCKNnjYtE5RhyCDiug0rxTPbhUugz4/jBrnuhwRQf5c9KAPU9L8T2twMpKc+h4rqLPVUZFw/bmvASeQwOG9RW7pXiW6s8LKPMjUYyByKAPdYbmOU9QPbqKfJaRSqcIQTxlef0rzrRfE8NzgRMN2OjcGussdVDgFWwx70AWWsHjztO4fT+lRNbvjADDjk1q2+o5ZSV3dvxqyZY3AO0En2oA5xVJB3H7vY1IqZ2/Lx1GD0rbmtLeZuAUbGcj/69VpbUxnchDL7DBFAFaIjeCvFWAxdePXrUMic5XPzevFSRRk4U8ccUASQ3DxSAhuPrzWxZ6tMoxuLD3rIFrgZJx2oH7rqc8/SgDr7fUYJ1CycMeuafLZW1wnyBM+uK5MTDI4AarVvevF904GaALOpeF4LpWVoYpFbghhmvNfE/wAIra4RpLKJbSXPBRTj8s16vaaxkbZRnHetOK4inHB69jQB8la18Pdd0lmf7M11EvO+Lrj6VzexVn2spSQHBVhgj8K+1p7GCYHevNcd4q+G2ka+m6VGjnU5WVDhh/jQB5fMOSWyec1mXIO5mxknhR3Na9wCu4n1q54b0hrm6jupB+7XJVT/ADoAueCtG+wwvd3ahJm45P3R6UurXvmTnY33eBV/XroJCtvCeM8kdTXL3DOcrx6E0AOa6WVJERuQcru7GqrRyGCbzRvQDO4jge1UZZIoJFfazuh4GcCpRqrTKyXBKqxwVA4oAgikUSHy/mJ4VsYHNULpGaTYx+YHLeta0lkWZVDHaenuKf8AZVRGVlG3dy59PQ0AYZt5ptg8oP0AyOAPf0qVLW51CdzLCDzjCDAUV0EskcEeGXYvHA6H6Vj6n4ktbF9pbaW6jBOR+FAFu38O7Q0jiOIkbPmPJNYniLwel8rTQzwrInct/OsTUfFl1cI8cSlEz8rlicYrD1G/uJjvfcN2AcGgClqtgNPZ4rieKJh1yc5/GucmuLcNzLv5/wCWY/xroGukIKsvJ655rNutMW7z5DIHXvjGaAMWW6O4iJVVe2eTULySScM5pZ4XgmeKVdrqcEUDvQBGFPua7r4ba/rOmW2vW+m6rqFpbrp09wIoLl41EuFAfAIG7AHPWuKrovBssUJ1zzZETfpc6LuYDcx24A9/agDn7iee7nluLmWSaeVy8kkjFmdickknkknvTAwHUUuBmkOM+9ADgwxxT1kPrUQB5zSgjFAFiOTnnip1fkc1QDe9SJJigDSjkGeTzVmOXGPSspJeeScGrEcg49KANmOYZBHWrcbhgCMVixSDPWrsMuOaANSMkYPHFWVccdcms+OTIFTKwxxQBfDnjB5qVWz3qnE4AJJGal3jv+lAFsOOmfyqXfkjnpVJWAHWpEbPANAFsncMjAP86TIwDzUSSDO1uKe5xk45oAXK4zQH+RqYDtOD1NSHHlc9c9aAIOA25Tg+oODWnYa/qFmylZyyD+FuePrWeygcdaQnAwFoA9C0jx1ACFuS8bd8rla7TSfEtncFfLuFO7jg14QSuORRtK4aNipz1U4NAH05bXsMpGH/ADrQQCRQRz9DXzdpnijUtPYAv5yejE5rsNH+JEEe1buOSI55I5FAHshtVOCI0PP8XWke0Xflo9q9sHpXHaT8RdLmbBuBn3BrsNN16xvoldGVvcUAI8cKsAS6t79Kr3NqSAU5Hc5zW+q28x/dsAT2IqOXTnTmN8H1FAHMNAynkH60mCp9sVuTQSY2yIvHcVVeAbcgc0AUoz69exq3BcNGSQ1J5GVPA/wqCSIjPzflQBtWuqbANzHHoa04L+GUhd2GNcftI6mpomKFSCcGgDz2z09tQuCoB8teuO/tXVOq2VqI4htI7DtWjpunx2VuFAHGc+9ZuplsNzyfegDm77MsuNwBxkk9qxZyRuPUDpzWtdpuzjj2FUZI4xGFXk9zigDHliMjYI3OeTzwKjFuV34BJB69lrUaN23swEcYBCjPJNRuAIhBEAufmY0AZ8V3LbsoJBXOMNzgetRalqfkI7iUepB6Cs7XtQit4mG8Eg9vWuDv72e4lJBIjz0J60Abeo+Irm8LrC2xM8H1rGIMv+sYsx5y3JqFJVZcH7wpwlBJ7H1oAkxtCqc9cgj0qtK0ezDsRg09yzSEjJqtOGMjblJU/mPwoApTSBT8hNRpPKDhcAEdh1qWWF2fKxk9xgcmozDInMnyemaADWoxcwJcBAJEAVwB1HY1jFRjgGtS+ugYyvRiu3APB96zMgCgBpQ4yOlH4U4tSFsjmgBvTrSZGelBx68000AKT+VNB60hOaSgBcmlBPrTc4ppNAE4bFSo+KqBqer8UAaEUxU8kYq9DMCODxWKr8ip43I6fWgDfhmIwTyKtRy4HBz+NYdvcb12nrVuOcelAGwso4xyKnWbmshJu5OKkWfjk4oA1RLUkUxzWWk4/CpVmGeCc0AaYlHXNTrMWwcVkrIDnnBp6zYPBoA1PNwfapfMBjHWs0T4Hc1K021gCMgd6ALeQOSaQnJJFV/MB+7TfNOeDkUAWgT3/WgHjLcAdKhL7uc0zzeueAKAJS3qfxqJnPOMHHNLvOORx61HJ8+AOKAGEq2CTj2FXtP1C7sG3WV5PA/cI5x+VZgUq/XGO1ToQeTnNAHoWg/E/XLAot2qXcS8E/davT/DfxP02++WW5jgk/uStj+dfPMOCCDwamjgyOQCAeeKAPr201a2uYwd0Tg9wc1d8q3nHy7QT/dNfIthf3+nMrWF3NDg52q3H5V3+g/E+6tWVNSt3lXH3425/I0Ae7Np6hfkwfqKpXNio5KkH17VzWifEbSLxEH2oRyE42S8HP4119vq9rOo2uG47GgDFntCmSBuz7VCq4OO38q6nbBcDIxn2qrcabuB8sj6UAc/fMUO1TjAzXMX8jMWyT1xiuh1aTMhCnGOprn7hQvzEZPagDHuwIU6MxPNVnj2yogUGRhwoHyr7mtSRGkJwOf5VTfkuFbCj7xoAoBY0SSSQs0UOck9GasrWLpbWxkm3BCy5wfvVsaoYrez82ZljiTnB9fU15h4h1I6jeNtLGFeFBoAx7+Z7iRnkJIJyBVF8YOBVmZgOPSqjEntgUAVJC27jg0zzXBznP1qVjzmq8rgAYoAmXUWjH+qUt2OaZPrNx1VIwx7lQcVSY9WqtK25s+tAFptUu5CMyICO6xgVRuLiaQ/PKzH3NMJwc0pIccCgCBjnrnPvTDUsgyeBwKiJxQAhNMJPrSlgaYaAAmkzRTcigBxOaRunHNMJ5pC3vQAuTSZ4pC2evX1pDQAucUoeo6KAJg+DmpY5cVUz70uaANFXIIKmrcNwScHAPrWRFOBjPIq2pVkyD3oA1RIe9SbzxWZDOV4YmrKkkDacrQBdWX1qRJmB61nbznrzUgkOeaANJZm7mpUuMn6VlCT65qZZcJ+lAGrBPufnoOam87Oec9+tY6z7YwAeT1pyz8YzzQBrrPxy1O87nORWP52Cec+1L9oOck/SgDYMxB44pS+R9aykugf4jUnn5Gc0AaYl6Dt6Upk6EcVmC4JPUge9SLMMZyTQBbLncTnJqW3k5xwMVSUkn+lTx4465oA1kwUGBg+tWo2wOCc1n20oGB+FXAcjr81AFkHnP8AWpVC4BxTFYeWOcdqXcW/h7YxQBLFh/lxtIPBHatjTfEGq6c4NpfSbQMbZDuB/OsdX2pilUEEHnbQB6Ro/wAUrq2CpqVtuHTfEf6GvRtB8bWepqvkzxsTyV3DIr50LnkjJB6ZoTIdZIyUcdGU4NAH0BfYaUgAVm3KAZduDnA/xrQu3xKVXknoapTRs3zKhKjoT3oAzZVLsY4xgYzVRxBZoxlkACfMxNW7+9i0+2Ms0ixj+JjxXlXijxC2ozS+UxFvnauRyRQBB4o146o7xRKUtw5PJyW9DXLTSjOEGT61LKxOew9KqscZI4/CgCBxjlutQSN1p8r471Sml+Y+vrQAk79c4qnI5Y4zRLJ1z09Kru46D8aAEmk4xVcnII7daV2yaiBOfagBCSRjijdgZFNPGc00d6AHsePrUBOOKez7OOpqFjg8mgBaYTjtSNIB0qNmJ70APL1GWNNyM80EigBSfWjNMLDNNLZ6EigCQ0Z98VET9aaTQBMWGeaTO7oRn3qItSbvQ0ASsWHUU0tkVGXppegCTdip7e6Mbc8juKplz6UzdQB0AKyRiSPGKWOYq2Mce9YkFzJCwKtx3HrWpC6XMZMbDcOo9KAL4cPzkZpQzY6jiqHKNzUqtu4B57UAWwQe/NSBmOB09apfMO/PelWUgFs9f5UAXPP5yOB0o84DgCqZnJGBj6UCY9+KALol5yaVZjyM/hVQSg8GpAwZeOTQBa8zjIPFPEhABqorbTnpTtxHOcg0AW0k5qdJgAMVniUMcA/hT1fB70Aa0UpZhzVuNucEZrIhlGeuKvQTE8LyaANFW2kHrir0MwJznOay0mQMA/PsKkhlwxwcD2oA385VMH35qeHBO0HGecGsqKYMM55FaFs+7JPUdKALRAHvT0y33goWoJHAwScnHWnRHnrkd6AJXJQjYRimRHP3iOTTyVH9Kj3AEDIzmgD6Ja2cuzHA3DB9hWV4g1KHTrJ3kbEca5xW5r9zFZptR9oAOTmvn7xprk+q3s0SyZs1PGP4iKAKfiPxFLq8xZlKwr91M/qaxZ2OAD1AqJmwwVADVWa5bdycZoAllYKAScmqc8ucmoZ7hgOo/CqLzsc8gUASzSE/SqUr5PFNlnbv+lVpJc9MfjQArtuPHbmonJ796Ug7QoI9+ahYkkkjigBGJqMnJpzMOeoHvUMkinpQA5mABzUW7nJ4qNnTu1ReZk0ASM2WwOTUbZ3dc0NKqjBIFQNOO1AEtIartNmmmUnrQBOW9DTS9QFj60wue9AFgtTS4quWppYUAWC9NLmoC1IX96AJy/tTS5qHcaTJoAmL0haosmkoAl30heo6KAJN1OimaKQPGcMKhooA6PTb+0vNsN4/kSMcByCV5/lWjqWjXOm4Z2SROzIciuLqaK6niGIppFHoGOKAOgWR2bafxNLJIX5wMDtWCt5N3c+/vUqXb8ZOKANYYBpciqCXJPU1IJD60AW8+xpQ2ORmq4f3p6v9KALImwQTUqSA98Zqjn3pVbmgC7vHYYNSK7fWqitnk04SehzQBejk2n5qsC44A4AFZYkJ71Krc88CgDXiuBuzjmrkUu44BGfpWGjkHrViObaRQB0cdwR8p5q9a3OWC8AVzMdzgnngVpabKZMkHvxmgDoC5GMdDU8bgciqAJCAsfyqzE2I+eh6UAWhIT179KaMhxzk8VXZscnFMMjBwU5BIzQB6d8S/EXmTGxtiRjmRvw6V5dO5yc9PStfWJDvYlizk885P51z11MEBA5b1oAhkmC7iBz61lT3HUE0/UL1QoVSB9Kw57k84waALclyApB4FUprpc98VUklLfeOKruwz64oAtPc+gJ/GmrNySQMDpVQsOMd6bJNt4XFAFozkKTgc1C14Vzt5xVORyT8zZ9qjLhenNAFxryRgOmPQ1A0xP3lGfaqxlx0xUZlJPNAFgyegxSeaQOOpqq0mO9RtJ6UAWWfH1qMycVXLk03NAE5kphkqOigB+80hbmm0UALk0lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSg4pKKAJFfFTJKe9VaUHFAGjHNnrU6NkZrLV6mSUgjmgDSUigHniqiTg9anVwehoAnydpzShuKiVs07p+FAE6OamV6qA5p6k0AW4z83HSpfNO7nqKpI+TjpTi5B9RQBcM+AxNdT4eQi0Ez/x9BXEQZnuEiH8R5x6V6HZlV0+JEGGX5aALW8kLwNvephJnAx0rP8w+btxwOtT+aAd3QmgCzMwIwM4FQl8ED3pC+VzjiqzyMHHpmgDp9R6tXN3XX8KKKAMG76vWdJ1NFFAFR6Y3WiigCM9fzqH+I0UUARSdT9ai70UUAMam9qKKAIm60lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUsfSiigCQVLH0oooAmj71OKKKAHp0p69aKKAE/ipz9RRRQBNov/H+K7i0+4aKKAI4v9c31p56miigCbuPpTP8Almn+9RRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This axillary view demonstrates the dislocation more clearly, along with an avulsion of the lesser tuberosity (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_39_34431=[""].join("\n");
var outline_f33_39_34431=null;
